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Abstract 41 
 42 
Indeterminate thyroid cytology (Bethesda III and IV) corresponds to follicular-patterned 43 
benign and malignant lesions, which are particularly difficult to differentiate on cytology 44 
alone. As approximately 25% of these nodules harbor malignancy, diagnostic 45 
hemithyroidectomy is still custom. However, advanced preoperative diagnostics are rapidly 46 
evolving.  47 
This review provides an overview of additional molecular and imaging diagnostics for 48 
indeterminate thyroid nodules in a pre-operative clinical setting, including considerations 49 
regarding cost-effectiveness, availability, and feasibility of combining techniques. Addressed 50 
diagnostics include gene mutation analysis, microRNA, immunocytochemistry, 51 
ultrasonography, elastosonography, CT, sestamibi scintigraphy, FDG-PET and diffusion-52 
weighted MRI.  53 
The best rule-out tests for malignancy were the Afirma® GEC and FDG-PET. The most 54 
accurate rule-in test was sole BRAF mutation analysis. No diagnostic had both near-perfect 55 
sensitivity and specificity, and estimated cost-effectiveness. Molecular techniques are rapidly 56 
advancing. However, given the currently available techniques a multimodality stepwise 57 
approach likely offers the most accurate diagnosis, sequentially applying one sensitive rule-58 
out test and one specific rule-in test. Geographical variations in cytology (e.g. Hürthle cell 59 
neoplasms) and tumor genetics strongly influence local test performance and clinical utility. 60 
Multidisciplinary collaboration and implementation studies can aid the local decision for one 61 
or more eligible diagnostics.  62 
Precis 63 
 64 
This review discusses the value of additional molecular and imaging diagnostics for thyroid 65 
nodules with indeterminate cytology, including considerations regarding cost-effectiveness, 66 
availability, and feasibility of combining techniques. Addressed diagnostics include gene 67 
mutation analysis, microRNA, immunocytochemistry, ultrasonography, elastosonography, 68 
CT, sestamibi scintigraphy, FDG-PET and diffusion-weighted MRI.  69 
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INTRODUCTION 103 
 104 
Indeterminate thyroid cytology is an eyesore to physicians. It largely corresponds to 105 
histopathologically follicular-patterned lesions, both benign and malignant, including 106 
follicular adenoma, noninvasive follicular thyroid neoplasm with papillary-like nuclear 107 
features (NIFTP), (encapsulated) follicular variant of papillary thyroid carcinoma (FVPTC or 108 
EFVPTC) and follicular thyroid carcinoma (FTC). These neoplasms are particularly difficult 109 
to differentiate on fine needle aspiration cytology (FNAC). In the case of FTC, cytology lacks 110 
the insight into the tissue structure like histology does: it does not show the capsular and/or 111 
vascular invasion that distinguishes a FTC from a benign FA. In FVPTC, the growth pattern 112 
is follicular and clearly identifying nuclear features of PTC can usually not be identified 113 
cytologically (1-3). Nevertheless, FNAC currently has a most prominent place in the 114 
diagnostic work-up of thyroid nodules. The Bethesda System for the Reporting of Thyroid 115 
Cytology was adopted in its current form in 2009, recognizing six diagnostic categories with 116 
an incremental risk of malignancy and clinical management guidelines. Although the 117 
Bethesda system created a much-used handhold by standardizing the cytological diagnosis 118 
and consecutive management of thyroid nodules worldwide, the system does not provide a 119 
clear answer for the heterogeneous group of nodules with indeterminate cytology (4,5). This 120 
includes cytology with atypia of undetermined significance or follicular lesion of 121 
undetermined significance (AUS/FLUS, Bethesda III), and cytology (suspicious for a) 122 
follicular neoplasm (SFN/FN) or (suspicious for a) Hürthle cell neoplasm (SHCN/HCN, 123 
Bethesda IV). Similar indeterminate cytological categories are found in the British Thyroid 124 
Association Thy system and Italian SIAPEC-IAP classification: Thy3a and Thy3f, and TIR3A 125 
and TIR3B, respectively (Table 1) (6,7). 126 
Alongside a doubled incidence of thyroid carcinoma over the past two decades and a 127 
prevalence of thyroid nodules stretching far beyond the 5% for palpable nodules – explained 128 
by the incidental detection of nonpalpable nodules and clinically occult thyroid cancers on 129 
imaging studies – the need for a more accurate diagnostic procedure has grown (8). This urge 130 
was further emphasized when other research groups were unable to reproduce the prevalence 131 
of the cytological categories and corresponding malignancy risks proposed by Cibas et al., 132 
especially those of the AUS category (4,9,10). Insuperable variations in the worldwide patient 133 
populations, and intra- and interobserver variation in the assessment of thyroid cytology were 134 
named as likely underlying causes (4,5,10,11). Yet, it raised questions concerning the overall 135 
approach of thyroid nodule diagnosis and whether cytology is the best starting ground. Cost-136 
effectiveness is a major benefit of cytological examination, yet a more accurate test may 137 
eventually replace cytological examination completely (12,13). At present, however, a 138 
supplemental diagnostic procedure is specifically warranted for cytologically indeterminate 139 
thyroid nodules. Diagnostic hemithyroidectomies are still customarily performed to obtain a 140 
definite histological diagnosis. With a benign histopathological result in approximately three 141 
in four cases, surgery was not only unbeneficial but also exposed the patient to unnecessary 142 
surgical risks. In the case of malignant lesions, a second-stage completion thyroidectomy is 143 
often indicated, which is associated with additional costs and higher risks of surgical 144 
complications (14-17). An additional preoperative test or combination of tests for thyroid 145 
nodules with indeterminate cytology should prevent unbeneficial diagnostic 146 
hemithyroidectomies for benign nodules, limit the number of two-stage surgeries for thyroid 147 
malignancies, or both. With rapidly advancing technology, the possibilities for additional 148 
diagnostic techniques seem endless: the applications of existing diagnostics such as 149 
ultrasound, PET/CT and immunocytochemistry are extended and more clearly demarcated for 150 
use in indeterminate thyroid nodules. High-tech molecular tests such as gene mutation panels, 151 
gene or microRNA expression profiles and sequencing techniques are hot-topic (4,18-22). 152 
Every currently known engagement point from the genotype to the phenotype of the tumor is 153 
being explored. Combined, the various research fields encompass an extensive range of 154 
investigative methods. Individually they usually focus on one or two methods only, making 155 
one-to-one comparison of these diagnostics difficult. The 2015 American Thyroid 156 
Association (ATA) guidelines suggested several additional tests, but a definitive answer or 157 
complete overview of all available tests is still lacking (23).  158 
Alongside higher-level expert discussions and lobbying of med tech companies, clinical 159 
endocrinologists and thyroid surgeons ponder about the best solution for their individual 160 
patients. Their choices depend on the characteristics of their patient populations, availability 161 
and costs of a certain test, and personal preference. In any case, a useful additional test should 162 
be accurate, accessible, affordable and affect patient management.  163 
This review aims to provide practical considerations for physicians involved in the 164 
management of patients with thyroid nodules. It gives an overview of the available literature 165 
on additional diagnostic tests for thyroid nodules with indeterminate cytology. We will work 166 
our way down from genotype to phenotype, discussing both anatomical and functional 167 
techniques, from the state-of-the-art molecular and imaging biomarkers as well as widely 168 
available conventional imaging techniques. The ability of a test to distinguish between 169 
malignant and benign nodules in a preoperative setting is discussed, focusing on clinical 170 
validation and utility, and including the development phase, cost-effectiveness and 171 
availability of each technique, where appropriate. Table 2 provides a summarized overview of 172 
the discussed diagnostics and their main attributes.  173 
 174 
1. MOLECULAR BIOMARKERS  175 
 176 
1.1. Gene mutation analysis and Gene expression  177 
 178 
In the last decades, researchers have unraveled important molecular mechanisms behind the 179 
thyroid tumorigenesis, and designated a great number of genetic alterations that are related to 180 
the various types of thyroid carcinoma. Several of these mutational markers have found their 181 
way to the preoperative diagnosis of indeterminate thyroid nodules. The most common 182 
markers are the somatic BRAF and RAS point mutations, and RET/PTC rearrangement, all of 183 
which involve the mitogen-activated protein kinase (MAPK) signaling pathway (24-26).  184 
In the 2015 ATA guidelines the potentially strong diagnostic impact of molecular testing is 185 
explicitly unfolded, focusing on BRAF testing and the – at that date – two main commercially 186 
available tests: the seven-gene mutation panel miRInform® thyroid (Asuragen Inc., Austin, 187 
Texas) and the Afirma® gene expression classifier (Veracyte, Inc., South San Francisco, CA). 188 
The ATA recommends considerate application of one of these molecular tests for Bethesda III 189 
and IV nodules, provided that the result could change the treatment strategy (23).  190 
In the following chapters, the diagnostic potential of mutation analysis in indeterminate 191 
thyroid nodules is discussed, including the tests mentioned in the guidelines as well as other 192 
individual molecular biomarkers and multi-gene panels addressed in literature.  193 
 194 
1.1.1. BRAF mutation 195 
 196 
B-type RAF kinase (BRAF) is a serine–threonine kinase belonging to the rapidly accelerated 197 
fibrosarcoma (RAF) family, and the most potent mitogen-activated protein kinase (MAPK) 198 
pathway activator. Point mutations in the BRAF proto-oncogene occur in various human 199 
cancers. The somatic BRAFV600E mutation is the most common activating mutation in many 200 
carcinomas, including thyroid carcinoma (24). This missense mutation consists of a thymine-201 
to-adenine substitution at nucleotide 1799 (c.1799T>A), resulting in an amino acid 202 
substitution where valine is replaced with glutamate at codon 600 (hence V600E)(27,28). 203 
BRAF has an important function in cell proliferation, differentiation, and apoptosis. 204 
Upregulation of BRAF through the BRAFV600E activating mutation is associated with 205 
tumorigenesis (28). In differentiated thyroid cancer, the BRAFV600E mutation is exclusive to 206 
PTC, occurring in 50% to 80% of these tumors (24,25,29-39). The BRAFV600E mutation has 207 
been prognostically associated with poor clinicopathological outcomes, such as increased 208 
incidence of extrathyroidal invasion, recurrence of disease, and distant metastasis of the tumor 209 
(40-42).  210 
BRAF mutation analysis has been extensively studied as a rule-in test for thyroid carcinoma. 211 
The BRAF mutation is superior to other mutations in its oftentimes 100% specificity – a 212 
positive mutation could prevent two-stage surgery for an indeterminate thyroid nodule (21,29-213 
31,35-38,41-76). Even though the BRAF mutation was found in a majority of PTC in a 214 
number of studies, the prevalence of the BRAF mutation in indeterminate cytology ranged 215 
from 0% to 48% in individual studies (44,46,48,59,65,70). Reported sensitivities were 216 
therefore heterogeneous and generally poor, ranging from 0% to 83% (29,34,39,46). Other 217 
types of thyroid carcinoma occurring in indeterminate nodules, including FTC, FVPTC and 218 
Hürthle cell carcinoma (oncocytic variant of follicular thyroid carcinoma, FTC-OV), were 219 
respectively never or infrequently BRAF mutation-positive (31,37,38,42,50,57,76). 220 
Predominated by follicular type carcinoma, the BRAF mutation rarely occurs in Bethesda IV 221 
cytology (29,31,37,41,50,52,54,57,59,60,63,65,66,70,73-80).  222 
Likely contributors to the observed heterogeneity are known global variations in the 223 
occurrence rates of PTC and BRAF mutations. In South Korea, where iodine consumption is 224 
high, 90% to 95% of thyroid cancers are PTC. More specifically, the proportion of BRAF -225 
mutated PTC is very high: rates of 80% to more than 90% are reported (34,46,77). 226 
Consequently, BRAFV600E mutation analysis might have both high specificity and high 227 
sensitivity in these populations. Studies with higher sensitivities were more often of South 228 
Korean origin and frequently demonstrated sensitivity above 40%, with the prevalence of 229 
BRAF mutations reported as high as 30% to 48%. (34,39,46,47,73,81-83). Conversely, the 230 
majority of studies with sensitivity below 10% were conducted in Western countries (USA, 231 
Europe or Canada), with some studies reporting no BRAF mutations at all 232 
(21,31,37,45,48,52,56-59,61,62,65,69,70,76,80). 233 
Some South Korean studies based surgical decision-making on the result of the BRAF 234 
mutation analysis: surgery was relatively less often performed in BRAF mutation-negative 235 
indeterminate nodules (34,39,78,83). Such a surgical management strategy is not 236 
oncologically safe for Western countries (e.g. Europa or Northern America), where 80% to 237 
90% of thyroid carcinomas are PTC and reported rates of BRAF-mutated PTC vary from 30% 238 
to 40% (34,46,77). Moreover, even though the true sensitivity of BRAF mutation analysis is 239 
presumably high in South Korea for the mentioned epidemiological reasons, the conservative 240 
management of BRAF mutation-negative nodules likely magnified test sensitivity by 241 
underestimating the rate of BRAF-negative malignant nodules in these studies. Altogether we 242 
estimate that approximately one in five South Korean patients would benefit from BRAF 243 
mutation analysis, opposite mere one in 25 patients from other countries.  244 
 245 
BRAF mutation in papillary microcarcinoma 246 
Papillary microcarcinoma (mPTC) have lower BRAF mutation rates (53,58,63,68,73,76,84). 247 
The ATA guidelines are reserved with regard to the recommended clinical management of 248 
positive BRAF mutation in mPTC, as its relation to extrathyroidal spread and positive lymph 249 
node metastases is not as clear as in larger thyroid carcinoma. Although there are studies that 250 
associate mPTC to factors of poorer prognosis, the 2015 guidelines recommend that BRAF-251 
mutated mPTC are treated as low-risk malignancies (23,35).  252 
 253 
BRAFK601E point mutation 254 
A less common activating BRAF mutation is BRAFK601E (c.1801A>G), which occurs 255 
considerably less frequently than the BRAFV600E variant and is associated with FVPTC with 256 
high specificity (85). Clinically, the characterization of a small cohort of thyroid malignancies 257 
with a BRAFK601E mutation showed better outcomes than for BRAFV600E mutated tumors: no 258 
extrathyroidal tumor extension, recurrence, lymph node or distant metastasis were reported in 259 
indeterminate BRAFK601E positive tumors with a median follow-up of 20 months (range 4-47) 260 
(86).  261 
 262 
Availability, cost-effectiveness and limitations of BRAF mutation analysis 263 
Altogether, the consistent perfect specificity in a large number of studies supports the use of 264 
BRAF mutation analysis in obviating two-stage surgery. The technique is increasingly 265 
available in the clinical setting worldwide. A prior meta-analysis of eight studies questioned 266 
the cost-effectiveness of BRAFV600E mutation analysis in indeterminate thyroid nodules based 267 
on a mere 4.6% mean prevalence of the mutation (87). Cost-effectiveness studies concerning 268 
sole BRAF mutation analysis in indeterminate thyroid nodules are lacking. Regardless, cost-269 
effectiveness is generally presumed, as average costs for testing are relatively low and 270 
decreasing over time. Depending on the applied molecular technique, reported costs for BRAF 271 
mutation analysis ranged between €7.50 and $123 per tested sample (53,63,72,88).  272 
 273 
Low sensitivity remains the main limitation of BRAF mutation analysis, irrespective of the 274 
type of indeterminate cytology. Proficiency of the test in preoperative patient management 275 
depends on the regional occurrence rate of BRAF-mutated PTC; in South Korea, more 276 
patients will benefit from BRAF mutation analysis, and the probability and extent of cost-277 
effectiveness are likely to increase (66). In other health care systems, such as in the UK, cost-278 
effectiveness is likely more constrained. Nonetheless, BRAF testing could still save 279 
approximately half the surgical costs in BRAF mutation-positive carcinoma (63,65). These 280 
global variations should be considered before local implementation of sole BRAF mutation 281 
analysis.  282 
 283 
1.1.2. RAS point mutation 284 
 285 
Point mutations in the gene family of retrovirus-associated DNA sequences (RAS) together 286 
constitute the second most frequently occurring genetic alteration in thyroid carcinoma. In 287 
indeterminate thyroid nodules, they are the most common genetic alteration, due to a strong 288 
association of RAS mutations with the follicular-patterned lesions that make up these 289 
cytological categories: follicular adenoma, FTC, FVPTC and noninvasive follicular thyroid 290 
neoplasms with papillary-like nuclear features (NIFTP) (1,3,31,59,89,90). Originally, two of 291 
the three homologous RAS genes were identified as viral genes of the oncogenic Harvey 292 
(HRAS) and Kirsten (KRAS) murine sarcoma virus; the third, NRAS, was first identified in 293 
neuroblastoma cells (91,92). The genes code for GTP-binding RAS proteins, which are 294 
involved in intracellular signaling in the MAPK/ERK pathway. Mutation causes overactive 295 
RAS signaling and could ultimately induce malignant transition (26).  296 
RAS mutation in thyroid carcinoma has been associated with favorable prognostic factors, 297 
such as encapsulation of the tumor and absence of lymph node metastases, but also with 298 
factors indicative of an adverse prognosis, such as poor cell differentiation (2). RAS mutations 299 
are not specific for carcinoma and found in both malignant and benign lesions (31,61,90). 300 
According to the 2015 ATA guidelines, Bethesda III or IV nodules with a RAS mutation 301 
should be treated similar to the Bethesda V category, as approximately 4 out of 5 are 302 
malignant (4,23). HRAS, KRAS and NRAS mutations are mutually exclusive. They are each 303 
associated with slightly different types of cytology and histology, and consequently a 304 
different clinical course. In general, point mutations in NRAS codon 61 and HRAS codon 61 305 
are said to occur most frequently (3,64). KRAS is associated with oncocytic lesions and a 306 
lower malignancy rate than other RAS mutations (93).  307 
A RAS point mutation is found in 0% to 38% of the indeterminate nodules (39,60). Moreover, 308 
approximately a third of all reported malignancies resulting from indeterminate thyroid 309 
cytology are RAS mutation positive, frequently FVPTC or FTC (31,37-39,76). Sporadic cases 310 
of RAS mutation-positive FTC-OV and MTC are reported (37,38). In individual studies, 311 
sensitivity and specificity of RAS mutation analysis ranged from 0% to 77% and from 75% to 312 
100%, respectively (39,60,90). Test performance was similar for Bethesda III and IV 313 
categories, although the mutation occurred more frequently in Bethesda IV nodules 314 
(21,29,31,39,50,59,60,76,80,90). Histopathologically benign nodules carrying a RAS mutation 315 
are histopathological follicular adenoma in most cases, but also oncocytic variant of follicular 316 
adenoma (Hürthle cell adenoma) or hyperplastic nodules (29,31,38,50,90). There is an 317 
ongoing discussion regarding the interpretation of a false positive RAS mutation. It is 318 
presumed that an oncogenic RAS mutation predisposes a follicular adenoma for progression 319 
into follicular carcinoma – a RAS-mutated follicular adenoma should be considered a 320 
premalignant pre-invasive follicular neoplasm. These assumptions put false-positives in a 321 
different light, as it would justify resection of such lesions through hemithyroidectomy. 322 
Consequently, the lesions could also be considered true-positives – improving the specificity 323 
of RAS mutation analysis (1,21,39,59,61,71). However, the exact mechanisms behind the 324 
malignant potential and transition for RAS-mutated follicular adenomas are not yet clarified 325 
and difficult to appreciate in a clinical setting. 326 
Similar to BRAF, there was evident global variation in the distribution of RAS mutations. 327 
Many European and American studies reported a clear predominance of RAS mutations over 328 
BRAF mutations. Solely a Brazilian study of 116 Bethesda III and 20 Bethesda IV thyroid 329 
nodules reported only BRAF mutations and not a single RAS mutation (60). The previously 330 
described predominance of BRAF mutations in South Korean populations was confirmed in 331 
the sole study that investigated both point mutations in one population (39). Combined 332 
BRAF/RAS mutation analysis could be considered, although geographical differences in the 333 
distribution of the two genetic alterations strongly influence feasibility. A gene mutation 334 
panel consisting of more genetic alterations (discussed in a next chapter) is most likely more 335 
useful. 336 
Sole RAS mutation analysis is not accurate in the preoperative setting. Although specificity is 337 
high, only two out of three RAS mutation positive indeterminate nodules are 338 
histopathologically malignant, evidently fewer than assumed and previously described in the 339 
ATA guidelines. Therefore, RAS mutation positive indeterminate thyroid nodules should be 340 
surgically managed with no more than hemithyroidectomy. Whether hemithyroidectomy is 341 
justified for RAS-mutated follicular adenomas as a precancerous lesion, is yet under debate. 342 
 343 
1.1.3. RET/PTC rearrangement 344 
 345 
Rearrangements of the RET proto-oncogene arise from the fusion of the 3’ end of RET to the 346 
5’ regions of unrelated genes that are expressed in thyroid follicular cells. Proto-oncogene 347 
RET encodes for a transmembrane receptor with a tyrosine kinase domain; a RET/PTC 348 
rearrangement causes inappropriate overexpression of that domain. It activates the MAPK and 349 
PI3K/AKT pathways and stimulates malignant transition of the cell through BRAF (94,95). 350 
At least 12 different fusion variants have been detected until today, of which RET/PTC1 and 351 
RET/PTC3 are the most common. They have a well-known association with PTC. Cases of 352 
both rearrangements in a single lesion are also reported (2,94,96,97). RET/PTC 353 
rearrangements, especially RET/PTC3, occur more frequently in PTC in children or patients 354 
that were exposed to ionizing radiation and are clinically associated with the presence of 355 
lymph node metastases (2). Worldwide variations in frequency of RET/PTC rearrangements 356 
exist, dependent on demographics and ethnicity. The RET/PTC rearrangement is present in 357 
42% of PTC in Western populations with a predominance of RET/PTC1, and in 37% of PTC 358 
in Asian populations with a predominance of RET/PTC3. Without radiation exposure, in 359 
female PTC patients RET/PTC1 is predominant (98). The rearrangements are also found in 360 
benign nodules, especially in patients that were exposed to ionizing irradiation (29,97). Alike 361 
RAS mutations, it is assumed to be an activating genetic alteration and it is argued that a 362 
histopathologically benign nodule with a RET/PTC rearrangement should be considered a 363 
precancerous lesion.  364 
RET/PTC rearrangements are seldom found in indeterminate nodules. In many studies, no 365 
RET/PTC translocation was found at all. Most studies investigated RET/PTC in light of a 366 
gene mutation panel and paid it no specific attention 367 
(21,29,31,37,38,45,49,50,55,59,61,62,64,70,76,80,96). Only Guerra et al. solely investigated 368 
the RET/PTC rearrangement in 101 thyroid nodules of all cytological categories. In this 369 
Italian study, RET/PTC rearrangements were found in 18 of the 50 PTC (36%) using RT-PCR 370 
and Southern-Blot. All these RET/PTC-positive carcinomas were Thy4 or Thy5 nodules on 371 
cytology. Among the 24 Thy3 nodules, two nodules with a RET/PTC3 rearrangement were 372 
histopathologically benign (96).  373 
Noteworthy, Sapio et al. detected two RET mutations during their RET/PTC assessments. In 374 
contrast to the RET/PTC translocation, RET point mutations are related to sporadic and 375 
familial MTC (45,99). Surgery confirmed histopathological MTC in the RET-mutated nodules 376 
(45). 377 
 378 
Even though previous histological studies undeniably associated RET/PTC1 and RET/PTC3 379 
rearrangements to PTC, the low prevalence of the rearrangement in indeterminate cytology is 380 
a major downside. Testing exclusively for this genetic alteration in indeterminate nodules is 381 
not advantageous, even if issues regarding the number of tested variants and sensitivity of 382 
molecular techniques are overcome. The 2015 ATA guidelines only advise RET/PTC testing 383 
in context of a gene mutation panel (23).  384 
 385 
1.1.4. PAX8/PPARγ rearrangement 386 
 387 
The PAX8/PPARγ rearrangement arises from a fusion of the promoter and 5’-coding portion 388 
of the thyroid-specific transcription factor PAX8 gene to the gene of the nuclear receptor 389 
peroxisome proliferator-activated receptor γ (PPARγ) (100,101). The role of the product of 390 
this translocation – the PAX8/PPARγ fusion protein – is not yet understood, as the DNA 391 
binding sites of both original proteins are uniquely preserved in the fusion (101). In the 392 
normal thyroid, transcription factor PAX8 is involved in differentiation of thyrocytes and 393 
regulation of the expression of thyroid-specific genes encoding thyroperoxidase, 394 
thyroglobulin and the sodium/iodide symporter (102). Nuclear receptor PPARγ has multiple 395 
presumed functions, including involvement in the regulation of lipid metabolism, 396 
adipogenesis and insulin sensitivity (101,103).  397 
The chromosomal translocation PAX8/PPARγ was first discovered in – and traditionally 398 
associated with – FTC and follicular adenoma (100). It is reported in 30% to 45% of FTC and 399 
in up to 33% of follicular adenoma (50,104-106). However, several studies have also 400 
uncovered varying amounts of FVPTC carrying the translocation, with published rates up to 401 
38% (104,107,108). It has not been reported in benign or malignant Hürthle cell neoplasms 402 
(105,109). 403 
PAX8/PPARγ is often related to well-differentiated malignancies with a relatively favorable 404 
prognosis. Capsular and vascular invasion are reported to a lesser extent in FTCs with a 405 
PAX8/PPARγ rearrangement than in RAS-mutated tumors (105). Widely invasive features are 406 
not reported. PAX8/PPARγ-mutated FVPTC are mostly encapsulated, following an indolent 407 
clinical course with minimal disease recurrence despite the presence of some capsular and 408 
vascular invasion at presentation (105-107). In contrast to the BRAF, RAS and RET/PTC 409 
genetic alterations in thyroid carcinoma, the PAX8/PPARγ rearrangement does not involve 410 
the RAS-RAF-MAPK pathway. Nikiforova et al. hypothesized that oncogenesis of follicular-411 
type tumors likely takes place through two different molecular pathways: a RAS-mutation 412 
driven and PAX8/PPARγ rearrangement driven pathway (105).  413 
Similar to the RET/PTC rearrangement, the PAX8/PPARγ rearrangement rarely occurred in 414 
indeterminate thyroid cytology. Approximately two-thirds of the indeterminate nodules 415 
carrying the rearrangement were histopathologically malignant, most often FVPTC or FTC 416 
(21,31,37,38,49,55,59,61,62,70,76,80,109). False-positive results corresponded to follicular 417 
adenomas (61,62,70). Similar to RAS mutations, histopathologically benign PAX8/PPARγ-418 
mutated nodules are likely premalignant lesions, or pre-invasive FTC. Eszlinger et al. 419 
observed a microfollicular morphological growth pattern in two of the PAX8/PPARγ-positive 420 
follicular adenoma, supporting this hypothesis (61).  421 
Still, PAX8/PPARγ rearrangement is a rare rearrangement associated with (encapsulated) 422 
follicular tumors. Similar to RET/PTC rearrangements, the PAX8/PPARγ rearrangement 423 
should only be assessed in indeterminate thyroid nodules in combination with more frequently 424 
occurring genetic alterations in a gene mutation panel.  425 
 426 
1.1.5. Other genetic alterations 427 
 428 
hTERT 429 
The enzyme human telomerase is involved in the maintenance of the chromosomes’ 430 
telomeres, which are essential for cell life and proliferation. The catalytic subunit of 431 
telomerase is human telomerase reverse transcription (hTERT). In normal thyroid cells, it is 432 
inactive. Inappropriate reactivation is associated with malignancy and inflammatory thyroid 433 
disease (110). hTERT promotor mutations were previously observed in both PTC and FTC, 434 
sometimes together with a BRAF mutation. The mutation is strongly correlated to mortality in 435 
differentiated thyroid carcinoma (111). hTERT gene expression is potentially accurate in the 436 
preoperative differentiation of indeterminate nodules, with 57% to 88% sensitivity and 75% 437 
to 85% specificity demonstrated in two small clinical series of cytological follicular 438 
neoplasms (112,113).  439 
 440 
TRK 441 
The tyrosine receptor kinase (TRK) rearrangement arises from a translocation of the NTRK1 442 
gene, which is normally expressed in the central and peripheral nervous system and involved 443 
in cell differentiation. The TRK rearrangement is associated with PTC and presumably with 444 
an adverse prognosis, although evidence is limited (114). In feasibility studies in 445 
indeterminate thyroid cytology, not a single TRK rearrangement has been detected – it is most 446 
likely not a useful marker (45,49,50).  447 
 448 
HMGA2 449 
Proteins high mobility group AT-hook (HMGA) 1 and 2 regulate the structure and function of 450 
chromatin. Normally only expressed during embryogenesis, the overexpression of HMGA in 451 
adult tissues is associated with malignancy (115). Lappinga et al. demonstrated that HMGA2 452 
could be a promising additional biomarker. Using ROC curve analysis, a >5.9-fold HMGA2 453 
overexpression had 76% sensitivity and 98% specificity in SFN/FN nodules (116). To date no 454 
other studies attempted to validate these results.  455 
 456 
Galectin-3 and CD44v6 457 
One Croatian study used RT-PCR to investigate the simultaneous expression of galectin-3 and 458 
CD44v6, two molecular biomarkers better known for their application in 459 
immunohistochemistry of their expression products (117). CD44v6 normally functions as the 460 
cell-surface receptor for hyaluronic acid. Overexpression is found in various human cancers, 461 
including thyroid (117,118). In indeterminate thyroid nodules, a positive test for either one of 462 
the two biomarkers resulted in 100% sensitivity and 60% specificity. It is presumed that 463 
similar results for these markers are achieved with the more economical 464 
immunohistochemistry techniques (118,119).  465 
 466 
1.1.6. 7-Gene Mutation Panel 467 
 468 
Ongoing research in the past years has demonstrated that assessment of individual oncogenic 469 
mutations generally has limited clinical utility in indeterminate thyroid cytology. Combining 470 
forces of individual genetic alterations into a gene mutation panel, however, likely improves 471 
diagnostic accuracy, especially as mutations are mutually exclusive in most cases. These gene 472 
mutation panels typically assess the seven genetic alterations – gene mutations as well as gene 473 
fusions – that occur most frequently in differentiated thyroid carcinoma, including 474 
BRAFV600E, BRAFK601E, NRAS codon 61, HRAS codon 61 and KRAS codon 12-13 point 475 
mutations and RET/PTC1, RET/PTC3 and PAX8/PPAR gene rearrangements (31,55). The 476 
best known panel is the commercially available miRInform® thyroid (Asuragen Inc., Austin, 477 
Texas, USA), currently rebranded as the ThyGenX® Thyroid Oncogene Panel (Interpace 478 
Diagnostics, Parsippany, NJ, USA). The miRInform® thyroid tests 17 specific genetic 479 
alterations in these seven genes (59). It is marketed as a rule-in test for thyroid malignancy. 480 
 481 
The first large clinical utility study to investigate the miRInform® thyroid test was published 482 
in 2011. Nikiforov et al. prospectively included 1,056 FNAC samples, 92% of which had 483 
sufficient epithelial cells and nucleic acids to pursue molecular testing. Residual FNAC 484 
material was used for mutation analysis – no additional aspirates were required. 485 
Unfortunately, surgery was performed for only 461 of 900 (51%) indeterminate thyroid 486 
nodules, independent of the test outcome; these operated cases were included in their final 487 
analysis. It is not reported whether nonsurgically managed nodules were mutation-positive or 488 
-negative. Sensitivity and specificity were 63% and 99% in the 247 Bethesda III nodules, and 489 
57% and 97% in the 214 Bethesda IV nodules, respectively. The authors suggested that the 490 
high PPV of the miRInform® thyroid in these indeterminate thyroid nodules (88% and 87%, 491 
respectively) warrants a direct total thyroidectomy instead of two-step surgery in patients with 492 
a positive test (31).  493 
None of the subsequent studies matched the initially reported excellent specificity. The next 494 
industry-sponsored prospective study by Beaudenon et al. reported 47% sensitivity and 88% 495 
specificity in 80 Bethesda III and IV nodules. Surprisingly, not a single BRAF mutation was 496 
detected (59). Valderrabano et al. reported not a single mutation in 47 included Bethesda III 497 
nodules. Moreover, only 1 of 18 nodules with Hürthle cell cytology in this study tested 498 
positive, suggesting that Hürthle cell nodules may carry different mutations than the ones 499 
investigated by the miRInform® thyroid (76). Ohori et al. demonstrated that genetic 500 
alterations less frequently occurred in the textbook colloid-poor Bethesda IV cytology 501 
compared to the less common colloid-rich variant. Differences in etiology are unknown, but 502 
the authors hypothesized that the two types have subtle histopathological differences. The 503 
colloid-rich thyroid carcinomas likely more often develop through the well-known mutations 504 
included in the miRInform® thyroid test, whereas mutations that elicit colloid-poor thyroid 505 
carcinoma are yet unknown (37). 506 
 507 
Simultaneously with the American miRInform® studies, five European studies independently 508 
investigated whether a panel of the same 7 genes could reliably be assessed using different 509 
methods (38,55,61,62,70). In three separate studies, Eszlinger et al. demonstrated that testing 510 
was also feasible on routine air-dried FNAC samples from indeterminate thyroid nodules. 511 
Over the course of these studies, sensitivity of this method improved from 18% to 49% and 512 
specificity from 86% to 93%, respectively. The use of air-dried FNAC samples for mutation 513 
analysis could advance the implementation of mutation analysis in daily practice, as specific 514 
storage conditions of fresh FNAC samples for mutation analysis are no longer required 515 
(38,61,62). Mancini et al. showed that high-resolution melting (HRM) analysis is an accurate 516 
screening method for the seven genetic alterations, with 56% sensitivity and 90% specificity. 517 
HRM is a post-PCR procedure that does not require significant additional resources. This 518 
could reserve the costlier direct sequencing procedures solely for samples with abnormal 519 
HRM results, thereby reducing the overall costs of mutation analysis (55).  520 
 521 
Overall, reported sensitivities and specificities of a 7-gene mutation panel in indeterminate 522 
thyroid nodules ranges from 18% to 69% and 86% to 99%, respectively (22,37,61). It is an 523 
adequate diagnostic tool with a high rule-in capacity in indeterminate nodules. Test 524 
performance was similar in Bethesda III and Bethesda IV nodules, although the latter more 525 
frequently had a positive test result based on the higher prevalence of RAS mutations (31,59). 526 
Due to the common RAS mutations, PPV of the 7-gene mutation panel never exceeds 90% in 527 
a range of realistic 15% to 40% prevalence of malignancy. As such it is debatable whether a 528 
positive test warrants immediate single-stage total thyroidectomy. It translates into an 529 
inappropriate overtreatment in a significant number of patients with a positive test but benign 530 
final histology at higher risk of surgical complications and all requiring lifelong levothyroxine 531 
supplementation. Deliberate surgical decision-making should consider the underlying positive 532 
mutation rather than mere the positive test itself. 533 
The limited size of the seven-gene gene mutation panel keeps the costs per test low compared 534 
to other, larger molecular panels. Reported prices of the 7-gene mutation panel all concern the 535 
commercial miRInform® thyroid (or ThyGenX® Thyroid Oncogene Panel) and range 536 
between $425 and $1,700 (120,121). Implementation of miRInform® testing for 537 
indeterminate nodules theoretically resulted in a 20% cost reduction in the USA: the 538 
prevented two-step surgical procedures would outweigh the added expenses for miRInform® 539 
testing and increased number of total thyroidectomies – including those for nodules with a 540 
false-positive test (120). In a European setting, treatment and hospitalization costs are 541 
generally lower and miRInform® would most likely not be cost-effective (14). However, 542 
these cost-effectiveness studies both adopted the unequalled test performance from the initial 543 
key publication – true cost-effectiveness may be less optimistic (14,31,120,121). 544 
 545 
1.1.7. Next Generation Sequencing 546 
 547 
To improve the sensitivity of the miRInform® thyroid test, the existing 7-gene mutation panel 548 
was expanded to include additional gene mutations, fusions and translocations, and a 549 
microRNA gene expression panel. In addition, it adopted promising next generation 550 
sequencing (NGS) techniques. NGS enables the simultaneous targeted testing for multiple 551 
mutations in large gene panels and is faster, more sensitive and more cost-effective than 552 
traditional Sanger sequencing and other PCR-based methods (71,80,122). As NGS only 553 
requires a very small amount (5-10 ng) of nucleic acids, remainder material from regular 554 
FNAC passes suffices and no additional aspirates are required (80,122). The first thyroid-555 
specific NGS-based gene panel was the ThyroSeq® v1, presented in 2013. It detected gene 556 
variations in 110 of 145 investigated thyroid cancer tissue samples and 5 of 83 benign 557 
specimens. Unfortunately, indeterminate FNAC samples were not analyzed separately in this 558 
study. Nonetheless, Nikiforova et al. demonstrated that NGS had a very high success rate and 559 
could be a promising molecular technique for thyroid FNAC samples (122).  560 
 561 
Following the ThyroSeq® v1, the road was paved for further exploration of NGS-based 562 
diagnostics. Soon, the ThyroSeq® v2 (CBLPath, Ocala, FL, USA) was developed, with a 563 
number of primers for TERT promotor variants added to its panel. It simultaneously tested for 564 
point mutations in 13 genes and for 42 types of gene fusion products (80). The ThyroSeq® v2 565 
was tested on 143 Bethesda IV thyroid nodules. Forty-two genetic alterations were found, 566 
most frequently NRAS. Diagnostic accuracy of the ThyroSeq® v2 was 92%, with astonishing 567 
90% sensitivity and 93% specificity (80).  568 
More recently, Nikiforov et al. tested the ThyroSeq® v2.1 – including point mutations in 14 569 
genes and 42 gene fusion transcripts – in 462 Bethesda III nodules. Based on the promising 570 
results of the previous study, surgery was withheld for 362 of 431 ThyroSeq®-negative 571 
patients. In the 95 patients with available histopathology, the ThyroSeq® v2.1 demonstrated 572 
91% sensitivity and 92% specificity. Additionally, diagnostic accuracy was estimated for 573 
malignancy rates varying between 6% and 48%: PPV would range from 42% to 91%, NPV 574 
from 92% to 99%. Within reasonable limits the ThyroSeq® v2.1 is highly reliable to rule out 575 
malignancy (21).  576 
Le Mercier et al. retrospectively tested a different commercially available 50-gene NGS 577 
panel, the Ampliseq™ Cancer Hotspot Panel v2 (ThermoFisher, San Diego, California, 578 
USA), which is a tumor-nonspecific NGS panel for detection of somatic tumor variants. This 579 
panel does not include thyroid-specific RET/PTC, PAX8/PPAR and NTRK1 580 
rearrangements. Albeit the study only assessed 34 FNAC samples, with a 71% sensitivity and 581 
89% specificity in indeterminate thyroid nodules the Ampliseq™ panel seems less accurate 582 
than the ThyroSeq® (71). 583 
 584 
The high diagnostic accuracy is also a downside to NGS. Highly sensitive, NGS is able to 585 
identify mutant alleles at very low levels (<10%). A low percentage of mutant alleles might 586 
reflect a subclone within the nodule, which is not histopathologically identified as carcinoma. 587 
This detection of germline or clinically insignificant low-level somatic mutations in benign 588 
nodules could decrease NGS specificity (22,80). Nikiforov et al. suggested that the next 589 
improvement of the NGS-related tests should therefore be to determine accurate threshold 590 
levels for the various gene variations (80).  591 
NGS encompasses crucial technology that is rapidly advancing. The ThyroSeq® v3 was 592 
recently announced, promoting to encompass no less than ~95% of genetic alterations 593 
occurring in PTC. Extraordinary diagnostic accuracy above 90% is anticipated, including high 594 
accuracy in Hürthle cell lesions. Results of the prospective studies validating this new version 595 
will likely be published shortly. Nonetheless, NGS techniques currently have limited global 596 
availability, with the exception of some European countries and the USA. The ThyroSeq® is 597 
available for $3,200 per test (123). In contrast, the thyroid non-specific AmpliSeq™ panel can 598 
be ordered online for only €230 (124). Independent prospective studies are needed to validate 599 
its performance and predicted cost-utility in different patient populations, and confirm the 600 
superior position of the ThyroSeq® and other NGS techniques. 601 
 602 
1.1.8. Afirma® Gene Expression Classifier 603 
 604 
In molecular diagnostics, the chief competitor of the 7-gene mutation panel is the commercial 605 
Afirma® gene expression classifier (GEC) (Veracyte Inc., South San Francisco, CA, USA). 606 
The GEC uses quantification of the mRNA-expression of 167 genes and a proprietary 607 
classification algorithm to determine the probabilities of malignancy in the samples’ 608 
expression patterns. The classification algorithm to discern a ‘benign’ (negative test) from a 609 
‘suspicious’ (positive test) thyroid nodule results from a successful designer study that trained 610 
the GEC in both a tissue set and diverse FNAC sample sets with known histopathology (125). 611 
Alexander et al. performed the first prospective, blinded, industry-sponsored clinical study to 612 
validate this Afirma® GEC in patients with indeterminate thyroid nodules (126). From 49 613 
hospitals 577 Bethesda III, IV and V FNAC samples were collected, obtained by two 614 
additional needle aspirates from thyroid nodules with a diameter of at least 1 cm. After 615 
exclusion of over half (312/577, 54%) of the samples for reasons such as nodules that were 616 
not surgically resected, duplicate specimens from the same nodule, and issues with specimen 617 
shipments to Veracyte, finally 265 FNAC samples were included in the analysis. Sensitivity 618 
of the Afirma® GEC was 90% in the 129 Bethesda III as well as the 81 Bethesda IV nodules 619 
with a useful GEC-negative test result in 38% (100/265), but specificity was merely 53% and 620 
49%, respectively (52% on average). Despite the relatively high malignancy rate in Bethesda 621 
III nodules and the high number of exclusions, this study is well conducted and recognized 622 
worldwide as the landmark study that demonstrated the strength of the Afirma® GEC (126). 623 
After the overwhelming results from this key-publication, popularity of the GEC took flight. 624 
It is marketed as a highly accurate rule-out test for malignancy in thyroid nodules with 625 
indeterminate cytology.  626 
 627 
In 2014, the first multicentre study that retrospectively assessed the clinical utility of the 628 
Afirma® GEC was published. Only 6% of reported GEC-negative Bethesda III, IV and V 629 
nodules eventually underwent surgery, of which one resulted in a 6 mm mPTC. 630 
Unfortunately, data on GEC negative nodules were only reported on an aggregate level; exact 631 
test performance rates in Bethesda III and IV nodules cannot accurately be extracted from the 632 
publication. Less than half of the GEC-negative nodules without surgery (71/163, 44%) had 633 
clinical or radiological follow-up, ranging from 1 to 24 months (median 8 months) – a limited 634 
duration compared to the natural, indolent course of differentiated thyroid carcinoma. The 635 
published paper does not describe whether the remaining 92 patients with GEC-negative 636 
nodules received any follow-up at all. Despite evident limitations to the applied reference 637 
standards, Alexander et al. concluded that their results confirm both the accurate test 638 
performance from their prior study as well as the large impact that the Afirma® GEC has on 639 
clinical decision-making for cytologically indeterminate thyroid nodules (127). 640 
 641 
Yet, physicians indeed seemed reassured by a negative GEC result based on the first studies 642 
alone (126,128). In many institutions in the USA the Afirma® GEC was immediately 643 
implemented in clinical practice. The retrospective studies that followed were mere post-644 
implementation utility studies, and generally reported very high but moderately consistent 645 
sensitivities. GEC-negative nodules were largely managed without surgery and considered 646 
true-negative, resulting in possible overestimation of test sensitivity. Long-term follow-up is 647 
not yet available to endorse a benign diagnosis in these cases (129,130). The high degree of 648 
missing histology was recognized by most of these studies as a major limitation 649 
(127,129,131-134). This was confirmed by the 2015 ATA guidelines: recognizing the 650 
Afirma® GEC as a promising diagnostic tool, the guidelines stress that it is a major 651 
shortcoming that external clinical validation studies with full histological follow-up of 652 
Afirma® GEC-negative nodules are still lacking (23). 653 
Not all studies were able to confirm the potential of the Afirma® GEC. Some struggled with a 654 
low benign call rate (i.e. useful negative test result that could lead to management change) 655 
(130,135). McIver et al. questioned the cost-effectiveness of the Afirma® GEC in their 656 
population, as the mere 22% (16/72) negative test rate was much lower than anticipated. 657 
Moreover, a quarter of these GEC-negative patients rejected the proposed conservative 658 
treatment of ultrasound-based follow-up and underwent surgery anyway; one of them was 659 
diagnosed with a 3.2 cm FTC with focal capsular and vascular invasion. Also, 84% of GEC-660 
positive nodules proved histopathologically benign, overall resulting in a disappointing 83% 661 
sensitivity and 10% specificity (130).  662 
Besides concerns regarding adequate clinical validation of test performance, the post-663 
implementation influence of the GEC on surgical decision-making for individual patients was 664 
also questioned. In line with the results of their preliminary study, Noureldine et al. 665 
demonstrated that Afirma® GEC testing had not aided surgical decision-making (135,136). In 666 
93% (206/222) of the included indeterminate nodules, a ‘benign’ or ‘suspicious’ GEC result 667 
did not affect management at all: the surgical strategy would have been identical had it been 668 
based merely on clinical, cytological or radiological suspicion. However, if management 669 
changes were based on the GEC result, they were more often wrong than right: 11 times 670 
GEC-positive results inappropriately tempted physicians into more aggressive surgery, and 671 
total thyroidectomy was performed instead of the initially recommended lobectomy for 672 
nodules that proved histopathologically benign. In contrast, in just four GEC-positive cases 673 
the more aggressive surgery was appropriate and the nodule was histopathologically 674 
malignant. Also, in just one patient surgery was withheld specifically due to a negative 675 
Afirma® GEC result. In the other unresected GEC-negative nodules surgery was not 676 
clinically indicated to begin with; the negative GEC-result merely endorsed conservative 677 
management (135). As the GEC was still a new technology when this study was conducted, it 678 
is possible that the involved physicians were unsure of the correct interpretation of the GEC 679 
results or hesitant to rely on a negative GEC result. However, clinical suspicions and 680 
physician and patient preference will always be considered when making surgical decisions.  681 
Yang et al. elegantly tried to solve the shortcoming (histological) follow-up by comparing 682 
their findings of GEC performance to a pre-GEC cohort of similar patients from their hospital 683 
in all of whom surgery was performed (11,131). The reported malignancy rates were 684 
comparable pre- and post-GEC implementation (18% versus 17%), and obviously relatively 685 
more surgeries were performed for benign nodules in the pre-GEC period. Assuming the true 686 
malignancy rates in the successively studied populations are indeed similar, the GEC only 687 
modestly reduced the number of futile surgeries for benign thyroid nodules from 66% to 52% 688 
(131). Altogether, the contribution of the Afirma® GEC to the surgical decision-making may 689 
be more limited than expected based on its diagnostic accuracy. 690 
 691 
 692 
Availability, cost-effectiveness and limitations of the GEC 693 
The Afirma® GEC is currently only available for routine use in the USA. There are high 694 
demands for the FNAC specimens regarding sample preservation and shipping. Cytology is 695 
revised by Veracyte cytologists and declined if not strictly Bethesda III or IV, with 14% to 696 
17% discordancy between local assessment and central review, comparable to known 697 
interobserver rates for thyroid cytology (5,126,135). Reported rates of nondiagnostic GEC test 698 
results due to insufficient quantity or quality of the mRNA are substantial, varying from 1% 699 
to 17% (130,132). Insufficient mRNA quality was often caused by problems with long 700 
duration of the sample shipment to Veracyte (126,130). Fourth, Afirma® GEC testing is 701 
expensive and is currently marketed for $3,500 (range $1,750 to $7,000) per test 702 
(121,131,137). Testing for medullary carcinoma and BRAF mutation is not included in the 703 
Afirma® GEC, but can be performed by Veracyte at additional costs (131). Yet, ancillary 704 
BRAF mutation testing may not be relevant, as Kloos et al. found that it improved sensitivity 705 
nor specificity of the GEC (57). 706 
Studies of cost-effectiveness yielded variable results, but most concluded that GEC testing 707 
would not be cost-effective over conventional surgical management or other diagnostic 708 
modalities in various clinical settings (14,121,137-140). The first of these studies proclaimed 709 
cost-effectiveness of the GEC even prior to publication of the first validation study by 710 
Alexander et al., and has been criticized for several important methodological caveats. This 711 
study professedly overestimated test specificity at 75%, overestimated the rate of permanent 712 
complications from thyroid surgery, and did not consider the regularly reported GEC test 713 
failures (15-17,130,137,138,141). A recent study determined population-dependent thresholds 714 
for feasible cost-effectiveness by comparing GEC performance to conventional surgical 715 
management in a local Bethesda III/IV population. GEC-guided management was not cost-716 
effective, adding $1,197 to the $11,119 expenses for conventional treatment while hardly 717 
improving QALYs. Sensitivity analysis showed that the GEC would only become cost-718 
effective if its specificity exceeds 71%, if it costs less than $2,640, or if the population 719 
malignancy rate decreases from the actual 24% to below 9.2%. This price threshold for cost-720 
effectiveness decreases as the malignancy rate increases, as low as $2,023 per test at 35% 721 
cancer prevalence (137). 722 
Furthermore, existing inter-institutional differences in test performance have consequences 723 
for local applicability and effectiveness (127,134). Marti et al. compared GEC performance in 724 
distinct populations of two large hospitals. The reproducibility of the tests’ sensitivity and 725 
specificity was good, but utility strongly depended on the local prevalence of malignancy: as 726 
the population malignancy rate increased, a rarer negative GEC became less reliable to rule 727 
out malignancy. Oppositely, at low malignancy rates a negative GEC merely confirmed that 728 
the probability of cancer was low. In neither situation, the GEC changed the management 729 
strategy. GEC testing was most useful if the malignancy rate ranged between 15% and 21%, 730 
comparable to the prevalence reported by Alexander et al. (126,134).  731 
Finally, the degree of missing histology is a major limitation to the performed studies. None 732 
of the studies following the key publication by Alexander et al. had complete histopathologic 733 
follow-up; histopathological confirmation ranged between 35% and 82% of specimens (126).  734 
Missing histology mainly comprised GEC negative nodules, likely resulting in overestimated 735 
sensitivity (i.e. missing some malignancies in the many unoperated GEC-negative nodules) 736 
and underestimated specificity (i.e. relatively more GEC-positive nodules with benign 737 
histology (false-positives) were operated on than GEC-negative nodules with benign 738 
histology (true-negatives)). The trend that studies with higher surgical rates for GEC-negative 739 
nodules showed more moderate results supports these hypotheses (126,130,142).  740 
A recent meta-analysis by Santhanam et al. included seven studies and reported 96% pooled 741 
sensitivity and 31% pooled specificity for the GEC in Bethesda III, IV and V thyroid nodules 742 
with histopathological follow-up (143). The authors expected that more than 90% of patients 743 
with a negative test would be treated conservatively (143). However, in individual studies up 744 
to 25% of patients pursued surgery or conservative treatment despite GEC-based 745 
recommendation to do the opposite (127,130). This observation is crucial to cost-utility 746 
analyses. In addition, expensive rule-out tests such as the Afirma® GEC should not be 747 
performed in case surgery is considered for other reasons, such as cosmetic or mechanical 748 
complaints. 749 
 750 
GEC in Hürthle cell cytology 751 
Brauner et al. specifically validated the Afirma® GEC in 72 cytology samples suspicious for 752 
Hürthle cell neoplasm. They demonstrated that GEC testing could accurately have reduced 753 
the number of futile surgeries, although through a less profound reduction than in non-754 
oncocytic indeterminate thyroid nodules (132). Similar results were noticed in other studies: 755 
despite a relatively low risk of malignancy, the majority of Hürthle cell nodules were GEC-756 
positive. Regardless of good sensitivity, this unfavourable benign call rate in Hürthle cell 757 
cytology limits diagnostic efficacy in these nodules, increasing the number needed to test and 758 
negatively affecting possible cost-effectiveness (126,131,133,135,142,144). Diagnostic 759 
accuracy of the GEC would likely improve if Bethesda IV cytology suspicious for a Hürthle 760 
cell lesion was excluded from GEC testing. Otherwise, similar to the additional testing for 761 
medullary carcinoma, adaptations should be made to the Afirma® GEC to improve its clinical 762 
utility for Hürthle cell lesions. 763 
 764 
In conclusion, it is generally assumed that the Afirma® GEC accurately reclassifies 765 
approximately two out of five indeterminate thyroid nodules as benign with published 766 
sensitivities ranging between 83% and 100% and similar test performance in Bethesda III and 767 
IV nodules. Withholding diagnostic surgery from these patients seems safe 768 
(130,131,134,144). However, the diagnostic strength and potential cost-utility of Afirma® 769 
GEC strongly rely on its NPV – thus on the prevalence of malignancy and benign call rate in 770 
the targeted population. There are important concerns regarding the currently insufficient 771 
number of clinical validation studies with adequate rates of histopathological confirmation or 772 
long-term clinical follow-up. Physicians are strongly advised to locally validate Afirma® 773 
GEC test performance before considering test implementation in daily practice. Nonetheless, 774 
further large validation studies on the Afirma® GEC may soon become obsolete, as an 775 
updated version of the test, the Gene Sequencing Classifier (Veracyte Inc., South San 776 
Francisco, CA, USA), is currently being put into operation. Improved diagnostic accuracy is 777 
anticipated, with specific attention to the differentiation of Hürthle cell nodules.  778 
  779 
 780 
1.2. MicroRNA 781 
 782 
First described in thyroid cytology in 2006, evaluation of the expression levels of microRNA 783 
(also called miRNA) is among the newer and more promising approaches to differentiate 784 
between benign and malignant thyroid neoplasms (145,146). MicroRNAs are small 785 
endogenous noncoding ribonucleic acids (RNAs) of approximately 22 nucleotides in length. 786 
As negative regulators (i.e. silencers) of protein synthesis at a post-transcriptional level, they 787 
are involved in many intracellular processes, including cell growth, differentiation and 788 
proliferation. Dysregulation of microRNA expression is found in almost all types of human 789 
cancers (147). It reflects the deregulated expression of oncogenes and tumor suppressor genes 790 
(146,148-150). MicroRNA overexpression is present before morphological tissue changes are 791 
seen and therefore considered to be a part of premalignant changes in carcinogenesis (145). 792 
MicroRNA expression profiles are tissue-specific and can not only identify the tissue of 793 
origin, but also the histopathological subtype of the cancer and whether it concerns the 794 
primary tumor or a metastasis (148,151).  795 
MicroRNA expression profiles are similar among the various types of thyroid carcinoma, 796 
even though expression levels are often distinctively different (148). In histopathological 797 
studies, PTC was associated with an up to 11- to 19-fold upregulation of miR-146b, miR-221, 798 
miR-222, miR-181b, miR-187, and a downregulation of miR-1 and miR-138 compared to 799 
healthy thyroid tissue and benign nodules. Upregulation of miR-221, miR-222 and miR-187 800 
was also found in FTC, FTC-OV, poorly differentiated and anaplastic carcinoma 801 
(145,146,148,152,153). Overexpression of miR-146b-3p, miR-146b-5p and miR-375 was 802 
seen in both PTC and FVPTC (152,154). Furthermore, expression levels of miR-221 and 803 
miR-222 were reported about twice as high in FVPTC as compared to PTC or FTC (152). 804 
Only a few microRNAs were differently expressed between follicular neoplasm and FTC 805 
(155). Follicular adenoma was associated with the expression of miR-200a, whereas high 806 
expression of miR-31 was found in Hürthle cell adenoma (148). FTC is related to the 807 
differential expression of miR-146b, miR-7-5p, miR-346, miR-197 and miR-21, but results 808 
among studies are more heterogeneous (148,155,156). FTC-OV showed an expression pattern 809 
slightly similar to FTC, but also distinct overexpression of other microRNAs, such as miR-810 
339, miR-183, miR-197 and miR-885-5p (148,153).  811 
Accordingly, a diagnostic panel of a carefully selected combination of microRNAs and 812 
appropriate expression levels could aid in the preoperative distinction of indeterminate 813 
thyroid cytology (157). Recent meta-analyses struggled to reconcile the studies on microRNA 814 
in FNAC, as the investigated set of microRNAs was never identical and individual microRNA 815 
performance was infrequently described. In unselected cytology, estimated sensitivity of 816 
microRNA expression analysis ranged from 75% to 78% regardless of the investigated set; 817 
estimated specificity from 73% to 81% (156-158).  818 
In indeterminate thyroid cytology, different sets of microRNAs were evaluated; only several 819 
individual microRNAs were analyzed in more than one study. The selected microRNAs were 820 
first assessed in a test set of cytological and/or histopathological specimens and a cut-off for 821 
their expression level was determined. Subsequently, the significantly up- or downregulated 822 
microRNAs were validated in an independent set of (indeterminate) thyroid FNAC samples. 823 
Some studies developed a decision model for the validation step (149,154,159).  824 
The most promising results were presented by Keutgen et al. (159). Of the six microRNAs 825 
investigated in their test set, miR-21, miR-146b, miR-181a and miR-222 were differentially 826 
expressed in malignant nodules with prior indeterminate cytology. The subsequently 827 
developed support vector machine model incorporated miR-21, miR-222 and the 828 
insignificantly expressed miR-197 and miR-328. Prospective validation in an independent set 829 
of 72 indeterminate FNAC samples resulted in 100% sensitivity and 86% specificity. Five of 830 
the seven false positives had Hürthle cell cytology; excluding these, raised specificity to 95% 831 
(159). Notably, even though overexpression of miR-146b is often related to thyroid 832 
carcinoma, it proved not useful to Keutgen et al. to include in their prediction model (159). In 833 
contrast, Agretti et al. and Shen et al. included miR-146b as the key differentiators in their 834 
models. Agretti et al. assessed a frequently quoted set of microRNAs consisting of miR-146b, 835 
miR-155, miR-187, miR-197, miR-221, miR-222 and miR-224 (148,149). Published in 2008, 836 
Nikiforova et al. had demonstrated that this 7-microRNA set in FNAC samples had 100% 837 
sensitivity and 94% specificity if one of the included microRNAs showed an at least two-fold 838 
overexpression (148). Analytic validation of this model by Agretti et al. showed differential 839 
upregulation in PTC of all of these microRNAs except miR-197. In particular, miR-146b 840 
showed a >30-fold higher expression in PTC. A decision tree including miR-146b, miR-155 841 
and miR-221 was 98% accurate in the test set, but validation in an independent set of 842 
indeterminate FNAC samples was unsuccessful, yielding mere 60% sensitivity and 58% 843 
specificity (149).  844 
Vriens et al. used a microRNA array to detect 10 genes that were up- or downregulated by 845 
≥5-fold in thyroid malignancies. Four microRNAs (miR-100, miR-125b, miR-138 and miR-846 
768-3p) were significantly downregulated and accurately differentiated between benign and 847 
malignant follicular and Hürthle cell neoplasms in the test set. In their validation set of 125 848 
indeterminate FNAC samples, only miR-138 was moderately distinctive with 81% NPV. For 849 
Hürthle cell carcinoma, miR-138 and miR-768-3p were both 98% accurate (160).  850 
Finally, in a recent Italian study only miR-375 accurately differentiated between benign and 851 
malignant neoplasms. Subsequently, in TIR3 cytology excluding Hürthle cell lesions, a 12-852 
fold or higher overexpression of miR-375 perfectly distinguished benign from malignant 853 
lesions with 100% accuracy. It was also significantly differently expressed between TIR3A 854 
and TIR3B categories and correlated with a different malignancy risk (161).  855 
 856 
Availability and limitations of microRNA expression analysis 857 
MicroRNA expression analysis has advantages over other techniques. MicroRNAs are more 858 
stable than mRNA at maintaining their expression in formalin-fixed paraffin-embedded 859 
(FFPE) tissue samples as well as FNAC specimens, irrespective of the preservation method 860 
(e.g. archived FNAC slides or nucleic acid preservation solutions) (148,161). Recently 861 
microRNA expression was even successfully measured in serum (162). Moreover, microRNA 862 
expression levels measured with generic methods (e.g. quantitative RT-PCR) correspond well 863 
to their biological effect, as microRNAs affect biological processes without the additional 864 
step of protein synthesis (148).  865 
However, general limitations of FNAC also translate to concerns with microRNA analysis: 866 
scant cellularity or low levels of malignant cells in FNAC specimens could cause a false-867 
negative microRNA test result (149). Another limitation is the plurality of microRNAs 868 
associated with DTC in histopathological studies, causing vast heterogeneity between the 869 
limited number of studies in indeterminate cytology. Validation studies of the same 870 
microRNA set are lacking. Simultaneously, new microRNAs are still correlated to thyroid 871 
carcinoma. Ongoing research has yet to compose the optimal set of microRNAs. Recently, the 872 
first commercial test was marketed as the ThyraMIR™ (Interpace Diagnostics, Parsippany, 873 
NJ, USA). It evaluates the expression levels of miR-29b-1–5p, miR-31–5p, miR-138–1-3p, 874 
miR-139–5p, miR-146b-5p, miR-155, miR-204–5p, miR-222–3p, miR-375, and miR-551b-875 
3p. The ThyraMIR™ demonstrated 57% sensitivity and 92% specificity in 109 Bethesda III 876 
and IV FNAC specimens (22). Prospective clinical validation of the ThyraMIR™ could 877 
affirm the diagnostic value of microRNA expression profiling in indeterminate thyroid 878 
nodules in the pre-operative setting. 879 
 880 
1.3. Immunocytochemistry 881 
 882 
Tissue characterization through selective staining of expressed proteins, i.e. 883 
immunohistochemistry (IHC), is a technique that combines histopathology and biochemistry. 884 
Exploiting basic antigen-antibody interactions, IHC is able to visualize the distribution and 885 
localization of specific cellular components within the cell and in the proper tissue context. 886 
This includes tissue biomarkers specific for e.g. infection or malignancy. IHC has been fully 887 
incorporated in the histopathological routine and is crucial to morphological and molecular 888 
tissue characterization. When immunocytochemistry (ICC) – the application of this 889 
immunology-based technique in cytology – became available, the possibilities were extended 890 
to the preoperative setting, too. Specific immunomarkers have been developed to differentiate 891 
between benign and malignant thyroid nodules. The 2015 ATA guidelines acknowledge ICC 892 
as a technique under development with limited prospective validation studies in indeterminate 893 
cytology (23). In unselected thyroid cytology, the much-used immunomarkers galectin-3, 894 
Hector Battifora mesothelial-1 (HBME-1) and cytokeratin 19 (CK-19) demonstrated 85%, 895 
83% and 80% sensitivity, and 90%, 79% and 79% specificity, respectively (163).  896 
 897 
1.3.1. Galectin-3 898 
 899 
Galectin-3 is a β-galactosyl-binding protein from the lectin group. It is involved in cell-cycle 900 
regulation, including cell migration and adhesion. Its exact function is still to be unraveled, 901 
but a role in the pathogenesis and progression of PTC is presumed (44,163-165). It is related 902 
to inhibition of apoptosis, induced by abnormal p53 expression (165). Galectin-3 can be 903 
present both in the intracellular as well as the extracellular matrix (166). Normal thyrocytes 904 
do not express galectin-3, but the physiological expression of galectin-3 in macrophages, 905 
neutrophils, mast cells and Langerhans cells provides an internal positive control of the 906 
investigated FNAC samples (167,168). Positive cytoplasmic staining – as opposed to nuclear 907 
staining – for galectin-3 is suspicious for malignancy and mainly associated with PTC 908 
(117,169,170). Galectin-3 expression has also been associated with the malignant 909 
transformation of follicular neoplasms, as it was present in follicular adenoma as well as FTC 910 
(166,171,172). Encapsulated FVPTC and minimally invasive FTC showed less frequent and 911 
weaker staining (172,173).  912 
In 2001, Bartolazzi et al. argued that galectin-3 staining could accurately diagnose thyroid 913 
carcinoma in unselected thyroid cytology (117). Subsequent studies in indeterminate thyroid 914 
cytology mostly could not reproduce these promising results. With a positive stain in 915 
approximately a third of all nodules, sensitivity and specificity of galectin-3 ranged from 0% 916 
to 92% and from 68% to 100%, respectively (44,174-177). Merely Saggiorato et al. 917 
demonstrated that galectin-3 accurately differentiated follicular adenomas from FTC with 918 
92% sensitivity and 94% specificity if a cytoplasmic stain in ≥10% of the cells was 919 
considered positive (174). The prospective multicenter clinical validation study by Bartolazzi 920 
et al. demonstrated 78% sensitivity and 93% specificity in Thy3 nodules if a cytoplasmic 921 
galectin-3 stain in >5% of the cells was considered positive. Nineteen of the 22 false-positive 922 
nodules were follicular adenoma. However, a group of 33 difficult-to-diagnose (follicular) 923 
tumor of unknown malignant potential lesions was disregarded, 22 of which were galectin-3 924 
negative. If these neoplasms were considered malignant, sensitivity dropped to 69% (164). 925 
 926 
1.3.2. HBME-1 927 
 928 
HBME-1 is a monoclonal antibody targeting an unknown antigen on the microvilli of 929 
mesothelial cells. It is usually negative in normal thyroid follicular cells. Abnormal 930 
expression of HBME-1 shows cytoplasmic location with membrane accentuation. It is 931 
associated with, but does not necessarily indicate PTC (165,169,178,179). Its low detection 932 
limit enables assessment in liquid based cytology (180). Reported sensitivity and specificity 933 
of HBME-1 in indeterminate nodules ranged from 61% to 100% and from 75% to 96%, 934 
respectively (174,176,180,181). Approximately two out of five nodules showed positive 935 
staining. If only non-oncocytic follicular neoplasms were selected, Saggiorato et al. 936 
demonstrated that HBME-1 had excellent 93% sensitivity and 98% specificity in 937 
indeterminate thyroid nodules (174).  938 
 939 
1.3.3. Cytokeratin 19 940 
 941 
Cytokeratin 19 (CK-19) is a type I keratin. It belongs to the group of intermediate filament 942 
proteins, which arrange the cell cytoskeleton and structural integrity. CK-19 is widely present 943 
in epithelial cells, but also found in basal cells layers of stratified epithelium (174,182). 944 
Strong and diffuse abnormal expression of CK-19 indicates PTC, including FVPTC. 945 
Expression in FTC is less intense and more variable, warranting nuanced interpretation of 946 
CK-19 staining intensity. CK-19 usually shows no or only focal expression in follicular 947 
neoplasms, hyperplastic nodules and adenomatous goiter (174,178,182,183). The reported 948 
sensitivities and specificities for CK-19 staining in indeterminate cytology ranged from 76% 949 
to 88% and 80% to 100%, respectively (174,180,182). Lacoste-Collin et al. demonstrated the 950 
importance of an accurate threshold. CK-19 staining in 31 Bethesda IV nodules accurately 951 
diagnosed five out of six malignancies, including a PTC, two FTC and two out of three 952 
FVPTC. At a threshold of ≥30% stained cells, 5 of 25 benign lesions tested false-positive; at a 953 
more sensitive threshold of ≥10% stained cells, 12 of 25 tested false positive (180).  954 
 955 
1.3.4. Other immunocytochemistry markers 956 
 957 
Immunohistochemistry studies identified more potential ICC markers. Some, like CD44v6, 958 
have not yet been investigated in indeterminate cytology (117). Other markers were 959 
sporadically investigated in preclinical studies, including Ki-67, TROP-2, emerin, keratan 960 
sulphate, thyroperoxidase, CD57 and GLUT-1.  961 
Nuclear protein Ki-67 is expressed in nearly all cell cycle phases in proliferating cells. It is 962 
associated with poor prognosis in PTC (184). The percentage of cells with Ki-67 expression is 963 
considered the tissues’ proliferative index. At a cutoff of ≥1% Ki-67 was 85% sensitive and 964 
71% specific for thyroid carcinoma in Bethesda IV nodules. A combination of HBME-1, CK-965 
19 and Ki-67 immunomarkers was 91% accurate to diagnose malignancy (180). Ki-67 966 
expression is likely only distinctive for follicular type carcinoma; expression in PTC is 967 
generally low (180,184,185).  968 
Glycoprotein human trophoblast cell surface marker (TROP-2) is overexpressed on the cell 969 
surface of different epithelial carcinoma (e.g. breast, colon) and associated with tumor 970 
aggressiveness and poor prognosis. In indeterminate thyroid cytology, it was only assessed in 971 
one small subseries of Bethesda III samples, correctly diagnosing the three included 972 
carcinoma and all but one of the nine benign nodules (186).  973 
Emerin staining emphasizes features of the nuclear membrane often seen in PTC, such as 974 
irregularities and invaginations. Consequently, the stain could facilitate the morphological 975 
diagnosis of PTC and especially the more difficult-to-diagnose FVPTC (176,187). In 53 Thy3 976 
nodules assessed by Asioli et al., positive emerin staining was highly specific for PTC 977 
(including FVPTC), but misdiagnosed all FTCs (176).  978 
Another immunomarker associated with PTC is keratan sulphate, an abnormal 979 
glycosaminoglycan complex. It was 98% specific in indeterminate cytology, but correctly 980 
predicted PTC only; its sensitivity was poor at 48% (174). 981 
The expression of thyroid peroxidase (TPO) is related to benign follicular neoplasms. A 982 
negative TPO stain was 80% sensitive and 86% specific for thyroid malignancy (174).  983 
Finally, CD57 (Leu7) expression is associated with epithelial and nonepithelial malignancies, 984 
including thyroid carcinoma. Cytological staining was only investigated in a small series of 985 
indeterminate cytology, but seemed specific for PTC. In the same series, GLUT-1 was not a 986 
useful ICC marker – there were no positive stains (188).  987 
 988 
Combined use of immunocytochemistry markers 989 
Some research groups have suggested that evident single-marker galectin-3 positivity is 990 
sufficient to refer a patient for total thyroidectomy (164,170,177). The ATA guidelines did 991 
not adopt these suggestions, and many other researchers advocate that a panel of ICC markers 992 
should be applied to strengthen the suspicion of malignancy (23,165,174,179). Several panels 993 
were investigated in literature. Zhang et al. assessed a triple stain of galectin-3, HBME-1 and 994 
p27. P27 is a cyclin-dependent kinase inhibitor related to cell life span in normal thyroid cells. 995 
Downregulated in malignancy, positive P27 stain is related to benign histopathology. In a set 996 
of Bethesda III cytology samples, positive p27 staining with negative galectin-3 and HBME-1 997 
staining was 100% predictive of a benign nodule and occurred in 38% of samples. Loss of 998 
p27 staining in combination with positive galectin-3 and/or HBME-1 staining was 100% 999 
sensitive and 86% specific (165). Another study investigated galectin-3 and HBME-1 in 1000 
combination with a RET proto-oncogene stain, which reflects abnormal intracellular RET 1001 
proto-oncogene activity and presence of the RET/PTC rearrangement. Unfortunately, RET 1002 
staining was inaccurate in indeterminate thyroid nodules (181).  1003 
To find the most accurate combination of immunostains, Saggiorato et al. explored the 1004 
expression of galectin-3, HBME-1, thyroperoxidase, CK-19 and keratan-sulphate in 125 1005 
cytological follicular neoplasms, 24 of which were Hürthle cell lesions. Galectin-3 was not 1006 
only the most accurate marker individually, but also in combination with other stains. 1007 
Sequential HBME-1 staining of galectin-3-negative cases reached 98% sensitivity and 98% 1008 
specificity in non-oncocytic lesions. In oncocytic lesions, sequential CK-19 staining was more 1009 
preferred with 100% sensitivity and 100% specificity (174).  1010 
The common denominator between all these studies is the combined use of galectin-3 and 1011 
HBME-1. Unfortunately, clinical validation studies regarding this combination are limited. Its 1012 
seemingly promising diagnostic accuracy warrants further assessment in future prospective 1013 
studies. 1014 
 1015 
Performance of immunocytochemistry in Hürthle cell cytology 1016 
Expression of ICC markers in Hürthle cell nodules differs from non-oncocytic indeterminate 1017 
cytology. Hürthle cell carcinomas were distinguished in the cytological samples by typical 1018 
overexpression of markers associated with a high degree of cell proliferation, disorganized 1019 
tissue structure and intermediate differentiation, such as Ki-67, laminin, cyclin D1 and cyclin 1020 
D3. Overexpression reflects the known more erratic behavior of Hürthle cell carcinoma 1021 
(185,189). Moreover, markers that were highly diagnostic in indeterminate nodules in 1022 
general, also seem differently expressed in Hürthle cell lesions. Saggiorato et al. 1023 
demonstrated that two combinations of ICC markers were extraordinarily accurate: galectin-3 1024 
and CK-19 staining was 100% sensitive and 100% specific; galectin-3 and thyroperoxidase 1025 
staining was 100% sensitive and 85% specific (174).  1026 
In a previous meta-analysis, inclusion of Hürthle cell lesions was related to between-study 1027 
heterogeneity (163). Hürthle cell lesions require a biotin-free ICC method, as Hürthle cells 1028 
themselves are rich in biotin. Thus, much-used biotin-based methods may consequently cause 1029 
false positive and highly intensive staining in Hürthle cell neoplasms (166,172,181).  1030 
 1031 
Availability, cost-effectiveness and limitations of immunocytochemistry 1032 
Current application of immunocytochemistry is limited. Clinical validation studies for all of 1033 
the described immunomarkers are scarce, and no cost-effectiveness studies are available to 1034 
date. Yet, the technique is widely available, relatively inexpensive and fast in comparison to 1035 
other (molecular) techniques. Costs per immunostain vary up to €20, partly depending on 1036 
simultaneous local application of the technique and similar stains for immunohistochemistry.  1037 
Immunocytochemistry is preferably performed on cell block FNAC specimens, but can be 1038 
performed in all types of cytology, from direct smears to liquid-based cytology (179,181). 1039 
ICC is impossible when the FNAC specimen has poor cellularity or too much obscuring blood 1040 
(190). Also, immunostaining of cytology is technically more difficult than histological 1041 
staining, especially in (destained) cytology smears. Technical inconsistency and interobserver 1042 
variation likely lead to false-negative results (164,182). Stain intensity thresholds or 1043 
percentage of stained cells necessary to raise suspicion of malignancy vary in the available 1044 
literature. Consistent methodology and assessment thresholds should be determined to 1045 
improve reproducibility of ICC results.  1046 
Clinical validation studies of existing ICC markers are ongoing. Meanwhile, new markers are 1047 
also playing the field, searching for the interfaces between mutation analysis of highly 1048 
specific oncogenic driver mutations and accessible ICC techniques. For example, Leslie et al. 1049 
investigated ICC of the BRAFV600E mutation using the mutation specific antibody VE1 in a 1050 
small series of thyroid FNAC samples. Concordance between ICC and conventional 1051 
BRAFV600E mutation analysis was 85%. All samples that were BRAFV600E positive by either 1052 
method were confirmed as BRAFV600E positive PTC on histopathology. Of the eight included 1053 
indeterminate thyroid nodules, seven were histopathologically malignant and BRAFV600E 1054 
mutation was detected in two nodules: one by both methods, one only by molecular analysis. 1055 
The BRAFV600E specific antibody (VE1) stain was much weaker in cytology than in histology. 1056 
Moreover, costs of the VE1 antibody are currently high and optimization of methodology is 1057 
warranted. Yet, Leslie et al. demonstrated that BRAFV600E mutation analysis using ICC is a 1058 
promising alternative to mutation analysis (79). If future studies could validate these results in 1059 
larger cohorts of indeterminate thyroid nodules and detect reliable immunomarkers for other 1060 
oncogenic driver mutations, this technique unites the strengths of gene mutation analysis and 1061 
immunocytochemistry in one technique, though likely at lower costs.  1062 
 1063 
In general, ICC is a widely available and relatively inexpensive technique with a reasonable 1064 
diagnostic accuracy. Many immunomarkers seem to have a pronounced association with PTC. 1065 
Galectin-3 and HBME-1 were most frequently investigated, but their specificities and 1066 
sensitivities seem to fall short of justifying ICC-based surgical decision making. Diagnostic 1067 
accuracy of their combined use seems promising, yet current evidence is limited. Prospective 1068 
validation trials are warranted to confirm the diagnostic potential of ICC, including validation 1069 
of thresholds for stain positivity, panels of multiple immunostains and other methodology.  1070 
 1071 
2. CONVENTIONAL IMAGING 1072 
 1073 
2.1. Ultrasound 1074 
 1075 
Ultrasound (US) is one of the principal steps in the initial work-up of thyroid nodules. It is 1076 
cheap, fast, non-invasive and globally available, but accurate assessment strongly depends on 1077 
operator experience (191). Multiple meta-analyses showed that well-known US features such 1078 
as nodule hypoechogenicity, microcalcifications, irregular margins (including microlobulated 1079 
or ill-defined margins), and a taller-than-wide shape raise the suspicion for thyroid 1080 
malignancy and are mostly associated with PTC (191,192). Nonetheless, no single US feature 1081 
is sufficiently sensitive nor specific to accurately identify a malignant nodule in an unselected 1082 
population (191). Certain combinations of US features, however, may offer accurate closure. 1083 
The current ATA guidelines now include a flowchart recommending FNAC dependent on 1084 
nodule size and various combinations of US characteristics with an incremental risk of 1085 
malignancy (23). Despite the obvious importance of both ultrasound and cytology, the ATA 1086 
guidelines do not provide recommendations regarding (re-)interpretation of US characteristics 1087 
after FNAC has resulted in indeterminate cytology. Follicular-type malignancies typically 1088 
have a different US appearance. More often FTC may be iso- to hyperechoic, with a spherical 1089 
shape, smooth regular margins and no calcifications (193,194). FVPTC may also show FTC-1090 
like or benign features rather than the classic suspicious features, although microcalcifications 1091 
may be distinctive (194-196). In the past years, Brito et al. and Remonti et al. performed 1092 
meta-analyses on US assessment of unselected thyroid nodules. Both also briefly discussed its 1093 
diagnostic value in indeterminate nodules, including a mere limited number of studies and 1094 
also including cytology suspicious for malignancy. Increased central vascularization was most 1095 
predictive of malignancy with reported 96% specificity (192). Yet, in general US seemed less 1096 
accurate in indeterminate nodules than in unselected thyroid nodules (191,192).  1097 
 1098 
In the dozens of available original ultrasound studies, individual US features generally 1099 
demonstrated limited sensitivity in indeterminate thyroid nodules. Only the appearance of a 1100 
solid thyroid nodule – as opposed to varying degrees of cystic content – had high sensitivity. 1101 
Ranging between 46% and 100%, multiple studies demonstrated sensitivity above 90% 1102 
(18,19,197-201).  1103 
A number of classic suspicious US characteristics, such as a taller-than-wide shape, presence 1104 
of irregular margins and presence of microcalcifications, demonstrated valid specificity in 1105 
indeterminate thyroid nodules. Specificities for each of these characteristics ranged from 72% 1106 
to 99% (201-204), 65% to 100% (202,205,206) and 36% to 100%, respectively (207,208). 1107 
Despite the wide range, presence of microcalcifications was more than 90% specific in many 1108 
studies (197,198,200,202-204,206,207,209-211). Large nodule size (defined as a diameter 1109 
larger than 4 cm) was only investigated in a limited number of studies. Reported specificities 1110 
ranged between 69% and 94% (207,212).  1111 
Other features, such as a solitary nodule, hypoechogeneity and absence of a hypoechoic halo 1112 
were associated with thyroid malignancy, but less accurately differentiated between benign 1113 
and malignant indeterminate thyroid nodules (198,201,206,212-217). Additionally, opposing 1114 
the results from one of the mentioned meta-analyses, central vascularization also does not 1115 
seem very accurate in indeterminate thyroid nodules. Specificity ranged from 0% to 100%, 1116 
although multiple studies demonstrated extremely poor specificity (18,202,216-220).  1117 
 1118 
Results regarding two US features are remarkably contradicting. First, the absence of a 1119 
hypoechoic halo is typically considered suspicious for malignancy, but showed overall poor 1120 
and very heterogeneous diagnostic potential in indeterminate thyroid nodules (191). 1121 
Sensitivity and specificity ranged from 17% to 99% and 0% to 93%, respectively 1122 
(200,201,205,221,222). Presence of a hypoechoic halo is typically considered a benign 1123 
feature, but has also been associated with follicular types of thyroid carcinoma (223). Dogan 1124 
et al. reported 88% specificity for presence of a halo in AUS/FLUS nodules and 78% in 1125 
FN/SFN nodules (224). Second, the ultrasonographic nodule shape seems ambiguous. Similar 1126 
to the unselected population, a typically suspicious taller-than-wide shape was generally 1127 
specific for carcinoma, with reported specificities up to 99% (201,202,204). A spherical shape 1128 
is generally considered benign, but has also been associated with FTC (191,193,225). In two 1129 
studies in cytological follicular neoplasms, a spherical shape had an increased risk of 1130 
malignancy, with 86% to 97% sensitivity and 19% to 26% specificity (226,227). Chin et al. 1131 
even suggested that follicular neoplasms with a taller-than-wide shape could be treated 1132 
conservatively (227). The uniquely balanced rates of PTC, FVPTC and FTC resulting from 1133 
indeterminate cytology may explain why these and various other US characteristics have 1134 
different diagnostic accuracy than in the unselected population. Dependent on the local case 1135 
mix, accurate differentiation of indeterminate nodules using the classical suspicious US 1136 
features may or may not be feasible.  1137 
 1138 
Combination of ultrasound characteristics  1139 
A combination of US characteristics likely provides more accurate differentiation than 1140 
individual features. Different combinations were investigated in multiple studies 1141 
(81,197,198,200,204-206,216,228-233). Yoo et al. reported 100% specificity for the 1142 
combination of marked hypoechogenicity and taller-than-wide shape, a pattern that occurred 1143 
in 9.6% (24/249) of the included Bethesda III nodules (201). In the elastosonography study by 1144 
Rago et al., absence of a hypoechoic halo in combination with presence of microcalcifications 1145 
was 95% specific for thyroid malignancy, but only 6.4% sensitive (222). Maia et al. found 1146 
62% sensitivity and 89% specificity in Bethesda III and IV nodules if hypoechogenicity, 1147 
microcalcifications, an irregular margin and increased intranodular vascularity were 1148 
considered suspicious (230). Gulcelik et al. demonstrated that the US pattern of a solid, 1149 
hypoechoic nodule with microcalcifications had 95% sensitivity and 99% specificity. The 1150 
pattern was seen in 21% of cytological follicular neoplasms (234).  1151 
In multiple studies it was argued that cytological follicular neoplasms with a typically benign 1152 
ultrasound pattern – a regular shape, isoechoic, homogeneous, with well-defined margins, 1153 
cystic components or peripheral vascularity only, and not a single malignant feature - could 1154 
be safely followed up clinically instead of undergoing diagnostic surgery (200,225,228). 1155 
Consideration of more features generally increased the sensitivity of the US assessment at the 1156 
cost of its specificity (198,199). The terms of their interpretation were crucial: Norlén et al. 1157 
demonstrated that US was 95% sensitive and 48% specific if a Bethesda III nodule had either 1158 
hypoechoic appearance, irregular margins or microcalcifications. If solely the simultaneous 1159 
presence of all three features was considered suspicious for malignancy, sensitivity dropped 1160 
to 37% but specificity increased to 96% (231).  1161 
Altogether, diagnostic ultrasound scores or step-by-step algorithms could aid the 1162 
classification of US patterns and consequent risk of malignancy (200,228,235). Best-known 1163 
and most validated is the Thyroid Imaging Reporting and Data System (TIRADS), a 1164 
classification to risk-stratify thyroid nodules, designed by Horvath et al. and modified by 1165 
Kwak et al. following the example of the similar BIRADS classification for breast lesions 1166 
(236,237). The TIRADS assigns nodules to a risk category based on five suspicious US 1167 
features: solid appearance, (marked) hypoechogenicity, irregular margins, microcalcifications 1168 
and a taller-than-wide shape. Nodules without any of these features are likely benign and 1169 
categorized as TIRADS 3. Their risk of malignancy is ~1.7% in a cytologically unselected 1170 
population. TIRADS 4 includes suspicious nodules, which are further classified according to 1171 
an increasing malignancy risk into 4a (one suspicious US feature), 4b (two suspicious 1172 
features) and 4c (three or four suspicious features). Nodules with all five suspicious US 1173 
features are classified as TIRADS 5 and associated with a high 88% risk of cancer in an 1174 
unselected population (236). Studies that validated the TIRADS specifically in indeterminate 1175 
thyroid nodules, showed that diagnostic accuracy depended on the chosen cutoff score and 1176 
type of cytology (202,235,238-241). Although TIRADS 5 scores were infrequently assigned 1177 
in indeterminate nodules, a higher TIRADS score (4b/4c/5) was an accurate predictor of 1178 
malignancy, especially in Bethesda IV cytology (202,238,240). In Bethesda III nodules, lower 1179 
TIRADS scores (3/4a) could also rule out malignancy (238,241). Prospective validation 1180 
studies applying the TIRADS in indeterminate cytology are warranted to assess its possible 1181 
clinical utility in indeterminate nodules.  1182 
 1183 
US performance in Hürthle cell nodules 1184 
Cytological Hürthle cell nodules expressed a large variation of US characteristics 1185 
(203,208,212,223). Many malignant and most benign Hürthle cell nodules had a benign US 1186 
appearance (208,223). Only three US features possibly predictive of malignancy were 1187 
reported in individual studies: both hypoechogenicity and hyperechogenicity (as opposed to 1188 
isoechogenicity) (208), large nodule size (223), and microcalcifications (203). Despite limited 1189 
evidence, US evaluation does not seem reliable to differentiate Hürthle cell lesions.  1190 
 1191 
Availability and limitations of ultrasonography 1192 
The major advantages of ultrasound over other additional diagnostics are its already 1193 
permanent position in the workup of thyroid nodules, global availability and low costs. No 1194 
additional resources nor hospital visits are needed to include US interpretations in 1195 
preoperative management decisions and the investigation is noninvasive. Nonetheless, besides 1196 
known limitations concerning interobserver variability and less reliable interpretation of small 1197 
nodules, US feasibility in indeterminate thyroid nodules is limited by the presumed 1198 
differences in US appearance of papillary and follicular thyroid malignancies, illustrated by 1199 
the conflicting results for nodule shape and hypoechoic halo in indeterminate nodules. 1200 
Consequently, local diagnostic accuracy likely follows variations in the local 1201 
histopathological case mix.  1202 
In addition, many of the available ultrasound studies are retrospective, limiting the power of 1203 
the evidence. As the decision to perform FNAC is customarily based on the results of the 1204 
prior US, the prevalence of suspicious US features in indeterminate cytology in these studies 1205 
is presumably overestimated.  1206 
 1207 
Nonetheless, several individual US characteristics seem to have reasonable specificity in 1208 
indeterminate nodules, although insufficient for accurate diagnosis. A combination of US 1209 
features is likely more accurate, although current evidence does not support US-based 1210 
surgical decision-making. We propose that a future meta-analysis should use the individual 1211 
patient data from the large number of available original studies to develop an ultrasound 1212 
algorithm specifically for indeterminate thyroid nodules. The existing TIRADS needs 1213 
prospective validation.  1214 
Even though more advanced and less operator-dependent techniques might be preferred, US 1215 
features should always be assessed in current clinical practice. The presence of one or more 1216 
suspicious US features in a Bethesda III or IV nodule increases the suspicion of malignancy 1217 
and underpins the need for a definite diagnosis. Moreover, to centers or regions with limited 1218 
access to other (molecular) diagnostics, ultrasound may definitely have clinical utility, 1219 
pending local validation in the indeterminate population.  1220 
 1221 
2.2. Elastosonography 1222 
 1223 
Firm consistency of a thyroid nodule upon palpation is considered suspicious for malignancy 1224 
– an established principle during physical examination (242). Ultrasound elastosonography 1225 
(USE) is a dynamic ultrasound technique that is sometimes referred to as ‘electronic 1226 
palpation’. Tissue elasticity is evaluated by measuring tissue distortion while applying a 1227 
standardized dosed external force by the US transducer. It was first applied to the thyroid 1228 
gland by Lyshchik et al. in 2005 (243). Classic real-time qualitative USE is performed by 1229 
free-hand compression and a sine-wave or numerical scale showing how much pressure the 1230 
operator applies with the probe. A color-coded elastosonography image is superimposed on 1231 
the grey-scale US images: red and orange visualizes high tissue elasticity (soft tissue), green 1232 
represents intermediate elasticity and blue low elasticity (firm tissue). Several score systems 1233 
are available. The original score was developed by Itoh et al. in 2006 for the evaluation of 1234 
breast tumors and considers scores 1-3 benign on a scale of 1 (highest elasticity) to 5 (no 1235 
elasticity) (244). Rago et al. first applied it to thyroid tumors and modified it to a 3-point 1236 
score (222,245). Asteria et al. derived a modified 4-point score (246).  1237 
The earliest studies in thyroid nodules reported opportune results of USE as an additional 1238 
modality to B-mode ultrasound, but were heterogeneous in USE technique and study 1239 
population (247). A recent meta-analysis by Nell et al. included twenty studies on qualitative 1240 
USE prior to FNAC and concluded that qualitative USE is fit to diagnose benign nodules and 1241 
safely dismiss FNAC, provided that the usual elasticity score cutoff is abandoned and only 1242 
completely soft nodules (score 1 of all systems) are classified as benign. Pooled 99% 1243 
sensitivity and 99% negative predictive value demonstrated the ability of USE to reliably 1244 
rule-out malignancy in entirely soft thyroid nodules, composing 14% of their pooled study 1245 
population (248).  1246 
 1247 
In individual studies on USE in indeterminate nodules, sensitivity and specificity of 1248 
qualitative USE ranged from 47% to 97% and from 6% to 100%, respectively 1249 
(19,213,221,222,249). Results of several qualitative USE studies stand out. Lippolis et al. 1250 
showed an aberrant 6.1% specificity, because they reported only eight nodules with high 1251 
elasticity – 62 of 66 benign nodules were not elastic. The authors themselves suggest that a 1252 
rather homogenous study population with predominantly small nodules with a solid US 1253 
pattern, absence of cystic areas, and follicular histology with minimal colloid could be 1254 
explanatory for the poor specificity rather than operator-dependent causes (213). Such 1255 
possible relations remain undescribed in other studies. A meta-analysis on the value of USE 1256 
in indeterminate thyroid nodules demonstrated meager pooled 69% sensitivity and 75% 1257 
specificity (250). 1258 
 1259 
As manually applied pressure is difficult to standardize, qualitative USE is strongly operator 1260 
dependent (251). Different USE techniques have been developed to improve objectivity, such 1261 
as semi-quantitative tissue-to-nodule strain ratio indices (also based on manual compression). 1262 
Studies investigating semi-quantitative USE in indeterminate thyroid nodules reported 1263 
sensitivity and specificity ranging from 82% to 100% and from 88% to 100%, respectively 1264 
(215,217,219,249). Furthermore, quantitative shear wave USE measures the propagation 1265 
velocity of focused acoustic pulses – shear waves – from the probe, which correlate to tissue 1266 
stiffness (Young’s modulus) (18,252). It had 82% sensitivity and 88% specificity in a recent 1267 
prospective pilot study by Samir et al.(18). Performance of (semi-)quantitative USE seems 1268 
better than qualitative USE, but results are subject to overfitting from the ROC analysis 1269 
performed to determine the strain ratio cutoff value with the highest sensitivity and 1270 
specificity. None of the studies applied a predefined cutoff or validated their own cutoff 1271 
externally. Consequently, the resulting thresholds were hardly comparable (215,217,219,249).  1272 
 1273 
Altogether, the results from currently available studies cannot support surgical decision-1274 
making in thyroid nodules with indeterminate cytology using elastosonography in any of its 1275 
forms. Whereas color-coded qualitative USE has insufficient sensitivity and specificity, the 1276 
semi-quantitative method lacks validation. The power of the available evidence is additionally 1277 
limited by both methodological heterogeneity and the use of different USE techniques, image 1278 
processing and elasticity scoring methods across studies. Nevertheless, the suggested 1279 
promising rule-out capacity of qualitative USE when applying an alternative cutoff score of 1 1280 
in unselected nodules, deserves clinical validation in indeterminate thyroid nodules. Major 1281 
advantages of the technique are the minor extra costs of USE, as it can be performed during 1282 
regular thyroid US with the same equipment, and only adds approximately 5 minutes to the 1283 
procedure time per patient. Cost-effectiveness will largely depend on performance of USE, 1284 
but no cost-effectiveness studies in indeterminate thyroid nodules are available to date. 1285 
 1286 
2.3. Computed Tomography 1287 
 1288 
There are no studies that investigated computed tomography (CT) scanning in thyroid nodules 1289 
with indeterminate cytology. Prior studies indicated that CT cannot accurately differentiate 1290 
thyroid carcinoma (253,254).  1291 
 1292 
3. FUNCTIONAL AND MOLECULAR IMAGING 1293 
 1294 
3.1. 99mTc-MIBI  1295 
 1296 
Hexakis(2-methoxy-2-methylpropylisonitrile)technetium[99mTc] (99mTc-MIBI) is a 1297 
Technetium-99m-labeled radiopharmaceutical, primarily known for its use in myocardial 1298 
perfusion imaging since the 1980s and more recently the evaluation of hyperparathyroidism. 1299 
Uptake of 99mTc-MIBI, a lipophilic cation, reflects both perfusion and the number of active 1300 
mitochondria in the cells of the thyroid nodule and thus its oxidative burden (70,255).  1301 
99mTc-MIBI scintigraphy is more suitable for the differentiation between benign and 1302 
malignant thyroid nodules than scintigraphy with 99mTc-pertechnetate (99mTcO4
-) or 1303 
radioisotopes of iodide (often 131I-,123I- or 124I-). These latter tracers interrogate the sodium-1304 
iodide symporter of the thyrocyte and are frequently used to assess thyroid nodule functioning 1305 
to distinguish autonomous (“hot”) from hypofunctioning (“cold”) nodules. They are neither 1306 
specific nor effective to detect malignancy: benign nodules can be anything from hyper- to 1307 
hypofunctioning, and far outnumber the carcinomas. Still, thyroid malignancies are almost 1308 
always hypofunctioning: decrease of the sodium-iodide symporter or thyroid peroxidase are 1309 
hallmarks of cell dedifferentiation and lead to loss of iodide-trapping function and thus 99mTc-1310 
pertechnetate or radioiodine uptake (23,255-257). 99mTc-MIBI uptake is independent of iodide 1311 
trapping and organification in the thyrocytes. Nodules with increased uptake and late 1312 
retention of 99mTc-MIBI are suspicious for malignancy (70,255). A 2013 meta-analysis by 1313 
Treglia et al. demonstrated 82% sensitivity and 63% specificity for 99mTc-MIBI scintigraphy 1314 
in clinically suspicious, hypofunctioning, cytologically unselected thyroid nodules. 1315 
Hyperfunctioning benign adenomas can show false-positive increased uptake of 99mTc-MIBI 1316 
due to their increased metabolic needs, thereby decreasing test specificity (255).  1317 
Only three studies investigated the role of 99mTc-MIBI in indeterminate thyroid nodules. In all 1318 
studies, evaluation of thyroid nodules was performed by dual-time planar imaging: an early 1319 
image was made ranging from 10-20 minutes after injection of the radiopharmaceutical and a 1320 
delayed image 60-120 minutes post injection. The intensity of the 99mTc-MIBI uptake within 1321 
the nodule, and possible increased uptake or denoting retention on delayed imaging were 1322 
assessed and compared to the physiological washout of the tracer from normal thyroid tissue. 1323 
A visual pattern of increased 99mTc-MIBI uptake on early images that persisted or further 1324 
increased on the delayed images was generally considered suspicious for malignancy. The 1325 
individual study sensitivity and specificity for this interpretation ranged from 56% to 79% and 1326 
from 52% to 96%, respectively (19,70,258). Despite the limited number of available studies, 1327 
the performance of 99mTc-MIBI in indeterminate thyroid nodules seems insufficient and less 1328 
accurate than in cytologically unselected nodules (255).  1329 
Nonetheless, Giovanella et al. demonstrated that NPV for this method could increase from 1330 
88% to 100% if only the pattern of 99mTc MIBI uptake lower than or equal to the 1331 
pertechnetate uptake within the nodule was considered benign. As few benign lesions 1332 
expressed this uptake pattern, this would decrease the yield of this diagnostic (70).  1333 
Piccardo et al. did not preselect hypofunctioning lesions, but included all indeterminate 1334 
thyroid nodules. As expected given the explanation above, the specificity of 99mTc-MIBI was 1335 
poor: 52% (19). 1336 
Assessment of a retention index of the tracer based on semi-quantitative measurements of the 1337 
lesion to non-lesion uptake ratios for early and delayed 99mTc-MIBI images yielded better 1338 
accuracy. Optimal thresholds for the retention index were determined using ROC analysis and 1339 
unfortunately not externally validated (70,258). As such, it is unclear whether semi-1340 
quantitative 99mTc-MIBI retention indices are truly more accurate than conventional visual 1341 
assessment. Moreover, semi-quantitative analysis is still operator dependent, as it depends on 1342 
the manual definition of ranges of interest (ROI)(19).  1343 
 1344 
99mTc-MIBI in thyroid nodules with Hürthle cell cytology  1345 
Oncocytic cells are rich in mitochondria. Therefore, Hürthle cell lesions – malignant as well 1346 
as benign – frequently show a more intense and persistent 99mTc-MIBI uptake (258-260). Boi 1347 
et al. investigated 99mTc-MIBI in cold thyroid nodules with varying proportions of Hürthle 1348 
cells in the cytology samples. A relation between 99mTc-MIBI uptake and increased tissue 1349 
density of oncocytes was suggested (260). Subsequent studies also concluded that 99mTc-1350 
MIBI is not specific enough to differentiate indeterminate lesions with Hürthle cell cytology 1351 
(70,255,258). Excluding Hürthle cell nodules from 99mTc-MIBI assessment likely excludes 1352 
many false-positive tests while improving benign call rate, specificity and overall diagnostic 1353 
accuracy in indeterminate thyroid nodules.  1354 
 1355 
Availability, cost-effectiveness and limitations of 99mTc-MIBI 1356 
Imaging of 99mTc-MIBI requires conventional gamma cameras (with or without single-photon 1357 
emission computed tomography (SPECT) and CT), which are more widely available than 1358 
PET, especially in non-Western countries. Furthermore, the tracer itself is more widely 1359 
available due to relatively simple complexation using 99mTc-MIBI-kits together with the 1360 
favorable half-life of 99mTc (~6 hours) obtained from on-site generators. The radiation burden 1361 
of the recommended whole-body adult dose is 5-6 millisievert, but can be lowered by a factor 1362 
2-3 by partial-body imaging (261). However, the system resolution of state-of-art gamma 1363 
cameras is a factor 3 lower than of PET/CT cameras. This decreases the measured signal of 1364 
lesions smaller than 30 mm, increasingly limiting test sensitivity in smaller nodules. Average 1365 
costs of 99mTc-MIBI scanning range from €119 to €500 in Europe and from $669 to $1,156 in 1366 
the USA (139,262,263). From a German perspective, 99mTc-MIBI-based management was 1367 
cost-effective over Afirma® GEC-testing and conventional management. However, this study 1368 
inappropriately extrapolated auspicious performance parameters of 99mTc-MIBI in unselected 1369 
thyroid nodules (96% sensitivity and 46% specificity) to the indeterminate population, and 1370 
likely underestimated modelled costs for 99mTc-MIBI scanning and thyroid surgery 1371 
(14,120,138,139,262-264). Therefore, these assumptions regarding cost-effectiveness in 1372 
indeterminate thyroid nodules are decidedly questionable and require careful re-evaluation. 1373 
 1374 
Altogether, there is an increased risk of malignancy in thyroid nodules that show increased 1375 
99mTc-MIBI uptake, provided that hypofunctioning nodules are preselected. Nonetheless, test 1376 
performance in indeterminate thyroid nodules seems insufficient. Excluding Hürthle cell 1377 
lesions suggests high specificity, but does not resolve the reported poor sensitivity. However, 1378 
the number of studies currently available for indeterminate thyroid nodules is limited. We 1379 
believe prospective validation studies in non-oncocytic indeterminate thyroid nodules should 1380 
be performed. Future studies should also focus on external threshold validation for retention 1381 
indices to reduce operator dependency and increase accuracy and objectivity of 99mTc-MIBI. 1382 
Based on the current evidence, we recommend that 99mTc-MIBI scanning is not used in 1383 
surgical management decisions in indeterminate thyroid nodules without another adjunctive 1384 
test.  1385 
 1386 
3.2. FDG-PET 1387 
 1388 
Positron emission tomography (PET) using [18F]-2-fluoro-2-deoxy-D-glucose 1389 
(fluorodeoxyglucose or 18F-FDG), also known as FDG-PET, is an imaging modality that 1390 
exploits the basic principle that (malignant) tumours and inflammatory tissues are much more 1391 
metabolically active than normal tissues. Whereas normal tissues predominantly produce 1392 
energy by low rates of aerobic glycolysis followed by the citric acid cycle in mitochondria, 1393 
glycolytic rates of rapidly growing cancers can be up to 200 times higher. Subsequent lactic 1394 
acid fermentation takes place even if oxygen is plentiful (the Warburg effect) (265). Similar 1395 
to regular glucose, the glucose analogue 18F-FDG is internalized by transmembranous GLUT 1396 
transporters and converted by hexokinase to 18F-FDG-6-phosphate. However, unlike the 6-1397 
phosphorylation product of regular glucose, 18F-FDG-6-phosphate cannot be metabolized 1398 
further. It is trapped intracellularly and thus accumulates in the tissue. Subsequently, PET 1399 
scanning can visualize the increased glucose metabolism of the (abnormal) tissue (266). 1400 
Nowadays, FDG-PET is generally performed in combination with computed tomography 1401 
(FDG-PET/CT), mainly to correlate metabolically active regions to their anatomic substrates 1402 
and to correct for tissue-attenuation of the radioactive signal. It is increasingly applied in the 1403 
diagnostic work-up, staging and therapeutic response monitoring of various malignancies. For 1404 
thyroid cancer, FDG-PET is frequently used to characterize recurrent disease, especially if 1405 
dedifferentiation is expected in thyroid carcinomas that lost the capacity to concentrate 1406 
radioiodide, yet still have measurable serum values of the tumour marker thyroglobulin. It 1407 
may also be considered in the initial staging of poorly differentiated or invasive Hürthle cell 1408 
carcinoma. Moreover, FDG-avid thyroid incidentalomas require additional work-up by FNAC 1409 
when >1 cm (20,23). In the current ATA guidelines FDG-PET is not routinely recommended 1410 
for the diagnostic workup of indeterminate thyroid nodules due to limited clinical validation, 1411 
despite a 2011 meta-analysis by Vriens et al. that demonstrated 95% sensitivity and 96% 1412 
NPV in indeterminate thyroid nodules larger than 15mm (23,267).  1413 
Results of available individual studies were mutually consistent despite limited sample sizes. 1414 
Especially the first studies showed extremely promising results, each reporting 100% 1415 
sensitivity (266,268-270). De Geus-Oei et al. argued that implementation of FDG-PET could 1416 
reduce the number of futile hemithyroidectomies for benign nodules by 66%, likely 1417 
outweighing the costs of the extra scans and suggesting cost-effectiveness of this technique in 1418 
the preoperative setting (269). A subsequent study suggested a less optimistic 39% reduction 1419 
in futile surgeries, following a lower benign call rate (270). More recent studies demonstrated 1420 
more modest performance of FDG-PET(/CT) (19,20,271-273). Overall, reported sensitivity 1421 
and specificity of FDG-PET(/CT) to detect thyroid carcinoma in indeterminate thyroid 1422 
nodules ranged from 77% to 100% and from 33% to 64%, respectively. A negative index test 1423 
was reported in approximately 40% of patients (19,20,266,268-274).  1424 
Several reasons for false-negativity were proposed, foremost small nodule size. It is how 1425 
Traugott et al. explained their 20% false negative FDG-PET scans: eight lesions were 1426 
histopathologically smaller than 1 cm. Excluding these, sensitivity and NPV increased to 1427 
100% (271). FDG-avidity in very small nodules may be missed on FDG-PET due to the low 1428 
volume of malignant cells and due to the partial volume effect: the detected FDG-1429 
concentration is underestimated dependent on nodule size in relation to the (limited) spatial 1430 
resolution of the scanner. In larger nodules, this effect is negligible (20,269). Although the 1431 
improving resolution of state-of-the-art PET scanners pushes the detection limit towards 10 1432 
mm, PET is less sensitive in lesions smaller than 15 mm on US. It less reliable to rule-out 1433 
microcarcinomas (267). Theoretically, the improving spatial resolution could also become a 1434 
limitation of the technique: not only will there be less false-negatives, but likely also more 1435 
false-positive results - leading to a decrease in the already limited specificity over time. In the 1436 
currently available literature no such downward trend is noted, but future studies should 1437 
monitor this possibility.  1438 
 1439 
Semi-quantitative FDG-PET 1440 
Semi-quantitative analysis of FDG-PET is performed using the maximum standardized uptake 1441 
value (SUVmax): the ratio between the maximum radioactivity concentration measured within 1442 
a region of interest on the PET image (the ‘hottest’ voxel) and the decay-corrected amount 1443 
injected radiotracer per unit of body mass. It reflects the FDG-concentration factor compared 1444 
to a homogenous distribution of the radiotracer (275). The SUVmax is generally significantly 1445 
higher in malignant than in benign lesions (20,269,270,272,273,275,276). There is a possible 1446 
correlation between higher SUVmax values and increasing size in nodules, insufficiently 1447 
explained by the abovementioned partial volume effect (20,276). Also, in FTC a higher SUV 1448 
was associated with capsular or vascular invasion (274). Nonetheless, even though Kresnik et 1449 
al. demonstrated that all carcinoma and Hürthle cell adenoma had an SUVmax ≥2 and all other 1450 
benign lesions an SUVmax <2, in multiple other studies the SUVmax of benign and malignant 1451 
indeterminate thyroid nodules overlapped. No threshold could accurately tell them apart 1452 
(20,269,270,272,273,275,276). Moreover, as SUVmax calculations strongly depend on image 1453 
acquisition and reconstruction methods, type of PET-scanner and other variable methodology, 1454 
reported absolute SUVmax thresholds are not simply valid for other institutions (20). 1455 
Standardized optimized FDG-PET protocols are required for inter-institution comparison of 1456 
study results and advancement of PET research (277,278).  1457 
 1458 
FDG-PET in thyroid nodules with Hürthle cell cytology 1459 
Multiple studies observed aberrant FDG-PET characteristics in indeterminate nodules with 1460 
Hürthle cell cytology: both benign and malignant lesions are mostly FDG-positive. Twenty-1461 
nine Hürthle cell lesions were reported by Deandreis et al., consisting 52% of their study 1462 
population and providing an explanation for their limited sensitivity (273). Moreover, Hürthle 1463 
cell adenoma generally demonstrated a significantly higher SUVmax than other benign lesions 1464 
(20,266,268,269,273,279). The proportion of Hürthle cell cytology in individual studies is 1465 
relatively small, but overall FDG-PET seems inadequate in these neoplasms. 1466 
 1467 
Availability, cost-effectiveness and limitations of FDG-PET 1468 
PET systems are less widely available than conventional gamma cameras. Moreover, 18F used 1469 
for 18F-FDG synthesis is produced in cyclotrons, and transport distances are limited due to the 1470 
short half-life of this isotope (~110 min). In Europe, FDG-PET/CT is approximately 1.5-2 1471 
times more expensive than 99mTc-MIBI SPECT/CT. The radiation exposure of FDG-PET/CT 1472 
is largely accounted for by the FDG dosage at approximately 19 μSv/MBq, i.e. about 3-4 mSv 1473 
for a typical activity of 185 MBq administered to an average adult (280). Insights regarding 1474 
common practice total-body FDG-PET/CT imaging are changing (271,273). The CT radiation 1475 
dose greatly varies, and can be less than 0.5 mSv for a low-dose CT of the neck region only. 1476 
When scanning the thyroid region only, a longer imaging time can compensate for a reduction 1477 
in FDG dose, which would lower the radiation burden as well as the costs. Such solutions 1478 
may counter prevailing reservations regarding ionizing radiation exposure. Additionally, 1479 
partial-body acquisition could limit the number of coincidental PET-positive findings. Much 1480 
of the criticism on FDG-PET focuses on these potential incidental findings, which require 1481 
additional diagnostics, are not always clinically relevant and may negatively impact potential 1482 
cost-effectiveness (281,282). Malignant ipsi- or contralateral thyroid incidentalomas are 1483 
reported while the nodule under investigation was histopathologically benign (271,272). PET-1484 
positive incidentalomas are histopathologically malignant in about 20% of patients (282). 1485 
Cost-effectiveness of FDG-PET/CT was modelled by Vriens et al. (14). From a Dutch health 1486 
care perspective, FDG-PET/CT driven treatment would decrease the rate of unbeneficial 1487 
diagnostic hemithyroidectomies for benign thyroid nodules by 35% and reduce the costs per 1488 
patient by €822 compared to the €8,804 expenses for conventional surgical treatment. Also, 1489 
FDG-PET/CT was favoured over the miRInform® and Afirma® GEC (14).  1490 
Contrasting the generally strong sensitivity, specificity of FDG-PET is consistently poor. The 1491 
underlying mechanism is not yet fully elucidated. The negative influence of Hürthle cell 1492 
cytology may be partly responsible. It could also be explained by cellular atypia, which was 1493 
significantly and independently related to FDG uptake, and found in both benign and 1494 
malignant lesions. Atypia was also related to the presence of Hürthle cells (273). Sebastianes 1495 
et al. hypothesized that FDG uptake is related to variations in gene expression patterns. They 1496 
suggested that genetic variations between populations may also explain the varying diagnostic 1497 
accuracy of FDG-PET between studies (270).  1498 
 1499 
In conclusion, FDG-PET(/CT) has the potential to accurately rule-out malignancy in all 1500 
indeterminate nodules except Hürthle cell lesions. It could prevent unnecessary diagnostic 1501 
surgery for a significant number of benign thyroid nodules. Sample sizes of existing studies 1502 
are small, but larger prospective trials are currently ongoing to settle the diagnostic value of 1503 
this technique and its utility in clinical practice. We recommend that these studies also focus 1504 
on identifying (genetic) causes for the occasional false-negativity and generally low 1505 
specificity of this technique. 1506 
 1507 
3.3. DW-MRI 1508 
 1509 
Diffusion-weighted magnetic resonance imaging (DW-MRI) is a functional nuclear magnetic 1510 
resonance imaging technique that evaluates the rate of random (Brownian) motion of water in 1511 
tissue, also called diffusivity. By applying diffusion-sensitizing magnetic gradients (the 1512 
strength and duration of which are expressed as b-values) different levels of diffusion-1513 
weighting are obtained: from non-diffusion images (b-value = 0 s/mm2) to highly diffusion 1514 
weighted images (i.e. b-value >800 s/mm2)(283). Lesions that show high signal intensity on 1515 
DW-MRI images with a high b-value thus show restricted diffusion. The apparent diffusion 1516 
coefficient (ADC, in mm2/s) is calculated based on the exponential relationship between 1517 
signal intensity and the corresponding b-value according to S(b)=S(0)*e-b*ADC. A high ADC 1518 
represents a high degree of diffusion; a low ADC represents diffusion restriction (283,284). 1519 
DW-MRI thus allows noninvasive quantification of tissue properties without ionizing 1520 
radiation exposure for the patient. Differentiation between benign and malignant tissues by 1521 
DW-MRI is based on the assumption that increased cell proliferation, cellular-density and 1522 
disorganized structures in malignant tissue restrict random motion and thus diffusion of water: 1523 
a lower ADC-value, together with high signal intensity at high b-values, is more suspicious 1524 
for malignancy (283,284). Oppositely, increased ADC-values suggest free movement of water 1525 
molecules in the tissue. It is found in for example edema, colloid follicles, fibrous tissue, 1526 
hemorrhage and calcification, all of which associated with benign tissues (285). Prior 1527 
application of DW-MRI in i.e. neuroradiology, breast and lymph nodes showed high 1528 
diagnostic accuracy (286,287). 1529 
Recent exploratory studies in small cohorts of thyroid nodules found distinctively higher 1530 
ADC values for benign than malignant nodules (283-285,288-292). A recent meta-analysis in 1531 
765 cytologically unselected thyroid nodules estimated that DW-MRI had 90% sensitivity and 1532 
95% specificity to distinguish thyroid carcinoma (293). Among the individual studies, 1533 
however, presented optimum ADC thresholds varied and were not externally validated (283-1534 
285,288-292).  1535 
Only one small study had assessed DW-MRI in indeterminate thyroid nodules to date. 1536 
Nakahira et al. reported a mean ADC value of 1.27 ± 0.29 *10-3 mm2/s in malignancies 1537 
opposite 1.95 ± 0.24 *10-3 mm2/s in benign nodules with indeterminate cytology. These 1538 
results were similar to those of their entire study population (n=42), in which a cutoff ADC 1539 
value of 1.95 ±0.24 *10-3 mm2/s was 95% sensitive and 83% specific (283). 1540 
 1541 
Availability and limitations of DW-MRI 1542 
DW-MRI is infrequently and only experimentally used in the workup of thyroid nodules. 1543 
Nonetheless, the worldwide availability and application of MRI is growing. As it uses no 1544 
ionizing but only radiofrequency radiation, the associated risk to the patients is limited, 1545 
provided that specific measures are taken for patients with MRI-incompatible implanted 1546 
devices or metal. No MRI-contrast is necessary for DW-MRI, thus avoiding gadolinium-1547 
associated toxicity. As the spatial resolution of MRI-scanners is still improving, technical 1548 
limitations of DW-MRI with regard to minimal lesion size are becoming less relevant 1549 
compared to SPECT and probably also PET. Still, spatial resolution of DW-MRI sequences is 1550 
less than that of conventional anatomical MRI-sequences.  1551 
There are several major limitations to DW-MRI. MRI is still a rather costly technique; 1552 
additional sequences such as DW-MRI adds scanner time (~5-10 min) per patient and thus 1553 
further increases costs. DW-MRI methodology is not standardized yet and its optimal settings 1554 
still unsettled, leading to varying ADC and b-values (283,289,292). Suboptimal methodology 1555 
or artifacts cause poor image quality, impede accurate interpretation and caused undesirable 1556 
exclusions from already small-sized studies, with reported exclusion rates up to 28% 1557 
(283,284,292). Image artifacts are often caused by inhomogeneity in pathologic tissues or by 1558 
their vicinity to interfaces between soft-tissues and bone or air, a source of MRI-artifacts 1559 
specifically in the thyroid region. Besides viable tumor tissue, malignant tumors partly exist 1560 
of components with high diffusivity, such necrosis, cystic components or intratumoral 1561 
hemorrhage (283,285). For accurate ADC measurement, such macroscopic areas should be 1562 
manually avoided when drawing a region-of-interest. However, avoiding microscopic areas of 1563 
similar origin, invisible to the human eye, is an impossible task (283). Furthermore, it is 1564 
hypothesized that the substantial amounts of follicular or Hürthle cells limit the diagnostic 1565 
accuracy of DW-MRI, specifically in indeterminate thyroid neoplasms. Follicular and Hürthle 1566 
cell neoplasms are known for their varying colloid tissue involvement. Histologically they 1567 
contain more fluid. Thus, DW-MRI would inaccurately provide a more benign image 1568 
(283,292). These hypotheses are currently based on very limited evidence. Further 1569 
prospective validation studies are desired to determine the possible diagnostic value of DW-1570 
MRI in indeterminate thyroid nodules. Future prospects also include improvements of the 1571 
technique, including consensus on methodology and standardization of acquisition 1572 
techniques.  1573 
 1574 
4. COMBINED AND MULTISTEP DIAGNOSTICS 1575 
 1576 
The previous chapters of this review addressed the large number of available diagnostic tools 1577 
to assess indeterminate thyroid nodules. Most studies focused on a single diagnostic technique 1578 
only. The elimination of between-study population-level differences is a major advantage 1579 
when comparing the performance of multiple diagnostics independently in one study, 1580 
optimally in a prospective, independent and blinded fashion. Moreover, assessment of 1581 
multiple techniques in one study allows investigation of the complementary value of multiple 1582 
techniques as a diagnostic tool by means of simultaneous or sequential testing while at the 1583 
same time aiding to further unravel tumor biology as a research tool, especially in the current 1584 
multidisciplinary in-hospital working environment. For example, the question how the 1585 
presence of a certain oncogenic mutation relates to the (positive) result of an FDG-PET scan 1586 
could be addressed.  1587 
Piccardo et al. compared 99mTc-MIBI, FDG-PET/CT and US plus USE in 87 indeterminate 1588 
TIR3 nodules with a 21% malignancy rate. FDG-PET/CT was the superior technique with 1589 
94% sensitivity and 58% specificity. Following a non-specific positive FDG-PET result, 1590 
review of ultrasound characteristics offered slight further differentiation; it improved 1591 
specificity to 77%. However, an additional negative 99mTc-MIBI scan increased specificity to 1592 
94%; this combination was found in 13% of patients (19). 1593 
Giovanella et al. performed both 99mTc-MIBI and a 7-gene mutation panel in cold 1594 
indeterminate thyroid nodules. Combined testing did not improve diagnostic accuracy. 1595 
Performance of the gene mutation panel was inferior to 99mTc-MIBI imaging. Of the seven 1596 
(11%) mutation-positive nodules (four RAS mutations and three PAX8/PPAR 1597 
rearrangements), only four were malignant. It is unclear whether the low sensitivity of the 1598 
gene mutation panel in this study can be explained by the selected population of 1599 
hypofunctioning nodules (70).  1600 
 1601 
Elastosonography and Ultrasonography 1602 
USE is superior to ultrasound in indeterminate thyroid nodules – both individual US 1603 
characteristics as well as combined US patterns described in various articles 1604 
(210,213,215,217,219,221,222). Two recent prospective studies demonstrated that additional 1605 
USE evidently improved the diagnostic accuracy of US. Garino et al. included nodule 1606 
stiffness as additional characteristic into a panel of US characteristics and demonstrated that 1607 
USE identified eight additional malignancies that would have been missed by US assessment 1608 
alone. Presence of one or more suspicious US/USE features was 100% sensitive; two or more 1609 
88% sensitive and 77% specific. Benign test results were found in 57% of patients. The 1610 
authors suggested that the 6.4% remaining risk of malignancy– similar to the benign cytology 1611 
category – would justify follow-up instead of diagnostic hemithyroidectomy in this group 1612 
(210). In another study of 315 Thy3 nodules, semi-quantitative USE correctly diagnosed 75% 1613 
of the histopathologically benign lesions that were considered suspicious for malignancy on 1614 
US, and 83% of the malignancies that were misdiagnosed as benign on US (217). These 1615 
results suggest that the existing TIRADS classification could be extended with tissue 1616 
elasticity features. In unselected thyroid nodules this improved TIRADS sensitivity, but not 1617 
specificity (240,294). The combination is a suitable topic for future research in indeterminate 1618 
thyroid nodules. Major benefit is that the two techniques are individually inexpensive and 1619 
obviously easily combined during one diagnostic procedure. Cost-effectiveness can be 1620 
anticipated.  1621 
 1622 
US and Mutation Analysis 1623 
US assessment was also reported in various studies on gene mutation analysis, presumably 1624 
because US data were usually readily available in clinical studies at no additional costs and 1625 
thus easily combined with results of more experimental techniques. Even though US 1626 
assessment improved the diagnostic accuracy of both FDG-PET and elastosonography, 1627 
combined use of ultrasound with the sensitive Afirma® GEC or specific BRAF mutation 1628 
analysis demonstrated little additional diagnostic value (57). Suspicious US features such as 1629 
hypoechogenicity, presence of calcifications and hypervascularity were not predictors of 1630 
malignancy in Afirma® GEC-positive nodules (144). Also, as expected by their individual 1631 
association to classic PTC, a positive BRAFV600E mutation was correlated to the presence of 1632 
suspicious US features in unselected nodules, including hypoechogeneity and the presence of 1633 
microcalcifications (29,66,78). BRAF mutation less frequently occurred in thyroid nodules 1634 
without suspicious US features (66,78). In Bethesda III and IV thyroid without suspicious US 1635 
features the prevalence of the BRAF mutation was only 1.5% (1/67) in the study by Seo et al. 1636 
– very low, particularly for a South Korean population – all while the malignancy rate was 1637 
still 18% (12/67)(66). Considering the negligible yield at additional costs, BRAF mutation 1638 
analysis might not be contributory in indeterminate nodules without suspicious US features. 1639 
An even lower yield from BRAF mutation analysis in US-unsuspicious nodules is presumed 1640 
in populations with a lower general prevalence of BRAF mutations. Additionally, these results 1641 
suggest a different US appearance of BRAF mutation-negative malignancies – or a different 1642 
molecular profile of thyroid carcinoma without suspicious US features. 1643 
RAS mutation analysis and assessment of the typical suspicious US features could be 1644 
complementary in the differentiation of indeterminate thyroid nodules, as follicular-type 1645 
thyroid carcinomas are associated with RAS mutations and infrequently showed the typically 1646 
suspicious US features (1,29,193-196). Combined assessment could improve diagnostic 1647 
accuracy of either technique in indeterminate thyroid nodules, identifying papillary thyroid 1648 
malignancies through classic suspicious US features and follicular-type carcinoma by RAS 1649 
mutation analysis. However, challenges for clinical practice continue to exist in the imperfect 1650 
specificity of RAS mutation analysis, and the interobserver variability and ambiguity of 1651 
certain US features.  1652 
 1653 
Immunocytochemistry and Mutation Analysis 1654 
In histopathology samples, certain genetic alterations were correlated to positive staining for 1655 
specific immunomarkers: PAX8/PPARγ rearrangement was associated with galectin-3 1656 
reactivity, and RAS point mutation with HBME-1 (105). Only one study investigated this 1657 
combination of techniques in indeterminate thyroid cytology. Although no significant 1658 
correlation was demonstrated between positive BRAFV600E mutation and galectin-3 1659 
overexpression – benefitting possible complementary use – no additional diagnostic value 1660 
was demonstrated either (44).  1661 
 1662 
MicroRNA and Mutation Analysis 1663 
Combined microRNA expression profiling and mutation analysis could accurately aid 1664 
diagnosis and prognosis of thyroid malignancy. Distinct microRNAs have been related to 1665 
oncogenic mutations. For example, miR-221, miR-222 and miR-146b were more 1666 
overexpressed in BRAF- and RAS-mutated PTC. High expression of miR-187 was associated 1667 
with RET/PTC rearrangement (148,295). The first step towards diagnostic integration of the 1668 
two techniques was taken by Labourier et al., who tested the commercially developed 10-1669 
microRNA thyroid classifier ThyraMIR™ simultaneously with the miRInform® thyroid (22). 1670 
The ThyraMIR™ was designed to increase the sensitivity of the miRInform® without 1671 
affecting its specificity. Combined use demonstrated 89% sensitivity and 85% specificity 1672 
(22). A recent decision analytics model for Bethesda III and IV nodules estimated that 1673 
combined miRInform® and ThyraMIR™ testing was cost-effective, reducing the rate of 1674 
unnecessary surgery (diagnostic hemithyroidectomy as well as two-step thyroidectomies) 1675 
from 88% to 20% and saving $1,384 per patient in the first year of treatment or $3,170 per 1676 
avoided surgery. However, it is not described how the economic consequences of the 15% 1677 
missed malignancies are accounted for in this model (140). The economic as well as medical-1678 
ethical consequences of such a high number of missed malignancies question the current 1679 
clinical utility of this combination of expensive techniques. 1680 
 1681 
In brief, the combined or sequential use of multiple diagnostics in indeterminate thyroid 1682 
nodules was infrequently studied. Regrettably, the available studies also mostly remained 1683 
within their own field of expertise: comparing tests either within the domain of pathological 1684 
(molecular) techniques or within the domain of imaging. Although a sequential combination 1685 
of a sensitive and an uncorrelated specific test might bring the solution that this clinical issue 1686 
has been waiting for, the most accurate combination of tests cannot reliably be determined 1687 
yet. 1688 
 1689 
5. RECENT DEVELOPMENTS AND FUTURE PROSPECTS 1690 
 1691 
5.1. The Cancer Genome Atlas 1692 
 1693 
Papillary thyroid cancer was one of the cancers targeted by the cancer genome atlas (TCGA) 1694 
research network, a large collaborative project by the National Cancer Institute (NCI) and 1695 
National Human Genome Research Institute (NHGRI). The incentive of the project is to map 1696 
genomic alterations occurring in 33 types of cancer in 11.000 patients and improve the 1697 
understanding, classification and extending possibilities for targeted therapy of these cancers 1698 
(296). Genetic alterations of all kinds were detected in nearly five hundred clinically non-1699 
aggressive PTCs (classical, follicular and tall cell variants) using one proteomic and six 1700 
genomic platforms. PTC harbored fewer somatic mutations than other human cancer types, 1701 
but if they were present, driver mutations were detected in the majority of the cancer cells. As 1702 
expected, the known driver mutations in the MAPK/ERK pathway were dominant, 1703 
confirming the mutually exclusive relation for BRAF and RAS point mutations and RET/PTC 1704 
rearrangements. Other detected genetic alterations included genetic variations of the TERT 1705 
promoter, PI3K and PPAR pathways, as well as new alterations of known and new drivers, 1706 
such as EIF1AX, PPM1D and CHEK2. Moreover, molecular subtypes of for example BRAF-1707 
mutated PTC were identified and linked to different clinical subtypes. The role of microRNA 1708 
in determining cancer phenotype was elaborated, allowing better understanding of clinical 1709 
behavior of various genetic variants of PTC. Somatic copy number alterations were mostly 1710 
linked to FVPTC. Ultimately, the TCGA Research Network envisions a reclassification of 1711 
thyroid carcinoma, abandoning the discrimination between PTC and FTC, and classifying 1712 
according to molecular subtypes instead of by histopathological subtype first (297). The 1713 
identified markers may not just have an application in the diagnosis of thyroid carcinoma, but 1714 
also in better risk-stratification of the different cancers and in targeted therapies. The plurality 1715 
of applications is best known for the BRAFV600E mutation, which has an association with 1716 
clinically more aggressive tumor behavior on several fronts. Also, non-thyroid malignancies 1717 
carrying a BRAF mutation are now (experimentally) treated with RAF inhibitors (298,299).  1718 
There is little doubt that molecular classification systems are the future of oncology 1719 
diagnostics in all types of human cancers. The position of histopathological assessment is 1720 
changing, but cannot be renounced. With the current knowledge of thyroid genomics, the 1721 
need to distinguish the mutated malignant from the mutated benign – premalignant – 1722 
neoplasms remains, with all due consequences for the surgical and postoperative treatment 1723 
strategy.  1724 
 1725 
Cytological application of the TCGA set was also already investigated in a recent study. 1726 
Pagan et al. validated a panel containing the genomic alterations identified by the TCGA in 1727 
88 FNAC samples selected from a previous cohort study, including 22 indeterminate thyroid 1728 
nodules (126,300). In the latter, 33% sensitivity and 84% specificity were demonstrated. In 1729 
the same set of patients, Pagan et al. also performed the Afirma® GEC. The GEC yielded less 1730 
false negatives and a much higher sensitivity. Even though technical limitations of the applied 1731 
sequencing techniques could leave RNA transcriptions with low expression levels undetected 1732 
and thus negatively influence sensitivity of the TCGA set, the scopes of the TCGA and GEC 1733 
most likely explain their difference in performance. The TCGA was developed using PTC 1734 
only. It did not include follicular lesions and their distinctive genetic alterations. Moreover, in 1735 
contrast to the GEC, the TCGA set was not optimized for preoperative diagnostic application 1736 
in indeterminate thyroid nodules (300). Consequently, the comparison performed by this 1737 
Veracyte-sponsored study seems unjust: it is obvious that the Afirma® GEC yielded better 1738 
diagnostic performance in this specific clinical setting. Yet, the results of this study did prove 1739 
that a large panel of genetic alterations such as the TCGA was not useful in clinical practice 1740 
without further expansion of the scope of the panel towards follicular thyroid neoplasms. Still, 1741 
the genetic alterations and their relations detected by TCGA are groundbreaking for the 1742 
progression of research. From these comprehensive sets of biomarkers, we may select new 1743 
combinations of genetic alterations for future clinical research to develop an accurate rule-in 1744 
or rule-out molecular test for indeterminate thyroid nodules.  1745 
 1746 
5.2. Proteomics 1747 
 1748 
Other molecular advances include protein expression diagnostics, or proteomic profiling. 1749 
These techniques allow for more detailed insight in the molecular biology and protein 1750 
expression of thyroid neoplasms. For example, matrix-assisted laser desorption ionization / 1751 
mass spectrometry imaging (MALDI-MSI) is able to simultaneously visualize the spatial 1752 
distribution of proteins and profile up- and downregulated protein expression in relation to the 1753 
morphological features of the thyroid specimen. These and related proteomic techniques 1754 
could identify new biomarkers for preoperative cytological diagnosis, but require high levels 1755 
of expertise. Application to thyroid cytology has so far been investigated by few studies 1756 
(301,302). Ex-vivo cytology studies show accurate and reproducible differentiation between 1757 
various lesions, including the currently difficult to diagnose Hürthle cell neoplasms (302). No 1758 
studies investigated the diagnostic value of proteomics in in-vivo indeterminate thyroid 1759 
cytology yet. 1760 
 1761 
DISCUSSION 1762 
 1763 
This review provides a comprehensive overview of the available literature on molecular and 1764 
imaging biomarkers as additional diagnostics for thyroid nodules with indeterminate cytology 1765 
(Bethesda III and IV) and their application in a clinical preoperative setting. Clinical utility 1766 
requires more from a diagnostic than mere well-validated test performance and high rule-in or 1767 
rule-out capacity. The 2015 ATA guidelines suggested that the ideal rule-out diagnostic for 1768 
thyroid carcinoma should have a NPV similar to a benign cytological diagnosis (~96.3%) and 1769 
the ideal rule-in test a PPV that is at least similar to a malignant cytological diagnosis 1770 
(~98.6%) (10,23). The balance between test sensitivity and specificity – and their prevalence-1771 
dependent derivatives PPV and NPV – directly reflects on feasibility and cost-effectiveness 1772 
estimates. A diagnostic with (near) perfect sensitivity but limited specificity is inefficient and 1773 
unlikely cost-effective: the NPV will be close to 100%, but the majority of nodules will test 1774 
positive. Therefore, instead of focusing on the reproducible highest sensitivity or specificity, a 1775 
diagnostic is better appreciated by end points such as desired minimal rates of accurately 1776 
prevented unbeneficial surgeries or accurately diagnosed carcinomas. More importantly, 1777 
clinical utility demands that implementation of the ancillary test leads to changes in patient 1778 
management and overall health benefits (303). All these requirements directly depend on a 1779 
plurality of epidemiological and economic factors within the tested population, such as the 1780 
local test availability, professional expertise and case mix – prevalence of malignancy as well 1781 
as the balance of various subtypes of indeterminate cytology including especially Hürthle-cell 1782 
neoplasms and BRAF-mutation. Additionally, clinical utility considerations should include 1783 
less tangible factors such as physician and patient preference, multidisciplinary decision 1784 
making and compatibility with everyday clinical routine and logistics in endocrine practice. 1785 
All things considered, global perspectives regarding the preferred diagnostic for indeterminate 1786 
thyroid nodules likely greatly differ.  1787 
 1788 
Recommendation for clinical use of rule-out tests 1789 
The most accurate currently available rule-out tests are the Afirma® GEC and FDG-1790 
PET(/CT) imaging. The Afirma® GEC had strikingly high sensitivity in nearly all studies 1791 
(127,129,131-134). However, there are concerns regarding the lack of strong validation 1792 
studies. With a high degree of missing histology, especially in GEC negative nodules, there is 1793 
a potentially strong diminution of the tests’ sensitivity if unresected GEC-negative lesions 1794 
were less often benign than presumed. In the USA, physicians should locally validate the 1795 
tests’ utility prior to implementation. However, with its limited global availability, high costs 1796 
and low probability of cost-effectiveness, clinical implementation of the Afirma® GEC 1797 
outside the USA is currently not favored (14,121,137-140).  1798 
FDG-PET/CT may be the preferred rule-out test for indeterminate thyroid nodules in a 1799 
European setting. With sufficient validation studies with complete histopathological follow-1800 
up, it demonstrated consistent high sensitivity and a benign test result in 40% of the patients, 1801 
although the number of currently published patients is moderate. Cost-effectiveness of FDG-1802 
PET over other diagnostics is presumed (14). Its popularity in the USA is more limited, 1803 
although the efficacy of this molecular imaging technique could likely compete with 1804 
molecular biomarkers panels, even if the costs per scan are somewhat higher than in Europe. 1805 
The main drawback of FDG-PET/CT is its – admitted minor – risk to the patient by using a 1806 
limited dose of ionizing radiation.  1807 
The recently announced version 3 of the ThyroSeq® may become a prime contender. 1808 
Dependent on the case mix, the ThyroSeq® v2.1 anticipated high negative predictive value 1809 
(21). However, the number of studies to confirm test performance and clinical utility in 1810 
different patient populations is limited. Clinical results for the ThyroSeq® v3 are eagerly 1811 
awaited. 1812 
Semi-quantitative elastosonography could be a suitable alternative, in particular in case a 1813 
more economic test is required. However, overfitting and lack of external cut-off validation 1814 
likely overestimated the performance of this technique in the limited number of available 1815 
studies. If future prospective studies can confirm its performance and thresholds of this 1816 
operator-dependent but globally accessible method, USE could become a more important 1817 
diagnostic in this field.  1818 
None of the diagnostic techniques under investigation in this review has a perfect NPV or 1819 
fulfills the threshold proposed by the ATA. A number of malignant nodules will be 1820 
misdiagnosed as benign on first assessment. Considering the typical indolent clinical course 1821 
of differentiated thyroid cancer, follow-up of these initially false-negative nodules will most 1822 
likely still result in timely diagnosis without relevant treatment delay and dismal prognostic 1823 
consequences. 1824 
 1825 
Recommendation for clinical use of rule-in tests 1826 
The best rule-in performance was unmistakably demonstrated by BRAF mutation analysis, 1827 
which showed perfect 100% specificity in an abundance of studies. Yet, strong regional 1828 
differences in prevalence of BRAF mutations have a major impact on its clinical utility, 1829 
especially when comparing South Korea to other countries. Moreover, the analysis most 1830 
likely has very low yield in Bethesda IV nodules, in which the mostly follicular type 1831 
malignancies are more frequently RAS-mutated (31,50,70,76). Testing for individual genetic 1832 
alterations other than the BRAFV600E point mutation is not useful. In American and European 1833 
settings, a gene mutation panel is likely preferred over any individual mutation analysis.  1834 
Promising rule-in capacity was also demonstrated for Galectin-3 immunocytochemistry. An 1835 
infrequently applied technique with limited validation studies, further prospective studies are 1836 
warranted to validate its performance in indeterminate thyroid nodules and endorse its 1837 
possible clinical use.  1838 
Besides BRAF mutation analysis, none of diagnostics meet the 2015 ATA requirements of an 1839 
ideal rule-in test. Compared to ruling-out tests, ruling-in tests face an additional challenge. 1840 
With a generally low frequency of thyroid carcinoma in indeterminate thyroid nodules, 1841 
achieving a reliable PPV – higher than 95% – can be a major challenge despite adequate test 1842 
specificity. Such high demands to a ruling-in test advocate the use of a ruling-out test in 1843 
populations with a limited pre-test probability of malignancy.  1844 
 1845 
Clinical recommendation for a step-wise approach 1846 
Most of the diagnostic modalities are optimized for either ruling in or ruling out malignancy. 1847 
No single diagnostic addressed in the current review currently has it all: both a near-perfect 1848 
sensitivity and a near-perfect specificity, and (proven) cost-effectiveness. It is extremely 1849 
challenging to develop such test performance parameters in a single diagnostic. Even 1850 
promising new diagnostics, such as the ThyroSeq® and ThyraMir™, require significant 1851 
further optimization to get near this diagnostic utopia.  1852 
With the diagnostics currently available in the clinical setting, a multimodality stepwise 1853 
approach could offer a conclusive diagnosis for indeterminate thyroid nodules, sequentially 1854 
combining one sensitive rule-out and one specific rule-in test. Unfortunately, thus far few 1855 
studies investigated this approach (19,70). Combinations of (molecular) imaging and somatic 1856 
genetics were especially scarce. There is currently insufficient evidence to accommodate 1857 
reliable interpretation of sequentially used tests, as performance of the second test is unknown 1858 
in a population preselected by the first. Besides choosing two accurate and uncorrelated tests 1859 
to achieve maximum diagnostic accuracy, the sequence of testing, local availability and costs 1860 
of the selected diagnostics are crucial. Costs of two or more additional tests may compromise 1861 
cost-utility estimates. Available cost-effectiveness studies for individual diagnostic modalities 1862 
were additionally greatly susceptible to global variations in population-dependent factors such 1863 
as pre-test probability of thyroid carcinoma and local test performance, and varying health 1864 
care costs including the surgical reimbursement rates (14,121,138,139). Reported surgical and 1865 
hospitalization costs range from $4,628 to $6,549 for hemithyroidectomy, $5,272 to $7,068 1866 
for completion thyroidectomy and $5,680 to $11,265 for initial total thyroidectomy. 1867 
Secondary expenses following surgery should be considered as well, including postoperative 1868 
observation, thyroid hormone replacement (approximately $150 per patient per year), 1869 
treatment for hypoparathyroidism (approximately $860 per patient per year), and resolution of 1870 
rare but potentially serious surgical complications (14,120,138,264). Secondary endpoints 1871 
such as quality of life and survival are of minor importance to cost-effectiveness, due to the 1872 
generally indolent course of differentiated thyroid cancer, adequate treatment options and 1873 
overall low disease-related mortality (14,138,139).  1874 
 1875 
Recent discussions in thyroid histopathology 1876 
Histopathology is classically based on microscopic assessment of tumor phenotype, aided by 1877 
immunohistochemistry. However, this ‘gold standard test’ is also subject to advancing 1878 
insights regarding tumor phenotype, increasingly aided by knowledge regarding tumor 1879 
genotype. Mutation-negative malignancies resulting from indeterminate cytology were 1880 
frequently identified as encapsulated follicular variants of papillary thyroid carcinoma without 1881 
histologic features of aggressive behavior (21,22,31,59,80). Also, several studies defined a 1882 
separate intermediate histopathological category called ‘(follicular) tumor of uncertain 1883 
malignant potential’ for encapsulated, well-differentiated follicular tumors with questionable 1884 
PTC-type nuclear changes (71,164,177,273). These examples illustrate one of the important 1885 
ongoing discussions in thyroid histopathology. In 2016, Nikiforov et al. proposed an official 1886 
downscaling of the classification of proven noninvasive encapsulated FVPTCs, renaming 1887 
them ‘noninvasive follicular neoplasm with papillary-like nuclear features’ (NIFTP). The 1888 
behavior of these neoplasms is benign unlike other thyroid carcinoma subtypes, showing no 1889 
evidence of recurrent disease after a median 13-year follow-up. About one in four of the 1890 
neoplasms in the retrospective cohort were mutated, most frequently carrying RAS (NRAS) or 1891 
PAX8/PPARγ alterations. Presence of a mutation likely predisposes the NIFTP to progress 1892 
into an invasive encapsulated FVPTC, justifying surgical resection. Treatment of NIFTP 1893 
should most likely be limited to hemithyroidectomy, waiving totalizing thyroidectomy and 1894 
radioiodine ablation (304). Although revolutionizing, this new nomenclature complicates 1895 
mutation-based preoperative decision-making (21,31,80). The justification to skip two-stage 1896 
surgery and perform a total thyroidectomy at once for mutation-positive nodules is the driving 1897 
force of the 7-gene mutation panel and similar tests, but would be overkill for the subgroup of 1898 
NIFTP (31). Nonetheless, most of the undesirable possible overtreatment for NIFTP is likely 1899 
resolved if RAS-mutated indeterminate nodules are treated with hemi- instead of total 1900 
thyroidectomy, as previously suggested. No comprehensive diagnostic test is currently 1901 
available to diagnose mutation-positive NIFTP preoperatively, as follicular tumor 1902 
invasiveness and encapsulation cannot be distinguished on cytology. 1903 
 1904 
Hürthle cell cytology 1905 
The Achilles heel of many diagnostics investigated in this review is cytology suspicious for a 1906 
Hürthle cell neoplasm (Bethesda IV SHCN/HCN). Hürthle cells are oxyphilic cells with 1907 
abundant cytoplasm and an enlarged nucleus with a prominent nucleolus. They are found in 1908 
benign thyroid diseases such as Hashimoto’s thyroiditis, but also occur in the notorious 1909 
Hürthle cell adenoma and carcinoma, the oncocytic variant of follicular adenoma and 1910 
carcinoma (4,185). Although Hürthle cell carcinomas (FTC-OV) are rare, their aberrant 1911 
clinical course and association with invasive features justifies the special attention given to 1912 
Hürthle cell cytology by the Bethesda and other classification systems. An accurate additional 1913 
diagnostic is desired. Disappointingly, several studies concluded that the investigated test was 1914 
accurate in all except Hürthle cell lesions (70,132,258,273). Immunocytochemistry handed 1915 
some solutions, although promising results of combined galectin-3 and CK-19 staining have 1916 
not yet been validated (174). Besides that, BRAF, RAS, RET/PTC or PAX8/PPARγ alterations 1917 
are only occasionally found (70,76). These findings support previous presumptions that 1918 
oncocytic thyroid nodules are a completely separate entity with a unique molecular and 1919 
phenotypic profile (305-308). Malignant transition in Hürthle cell nodules most likely 1920 
involves the PIK3CA-Akt-mTOR and Wnt/bèta-catenin pathways rather than the 1921 
MAPK/ERK pathway (305,308). Rare TP53 mutations, usually associated with poorly 1922 
differentiated and anaplastic carcinoma, were recently also identified in well-differentiated 1923 
Hürthle cell nodules (306). Also, recurrent FTC-OV have shown genome haploidisation, a 1924 
rare phenomenon in other types of differentiated thyroid carcinoma (309). Specific markers 1925 
for the preoperative molecular differentiation of Hürthle cell nodules should be developed. 1926 
Adaptation of existing tests to additionally suit Hürthle cell nodules (e.g. the Afirma® GEC) 1927 
is a strategy being explored, for example by the ThyroSeq® v3 and the Afirma® Gene 1928 
Sequence Classifier. Caution should be taken that these adaptations do not decrease the 1929 
diagnostic accuracy for non-oncocytic lesions. MicroRNA expression profiling of these 1930 
lesions is currently also under investigation (148,152). 1931 
 1932 
Strengths and limitations of the current review 1933 
There are several important strengths and limitations to this comprehensive review. This 1934 
review provides a complete overview of the available additional diagnostics for indeterminate 1935 
thyroid nodules, resulting from a careful and systematic literature selection and quality 1936 
appraisal. Different types of clinical data of various levels of evidence were considerately 1937 
presented. Nonetheless, this review is generally prone to inaccuracies from low study quality, 1938 
study heterogeneity and different types of bias. For some of the assessed diagnostics, the 1939 
limited number of available publications and small study cohorts contribute to heterogeneity 1940 
of data and loss of applicability. This mainly concerns studies on non-routine imaging 1941 
techniques. By nature, these clinical studies need to prospectively include subjects to 1942 
voluntarily undergo an extra investigation with – at least in the clinical validation phase – no 1943 
implications for individual patient management. These types of studies require more resources 1944 
than ‘further use’ tissue biobank studies. Consequently, the number of studies is more limited 1945 
and published series often are small. In contrast, cytological biomarker research gratefully 1946 
profits from available large tissue biobanks for initial validation studies. We believe 1947 
consistent results from properly designed imaging studies should not be disregarded due to 1948 
mere their sample size, but be appreciated by the quality of their study design and statistics.  1949 
Population-level study differences were often observed, not only related to test performance 1950 
but also strongly varying malignancy rates that were oftentimes much lower or higher than 1951 
expected from indeterminate thyroid nodules. Besides insuperable epidemiological variations, 1952 
the selection of indeterminate cytology, and the retrospective nature of many studies may 1953 
have contributed to these discrepancies.  1954 
The type of indeterminate cytology included by individual studies varied, likely leading to 1955 
between-study heterogeneity. Besides global variations and known intra- and interobserver 1956 
discordance, diverse definitions of indeterminate cytology were adhered (5). Nowadays, the 1957 
Bethesda system differentiates indeterminate from benign and suspicious cytology in a more 1958 
standardized manner in both literature and clinic. Bethesda III and/or IV and similar 1959 
categories from other classification systems were frequently applied. Unfortunately, some 1960 
studies also included small numbers of Bethesda V nodules without presenting results for 1961 
individual categories separately (127). Many other studies adhered to their own definition of 1962 
indeterminate cytology. This especially, but not exclusively, concerns studies published 1963 
before the introduction of the Bethesda system in 2009.  1964 
Retrospective study designs and subsequent selection bias – only including indeterminate 1965 
thyroid nodules that had undergone both thyroid surgery and (routine) pre-operative testing – 1966 
likely also caused overestimation of the true efficacy of certain techniques (e.g. BRAF 1967 
mutation analysis or ultrasound).  1968 
 1969 
CONCLUSION AND RECOMMENDATIONS 1970 
 1971 
In current-day practice, there are numerous additional diagnostics available to further assess 1972 
thyroid nodules with indeterminate cytology, all with advantages and disadvantages. This 1973 
review provided a comprehensive overview of the available literature on these techniques, 1974 
addressing both molecular and imaging biomarkers, aiming to provide an objective and 1975 
nuanced comparison of their performance and cost-effectiveness with regard to rightful 1976 
surgical decision-making. Many of these diagnostics have either an adequate rule-in or rule-1977 
out capacity, but no single currently available test seems to serve both purposes well. 1978 
Diagnostics from the different research fields likely complement each other in a 1979 
multimodality stepwise diagnostic approach towards. Notwithstanding, test performance is 1980 
always population-dependent. To correctly interpret the results, the prevalence of malignancy 1981 
and the performance, costs and feasibility of the desired diagnostic in the local patient 1982 
population should be known beforehand. Local implementation studies are strongly 1983 
recommended to confirm clinical utility. Most importantly, the local decision favoring or 1984 
opposing a certain diagnostic should be a deliberate and multidisciplinary one. Cooperation 1985 
between clinical endocrinologists, endocrine surgeons, pathologists, radiologists and nuclear 1986 
medicine physicians is crucial.  1987 
 1988 
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Abstract 41 
 42 
Indeterminate thyroid cytology (Bethesda III and IV) corresponds to follicular-patterned 43 
benign and malignant lesions, which are particularly difficult to differentiate on cytology 44 
alone. As approximately 25% of these nodules harbor malignancy, diagnostic 45 
hemithyroidectomy is still custom. However, advanced preoperative diagnostics are rapidly 46 
evolving.  47 
This review provides an overview of additional molecular and imaging diagnostics for 48 
indeterminate thyroid nodules in a pre-operative clinical setting, including considerations 49 
regarding cost-effectiveness, availability, and feasibility of combining techniques. Addressed 50 
diagnostics include gene mutation analysis, microRNA, immunocytochemistry, 51 
ultrasonography, elastosonography, CT, sestamibi scintigraphy, FDG-PET and diffusion-52 
weighted MRI.  53 
The best rule-out tests for malignancy were the Afirma® GEC and FDG-PET. The most 54 
accurate rule-in test was sole BRAF mutation analysis. No diagnostic had both near-perfect 55 
sensitivity and specificity, and estimated cost-effectiveness. Molecular techniques are rapidly 56 
advancing. However, given the currently available techniques a multimodality stepwise 57 
approach likely offers the most accurate diagnosis, sequentially applying one sensitive rule-58 
out test and one specific rule-in test. Geographical variations in cytology (e.g. Hürthle cell 59 
neoplasms) and tumor genetics strongly influence local test performance and clinical utility. 60 
Multidisciplinary collaboration and implementation studies can aid the local decision for one 61 
or more eligible diagnostics.  62 
Precis 63 
 64 
This review discusses the value of additional molecular and imaging diagnostics for thyroid 65 
nodules with indeterminate cytology, including considerations regarding cost-effectiveness, 66 
availability, and feasibility of combining techniques. Addressed diagnostics include gene 67 
mutation analysis, microRNA, immunocytochemistry, ultrasonography, elastosonography, 68 
CT, sestamibi scintigraphy, FDG-PET and diffusion-weighted MRI.  69 
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INTRODUCTION 103 
 104 
Indeterminate thyroid cytology is an eyesore to physicians. It largely corresponds to 105 
histopathologically follicular-patterned lesions, both benign and malignant, including 106 
follicular adenoma, noninvasive follicular thyroid neoplasm with papillary-like nuclear 107 
features (NIFTP), (encapsulated) follicular variant of papillary thyroid carcinoma (FVPTC or 108 
EFVPTC) and follicular thyroid carcinoma (FTC). These neoplasms are particularly difficult 109 
to differentiate on fine needle aspiration cytology (FNAC). In the case of FTC, cytology lacks 110 
the insight into the tissue structure like histology does: it does not show the capsular and/or 111 
vascular invasion that distinguishes a FTC from a benign FA. In FVPTC, the growth pattern 112 
is follicular and clearly identifying nuclear features of PTC can usually not be identified 113 
cytologically (1-3). Nevertheless, FNAC currently has a most prominent place in the 114 
diagnostic work-up of thyroid nodules. The Bethesda System for the Reporting of Thyroid 115 
Cytology was adopted in its current form in 2009, recognizing six diagnostic categories with 116 
an incremental risk of malignancy and clinical management guidelines. Although the 117 
Bethesda system created a much-used handhold by standardizing the cytological diagnosis 118 
and consecutive management of thyroid nodules worldwide, the system does not provide a 119 
clear answer for the heterogeneous group of nodules with indeterminate cytology (4,5). This 120 
includes cytology with atypia of undetermined significance or follicular lesion of 121 
undetermined significance (AUS/FLUS, Bethesda III), and cytology (suspicious for a) 122 
follicular neoplasm (SFN/FN) or (suspicious for a) Hürthle cell neoplasm (SHCN/HCN, 123 
Bethesda IV). Similar indeterminate cytological categories are found in the British Thyroid 124 
Association Thy system and Italian SIAPEC-IAP classification: Thy3a and Thy3f, and TIR3A 125 
and TIR3B, respectively (Table 1) (6,7). 126 
Alongside a doubled incidence of thyroid carcinoma over the past two decades and a 127 
prevalence of thyroid nodules stretching far beyond the 5% for palpable nodules – explained 128 
by the incidental detection of nonpalpable nodules and clinically occult thyroid cancers on 129 
imaging studies – the need for a more accurate diagnostic procedure has grown (8). This urge 130 
was further emphasized when other research groups were unable to reproduce the prevalence 131 
of the cytological categories and corresponding malignancy risks proposed by Cibas et al., 132 
especially those of the AUS category (4,9,10). Insuperable variations in the worldwide patient 133 
populations, and intra- and interobserver variation in the assessment of thyroid cytology were 134 
named as likely underlying causes (4,5,10,11). Yet, it raised questions concerning the overall 135 
approach of thyroid nodule diagnosis and whether cytology is the best starting ground. Cost-136 
effectiveness is a major benefit of cytological examination, yet a more accurate test may 137 
eventually replace cytological examination completely (12,13). At present, however, a 138 
supplemental diagnostic procedure is specifically warranted for cytologically indeterminate 139 
thyroid nodules. Diagnostic hemithyroidectomies are still customarily performed to obtain a 140 
definite histological diagnosis. With a benign histopathological result in approximately three 141 
in four cases, surgery was not only unbeneficial but also exposed the patient to unnecessary 142 
surgical risks. In the case of malignant lesions, a second-stage completion thyroidectomy is 143 
often indicated, which is associated with additional costs and higher risks of surgical 144 
complications (14-17). An additional preoperative test or combination of tests for thyroid 145 
nodules with indeterminate cytology should prevent unbeneficial diagnostic 146 
hemithyroidectomies for benign nodules, limit the number of two-stage surgeries for thyroid 147 
malignancies, or both. With rapidly advancing technology, the possibilities for additional 148 
diagnostic techniques seem endless: the applications of existing diagnostics such as 149 
ultrasound, PET/CT and immunocytochemistry are extended and more clearly demarcated for 150 
use in indeterminate thyroid nodules. High-tech molecular tests such as gene mutation panels, 151 
gene or microRNA expression profiles and sequencing techniques are hot-topic (4,18-22). 152 
Every currently known engagement point from the genotype to the phenotype of the tumor is 153 
being explored. Combined, the various research fields encompass an extensive range of 154 
investigative methods. Individually they usually focus on one or two methods only, making 155 
one-to-one comparison of these diagnostics difficult. The 2015 American Thyroid 156 
Association (ATA) guidelines suggested several additional tests, but a definitive answer or 157 
complete overview of all available tests is still lacking (23).  158 
Alongside higher-level expert discussions and lobbying of med tech companies, clinical 159 
endocrinologists and thyroid surgeons ponder about the best solution for their individual 160 
patients. Their choices depend on the characteristics of their patient populations, availability 161 
and costs of a certain test, and personal preference. In any case, a useful additional test should 162 
be accurate, accessible, affordable and affect patient management.  163 
This review aims to provide practical considerations for physicians involved in the 164 
management of patients with thyroid nodules. It gives an overview of the available literature 165 
on additional diagnostic tests for thyroid nodules with indeterminate cytology. We will work 166 
our way down from genotype to phenotype, discussing both anatomical and functional 167 
techniques, from the state-of-the-art molecular and imaging biomarkers as well as widely 168 
available conventional imaging techniques. The ability of a test to distinguish between 169 
malignant and benign nodules in a preoperative setting is discussed, focusing on clinical 170 
validation and utility, and including the development phase, cost-effectiveness and 171 
availability of each technique, where appropriate. Table 2 provides a summarized overview of 172 
the discussed diagnostics and their main attributes.  173 
 174 
1. MOLECULAR BIOMARKERS  175 
 176 
1.1. Gene mutation analysis and Gene expression  177 
 178 
In the last decades, researchers have unraveled important molecular mechanisms behind the 179 
thyroid tumorigenesis, and designated a great number of genetic alterations that are related to 180 
the various types of thyroid carcinoma. Several of these mutational markers have found their 181 
way to the preoperative diagnosis of indeterminate thyroid nodules. The most common 182 
markers are the somatic BRAF and RAS point mutations, and RET/PTC rearrangement, all of 183 
which involve the mitogen-activated protein kinase (MAPK) signaling pathway (24-26).  184 
In the 2015 ATA guidelines the potentially strong diagnostic impact of molecular testing is 185 
explicitly unfolded, focusing on BRAF testing and the – at that date – two main commercially 186 
available tests: the seven-gene mutation panel miRInform® thyroid (Asuragen Inc., Austin, 187 
Texas) and the Afirma® gene expression classifier (Veracyte, Inc., South San Francisco, CA). 188 
The ATA recommends considerate application of one of these molecular tests for Bethesda III 189 
and IV nodules, provided that the result could change the treatment strategy (23).  190 
In the following chapters, the diagnostic potential of mutation analysis in indeterminate 191 
thyroid nodules is discussed, including the tests mentioned in the guidelines as well as other 192 
individual molecular biomarkers and multi-gene panels addressed in literature.  193 
 194 
1.1.1. BRAF mutation 195 
 196 
B-type RAF kinase (BRAF) is a serine–threonine kinase belonging to the rapidly accelerated 197 
fibrosarcoma (RAF) family, and the most potent mitogen-activated protein kinase (MAPK) 198 
pathway activator. Point mutations in the BRAF proto-oncogene occur in various human 199 
cancers. The somatic BRAFV600E mutation is the most common activating mutation in many 200 
carcinomas, including thyroid carcinoma (24). This missense mutation consists of a thymine-201 
to-adenine substitution at nucleotide 1799 (c.1799T>A), resulting in an amino acid 202 
substitution where valine is replaced with glutamate at codon 600 (hence V600E)(27,28). 203 
BRAF has an important function in cell proliferation, differentiation, and apoptosis. 204 
Upregulation of BRAF through the BRAFV600E activating mutation is associated with 205 
tumorigenesis (28). In differentiated thyroid cancer, the BRAFV600E mutation is exclusive to 206 
PTC, occurring in 50% to 80% of these tumors (24,25,29-39). The BRAFV600E mutation has 207 
been prognostically associated with poor clinicopathological outcomes, such as increased 208 
incidence of extrathyroidal invasion, recurrence of disease, and distant metastasis of the tumor 209 
(40-42).  210 
BRAF mutation analysis has been extensively studied as a rule-in test for thyroid carcinoma. 211 
The BRAF mutation is superior to other mutations in its oftentimes 100% specificity – a 212 
positive mutation could prevent two-stage surgery for an indeterminate thyroid nodule (21,29-213 
31,35-38,41-76). Even though the BRAF mutation was found in a majority of PTC in a 214 
number of studies, the prevalence of the BRAF mutation in indeterminate cytology ranged 215 
from 0% to 48% in individual studies (44,46,48,59,65,70). Reported sensitivities were 216 
therefore heterogeneous and generally poor, ranging from 0% to 83% (29,34,39,46). Other 217 
types of thyroid carcinoma occurring in indeterminate nodules, including FTC, FVPTC and 218 
Hürthle cell carcinoma (oncocytic variant of follicular thyroid carcinoma, FTC-OV), were 219 
respectively never or infrequently BRAF mutation-positive (31,37,38,42,50,57,76). 220 
Predominated by follicular type carcinoma, the BRAF mutation rarely occurs in Bethesda IV 221 
cytology (29,31,37,41,50,52,54,57,59,60,63,65,66,70,73-80).  222 
Likely contributors to the observed heterogeneity are known global variations in the 223 
occurrence rates of PTC and BRAF mutations. In South Korea, where iodine consumption is 224 
high, 90% to 95% of thyroid cancers are PTC. More specifically, the proportion of BRAF -225 
mutated PTC is very high: rates of 80% to more than 90% are reported (34,46,77). 226 
Consequently, BRAFV600E mutation analysis might have both high specificity and high 227 
sensitivity in these populations. Studies with higher sensitivities were more often of South 228 
Korean origin and frequently demonstrated sensitivity above 40%, with the prevalence of 229 
BRAF mutations reported as high as 30% to 48%. (34,39,46,47,73,81-83). Conversely, the 230 
majority of studies with sensitivity below 10% were conducted in Western countries (USA, 231 
Europe or Canada), with some studies reporting no BRAF mutations at all 232 
(21,31,37,45,48,52,56-59,61,62,65,69,70,76,80). 233 
Some South Korean studies based surgical decision-making on the result of the BRAF 234 
mutation analysis: surgery was relatively less often performed in BRAF mutation-negative 235 
indeterminate nodules (34,39,78,83). Such a surgical management strategy is not 236 
oncologically safe for Western countries (e.g. Europa or Northern America), where 80% to 237 
90% of thyroid carcinomas are PTC and reported rates of BRAF-mutated PTC vary from 30% 238 
to 40% (34,46,77). Moreover, even though the true sensitivity of BRAF mutation analysis is 239 
presumably high in South Korea for the mentioned epidemiological reasons, the conservative 240 
management of BRAF mutation-negative nodules likely magnified test sensitivity by 241 
underestimating the rate of BRAF-negative malignant nodules in these studies. Altogether we 242 
estimate that approximately one in five South Korean patients would benefit from BRAF 243 
mutation analysis, opposite mere one in 25 patients from other countries.  244 
 245 
BRAF mutation in papillary microcarcinoma 246 
Papillary microcarcinoma (mPTC) have lower BRAF mutation rates (53,58,63,68,73,76,84). 247 
The ATA guidelines are reserved with regard to the recommended clinical management of 248 
positive BRAF mutation in mPTC, as its relation to extrathyroidal spread and positive lymph 249 
node metastases is not as clear as in larger thyroid carcinoma. Although there are studies that 250 
associate mPTC to factors of poorer prognosis, the 2015 guidelines recommend that BRAF-251 
mutated mPTC are treated as low-risk malignancies (23,35).  252 
 253 
BRAFK601E point mutation 254 
A less common activating BRAF mutation is BRAFK601E (c.1801A>G), which occurs 255 
considerably less frequently than the BRAFV600E variant and is associated with FVPTC with 256 
high specificity (85). Clinically, the characterization of a small cohort of thyroid malignancies 257 
with a BRAFK601E mutation showed better outcomes than for BRAFV600E mutated tumors: no 258 
extrathyroidal tumor extension, recurrence, lymph node or distant metastasis were reported in 259 
indeterminate BRAFK601E positive tumors with a median follow-up of 20 months (range 4-47) 260 
(86).  261 
 262 
Availability, cost-effectiveness and limitations of BRAF mutation analysis 263 
Altogether, the consistent perfect specificity in a large number of studies supports the use of 264 
BRAF mutation analysis in obviating two-stage surgery. The technique is increasingly 265 
available in the clinical setting worldwide. A prior meta-analysis of eight studies questioned 266 
the cost-effectiveness of BRAFV600E mutation analysis in indeterminate thyroid nodules based 267 
on a mere 4.6% mean prevalence of the mutation (87). Cost-effectiveness studies concerning 268 
sole BRAF mutation analysis in indeterminate thyroid nodules are lacking. Regardless, cost-269 
effectiveness is generally presumed, as average costs for testing are relatively low and 270 
decreasing over time. Depending on the applied molecular technique, reported costs for BRAF 271 
mutation analysis ranged between €7.50 and $123 per tested sample (53,63,72,88).  272 
 273 
Low sensitivity remains the main limitation of BRAF mutation analysis, irrespective of the 274 
type of indeterminate cytology. Proficiency of the test in preoperative patient management 275 
depends on the regional occurrence rate of BRAF-mutated PTC; in South Korea, more 276 
patients will benefit from BRAF mutation analysis, and the probability and extent of cost-277 
effectiveness are likely to increase (66). In other health care systems, such as in the UK, cost-278 
effectiveness is likely more constrained. Nonetheless, BRAF testing could still save 279 
approximately half the surgical costs in BRAF mutation-positive carcinoma (63,65). These 280 
global variations should be considered before local implementation of sole BRAF mutation 281 
analysis.  282 
 283 
1.1.2. RAS point mutation 284 
 285 
Point mutations in the gene family of retrovirus-associated DNA sequences (RAS) together 286 
constitute the second most frequently occurring genetic alteration in thyroid carcinoma. In 287 
indeterminate thyroid nodules, they are the most common genetic alteration, due to a strong 288 
association of RAS mutations with the follicular-patterned lesions that make up these 289 
cytological categories: follicular adenoma, FTC, FVPTC and noninvasive follicular thyroid 290 
neoplasms with papillary-like nuclear features (NIFTP) (1,3,31,59,89,90). Originally, two of 291 
the three homologous RAS genes were identified as viral genes of the oncogenic Harvey 292 
(HRAS) and Kirsten (KRAS) murine sarcoma virus; the third, NRAS, was first identified in 293 
neuroblastoma cells (91,92). The genes code for GTP-binding RAS proteins, which are 294 
involved in intracellular signaling in the MAPK/ERK pathway. Mutation causes overactive 295 
RAS signaling and could ultimately induce malignant transition (26).  296 
RAS mutation in thyroid carcinoma has been associated with favorable prognostic factors, 297 
such as encapsulation of the tumor and absence of lymph node metastases, but also with 298 
factors indicative of an adverse prognosis, such as poor cell differentiation (2). RAS mutations 299 
are not specific for carcinoma and found in both malignant and benign lesions (31,61,90). 300 
According to the 2015 ATA guidelines, Bethesda III or IV nodules with a RAS mutation 301 
should be treated similar to the Bethesda V category, as approximately 4 out of 5 are 302 
malignant (4,23). HRAS, KRAS and NRAS mutations are mutually exclusive. They are each 303 
associated with slightly different types of cytology and histology, and consequently a 304 
different clinical course. In general, point mutations in NRAS codon 61 and HRAS codon 61 305 
are said to occur most frequently (3,64). KRAS is associated with oncocytic lesions and a 306 
lower malignancy rate than other RAS mutations (93).  307 
A RAS point mutation is found in 0% to 38% of the indeterminate nodules (39,60). Moreover, 308 
approximately a third of all reported malignancies resulting from indeterminate thyroid 309 
cytology are RAS mutation positive, frequently FVPTC or FTC (31,37-39,76). Sporadic cases 310 
of RAS mutation-positive FTC-OV and MTC are reported (37,38). In individual studies, 311 
sensitivity and specificity of RAS mutation analysis ranged from 0% to 77% and from 75% to 312 
100%, respectively (39,60,90). Test performance was similar for Bethesda III and IV 313 
categories, although the mutation occurred more frequently in Bethesda IV nodules 314 
(21,29,31,39,50,59,60,76,80,90). Histopathologically benign nodules carrying a RAS mutation 315 
are histopathological follicular adenoma in most cases, but also oncocytic variant of follicular 316 
adenoma (Hürthle cell adenoma) or hyperplastic nodules (29,31,38,50,90). There is an 317 
ongoing discussion regarding the interpretation of a false positive RAS mutation. It is 318 
presumed that an oncogenic RAS mutation predisposes a follicular adenoma for progression 319 
into follicular carcinoma – a RAS-mutated follicular adenoma should be considered a 320 
premalignant pre-invasive follicular neoplasm. These assumptions put false-positives in a 321 
different light, as it would justify resection of such lesions through hemithyroidectomy. 322 
Consequently, the lesions could also be considered true-positives – improving the specificity 323 
of RAS mutation analysis (1,21,39,59,61,71). However, the exact mechanisms behind the 324 
malignant potential and transition for RAS-mutated follicular adenomas are not yet clarified 325 
and difficult to appreciate in a clinical setting. 326 
Similar to BRAF, there was evident global variation in the distribution of RAS mutations. 327 
Many European and American studies reported a clear predominance of RAS mutations over 328 
BRAF mutations. Solely a Brazilian study of 116 Bethesda III and 20 Bethesda IV thyroid 329 
nodules reported only BRAF mutations and not a single RAS mutation (60). The previously 330 
described predominance of BRAF mutations in South Korean populations was confirmed in 331 
the sole study that investigated both point mutations in one population (39). Combined 332 
BRAF/RAS mutation analysis could be considered, although geographical differences in the 333 
distribution of the two genetic alterations strongly influence feasibility. A gene mutation 334 
panel consisting of more genetic alterations (discussed in a next chapter) is most likely more 335 
useful. 336 
Sole RAS mutation analysis is not accurate in the preoperative setting. Although specificity is 337 
high, only two out of three RAS mutation positive indeterminate nodules are 338 
histopathologically malignant, evidently fewer than assumed and previously described in the 339 
ATA guidelines. Therefore, RAS mutation positive indeterminate thyroid nodules should be 340 
surgically managed with no more than hemithyroidectomy. Whether hemithyroidectomy is 341 
justified for RAS-mutated follicular adenomas as a precancerous lesion, is yet under debate. 342 
 343 
1.1.3. RET/PTC rearrangement 344 
 345 
Rearrangements of the RET proto-oncogene arise from the fusion of the 3’ end of RET to the 346 
5’ regions of unrelated genes that are expressed in thyroid follicular cells. Proto-oncogene 347 
RET encodes for a transmembrane receptor with a tyrosine kinase domain; a RET/PTC 348 
rearrangement causes inappropriate overexpression of that domain. It activates the MAPK and 349 
PI3K/AKT pathways and stimulates malignant transition of the cell through BRAF (94,95). 350 
At least 12 different fusion variants have been detected until today, of which RET/PTC1 and 351 
RET/PTC3 are the most common. They have a well-known association with PTC. Cases of 352 
both rearrangements in a single lesion are also reported (2,94,96,97). RET/PTC 353 
rearrangements, especially RET/PTC3, occur more frequently in PTC in children or patients 354 
that were exposed to ionizing radiation and are clinically associated with the presence of 355 
lymph node metastases (2). Worldwide variations in frequency of RET/PTC rearrangements 356 
exist, dependent on demographics and ethnicity. The RET/PTC rearrangement is present in 357 
42% of PTC in Western populations with a predominance of RET/PTC1, and in 37% of PTC 358 
in Asian populations with a predominance of RET/PTC3. Without radiation exposure, in 359 
female PTC patients RET/PTC1 is predominant (98). The rearrangements are also found in 360 
benign nodules, especially in patients that were exposed to ionizing irradiation (29,97). Alike 361 
RAS mutations, it is assumed to be an activating genetic alteration and it is argued that a 362 
histopathologically benign nodule with a RET/PTC rearrangement should be considered a 363 
precancerous lesion.  364 
RET/PTC rearrangements are seldom found in indeterminate nodules. In many studies, no 365 
RET/PTC translocation was found at all. Most studies investigated RET/PTC in light of a 366 
gene mutation panel and paid it no specific attention 367 
(21,29,31,37,38,45,49,50,55,59,61,62,64,70,76,80,96). Only Guerra et al. solely investigated 368 
the RET/PTC rearrangement in 101 thyroid nodules of all cytological categories. In this 369 
Italian study, RET/PTC rearrangements were found in 18 of the 50 PTC (36%) using RT-PCR 370 
and Southern-Blot. All these RET/PTC-positive carcinomas were Thy4 or Thy5 nodules on 371 
cytology. Among the 24 Thy3 nodules, two nodules with a RET/PTC3 rearrangement were 372 
histopathologically benign (96).  373 
Noteworthy, Sapio et al. detected two RET mutations during their RET/PTC assessments. In 374 
contrast to the RET/PTC translocation, RET point mutations are related to sporadic and 375 
familial MTC (45,99). Surgery confirmed histopathological MTC in the RET-mutated nodules 376 
(45). 377 
 378 
Even though previous histological studies undeniably associated RET/PTC1 and RET/PTC3 379 
rearrangements to PTC, the low prevalence of the rearrangement in indeterminate cytology is 380 
a major downside. Testing exclusively for this genetic alteration in indeterminate nodules is 381 
not advantageous, even if issues regarding the number of tested variants and sensitivity of 382 
molecular techniques are overcome. The 2015 ATA guidelines only advise RET/PTC testing 383 
in context of a gene mutation panel (23).  384 
 385 
1.1.4. PAX8/PPARγ rearrangement 386 
 387 
The PAX8/PPARγ rearrangement arises from a fusion of the promoter and 5’-coding portion 388 
of the thyroid-specific transcription factor PAX8 gene to the gene of the nuclear receptor 389 
peroxisome proliferator-activated receptor γ (PPARγ) (100,101). The role of the product of 390 
this translocation – the PAX8/PPARγ fusion protein – is not yet understood, as the DNA 391 
binding sites of both original proteins are uniquely preserved in the fusion (101). In the 392 
normal thyroid, transcription factor PAX8 is involved in differentiation of thyrocytes and 393 
regulation of the expression of thyroid-specific genes encoding thyroperoxidase, 394 
thyroglobulin and the sodium/iodide symporter (102). Nuclear receptor PPARγ has multiple 395 
presumed functions, including involvement in the regulation of lipid metabolism, 396 
adipogenesis and insulin sensitivity (101,103).  397 
The chromosomal translocation PAX8/PPARγ was first discovered in – and traditionally 398 
associated with – FTC and follicular adenoma (100). It is reported in 30% to 45% of FTC and 399 
in up to 33% of follicular adenoma (50,104-106). However, several studies have also 400 
uncovered varying amounts of FVPTC carrying the translocation, with published rates up to 401 
38% (104,107,108). It has not been reported in benign or malignant Hürthle cell neoplasms 402 
(105,109). 403 
PAX8/PPARγ is often related to well-differentiated malignancies with a relatively favorable 404 
prognosis. Capsular and vascular invasion are reported to a lesser extent in FTCs with a 405 
PAX8/PPARγ rearrangement than in RAS-mutated tumors (105). Widely invasive features are 406 
not reported. PAX8/PPARγ-mutated FVPTC are mostly encapsulated, following an indolent 407 
clinical course with minimal disease recurrence despite the presence of some capsular and 408 
vascular invasion at presentation (105-107). In contrast to the BRAF, RAS and RET/PTC 409 
genetic alterations in thyroid carcinoma, the PAX8/PPARγ rearrangement does not involve 410 
the RAS-RAF-MAPK pathway. Nikiforova et al. hypothesized that oncogenesis of follicular-411 
type tumors likely takes place through two different molecular pathways: a RAS-mutation 412 
driven and PAX8/PPARγ rearrangement driven pathway (105).  413 
Similar to the RET/PTC rearrangement, the PAX8/PPARγ rearrangement rarely occurred in 414 
indeterminate thyroid cytology. Approximately two-thirds of the indeterminate nodules 415 
carrying the rearrangement were histopathologically malignant, most often FVPTC or FTC 416 
(21,31,37,38,49,55,59,61,62,70,76,80,109). False-positive results corresponded to follicular 417 
adenomas (61,62,70). Similar to RAS mutations, histopathologically benign PAX8/PPARγ-418 
mutated nodules are likely premalignant lesions, or pre-invasive FTC. Eszlinger et al. 419 
observed a microfollicular morphological growth pattern in two of the PAX8/PPARγ-positive 420 
follicular adenoma, supporting this hypothesis (61).  421 
Still, PAX8/PPARγ rearrangement is a rare rearrangement associated with (encapsulated) 422 
follicular tumors. Similar to RET/PTC rearrangements, the PAX8/PPARγ rearrangement 423 
should only be assessed in indeterminate thyroid nodules in combination with more frequently 424 
occurring genetic alterations in a gene mutation panel.  425 
 426 
1.1.5. Other genetic alterations 427 
 428 
hTERT 429 
The enzyme human telomerase is involved in the maintenance of the chromosomes’ 430 
telomeres, which are essential for cell life and proliferation. The catalytic subunit of 431 
telomerase is human telomerase reverse transcription (hTERT). In normal thyroid cells, it is 432 
inactive. Inappropriate reactivation is associated with malignancy and inflammatory thyroid 433 
disease (110). hTERT promotor mutations were previously observed in both PTC and FTC, 434 
sometimes together with a BRAF mutation. The mutation is strongly correlated to mortality in 435 
differentiated thyroid carcinoma (111). hTERT gene expression is potentially accurate in the 436 
preoperative differentiation of indeterminate nodules, with 57% to 88% sensitivity and 75% 437 
to 85% specificity demonstrated in two small clinical series of cytological follicular 438 
neoplasms (112,113).  439 
 440 
TRK 441 
The tyrosine receptor kinase (TRK) rearrangement arises from a translocation of the NTRK1 442 
gene, which is normally expressed in the central and peripheral nervous system and involved 443 
in cell differentiation. The TRK rearrangement is associated with PTC and presumably with 444 
an adverse prognosis, although evidence is limited (114). In feasibility studies in 445 
indeterminate thyroid cytology, not a single TRK rearrangement has been detected – it is most 446 
likely not a useful marker (45,49,50).  447 
 448 
HMGA2 449 
Proteins high mobility group AT-hook (HMGA) 1 and 2 regulate the structure and function of 450 
chromatin. Normally only expressed during embryogenesis, the overexpression of HMGA in 451 
adult tissues is associated with malignancy (115). Lappinga et al. demonstrated that HMGA2 452 
could be a promising additional biomarker. Using ROC curve analysis, a >5.9-fold HMGA2 453 
overexpression had 76% sensitivity and 98% specificity in SFN/FN nodules (116). To date no 454 
other studies attempted to validate these results.  455 
 456 
Galectin-3 and CD44v6 457 
One Croatian study used RT-PCR to investigate the simultaneous expression of galectin-3 and 458 
CD44v6, two molecular biomarkers better known for their application in 459 
immunohistochemistry of their expression products (117). CD44v6 normally functions as the 460 
cell-surface receptor for hyaluronic acid. Overexpression is found in various human cancers, 461 
including thyroid (117,118). In indeterminate thyroid nodules, a positive test for either one of 462 
the two biomarkers resulted in 100% sensitivity and 60% specificity. It is presumed that 463 
similar results for these markers are achieved with the more economical 464 
immunohistochemistry techniques (118,119).  465 
 466 
1.1.6. 7-Gene Mutation Panel 467 
 468 
Ongoing research in the past years has demonstrated that assessment of individual oncogenic 469 
mutations generally has limited clinical utility in indeterminate thyroid cytology. Combining 470 
forces of individual genetic alterations into a gene mutation panel, however, likely improves 471 
diagnostic accuracy, especially as mutations are mutually exclusive in most cases. These gene 472 
mutation panels typically assess the seven genetic alterations – gene mutations as well as gene 473 
fusions – that occur most frequently in differentiated thyroid carcinoma, including 474 
BRAFV600E, BRAFK601E, NRAS codon 61, HRAS codon 61 and KRAS codon 12-13 point 475 
mutations and RET/PTC1, RET/PTC3 and PAX8/PPAR gene rearrangements (31,55). The 476 
best known panel is the commercially available miRInform® thyroid (Asuragen Inc., Austin, 477 
Texas, USA), currently rebranded as the ThyGenX® Thyroid Oncogene Panel (Interpace 478 
Diagnostics, Parsippany, NJ, USA). The miRInform® thyroid tests 17 specific genetic 479 
alterations in these seven genes (59). It is marketed as a rule-in test for thyroid malignancy. 480 
 481 
The first large clinical utility study to investigate the miRInform® thyroid test was published 482 
in 2011. Nikiforov et al. prospectively included 1,056 FNAC samples, 92% of which had 483 
sufficient epithelial cells and nucleic acids to pursue molecular testing. Residual FNAC 484 
material was used for mutation analysis – no additional aspirates were required. 485 
Unfortunately, surgery was performed for only 461 of 900 (51%) indeterminate thyroid 486 
nodules, independent of the test outcome; these operated cases were included in their final 487 
analysis. It is not reported whether nonsurgically managed nodules were mutation-positive or 488 
-negative. Sensitivity and specificity were 63% and 99% in the 247 Bethesda III nodules, and 489 
57% and 97% in the 214 Bethesda IV nodules, respectively. The authors suggested that the 490 
high PPV of the miRInform® thyroid in these indeterminate thyroid nodules (88% and 87%, 491 
respectively) warrants a direct total thyroidectomy instead of two-step surgery in patients with 492 
a positive test (31).  493 
None of the subsequent studies matched the initially reported excellent specificity. The next 494 
industry-sponsored prospective study by Beaudenon et al. reported 47% sensitivity and 88% 495 
specificity in 80 Bethesda III and IV nodules. Surprisingly, not a single BRAF mutation was 496 
detected (59). Valderrabano et al. reported not a single mutation in 47 included Bethesda III 497 
nodules. Moreover, only 1 of 18 nodules with Hürthle cell cytology in this study tested 498 
positive, suggesting that Hürthle cell nodules may carry different mutations than the ones 499 
investigated by the miRInform® thyroid (76). Ohori et al. demonstrated that genetic 500 
alterations less frequently occurred in the textbook colloid-poor Bethesda IV cytology 501 
compared to the less common colloid-rich variant. Differences in etiology are unknown, but 502 
the authors hypothesized that the two types have subtle histopathological differences. The 503 
colloid-rich thyroid carcinomas likely more often develop through the well-known mutations 504 
included in the miRInform® thyroid test, whereas mutations that elicit colloid-poor thyroid 505 
carcinoma are yet unknown (37). 506 
 507 
Simultaneously with the American miRInform® studies, five European studies independently 508 
investigated whether a panel of the same 7 genes could reliably be assessed using different 509 
methods (38,55,61,62,70). In three separate studies, Eszlinger et al. demonstrated that testing 510 
was also feasible on routine air-dried FNAC samples from indeterminate thyroid nodules. 511 
Over the course of these studies, sensitivity of this method improved from 18% to 49% and 512 
specificity from 86% to 93%, respectively. The use of air-dried FNAC samples for mutation 513 
analysis could advance the implementation of mutation analysis in daily practice, as specific 514 
storage conditions of fresh FNAC samples for mutation analysis are no longer required 515 
(38,61,62). Mancini et al. showed that high-resolution melting (HRM) analysis is an accurate 516 
screening method for the seven genetic alterations, with 56% sensitivity and 90% specificity. 517 
HRM is a post-PCR procedure that does not require significant additional resources. This 518 
could reserve the costlier direct sequencing procedures solely for samples with abnormal 519 
HRM results, thereby reducing the overall costs of mutation analysis (55).  520 
 521 
Overall, reported sensitivities and specificities of a 7-gene mutation panel in indeterminate 522 
thyroid nodules ranges from 18% to 69% and 86% to 99%, respectively (22,37,61). It is an 523 
adequate diagnostic tool with a high rule-in capacity in indeterminate nodules. Test 524 
performance was similar in Bethesda III and Bethesda IV nodules, although the latter more 525 
frequently had a positive test result based on the higher prevalence of RAS mutations (31,59). 526 
Due to the common RAS mutations, PPV of the 7-gene mutation panel never exceeds 90% in 527 
a range of realistic 15% to 40% prevalence of malignancy. As such it is debatable whether a 528 
positive test warrants immediate single-stage total thyroidectomy. It translates into an 529 
inappropriate overtreatment in a significant number of patients with a positive test but benign 530 
final histology at higher risk of surgical complications and all requiring lifelong levothyroxine 531 
supplementation. Deliberate surgical decision-making should consider the underlying positive 532 
mutation rather than mere the positive test itself. 533 
The limited size of the seven-gene gene mutation panel keeps the costs per test low compared 534 
to other, larger molecular panels. Reported prices of the 7-gene mutation panel all concern the 535 
commercial miRInform® thyroid (or ThyGenX® Thyroid Oncogene Panel) and range 536 
between $425 and $1,700 (120,121). Implementation of miRInform® testing for 537 
indeterminate nodules theoretically resulted in a 20% cost reduction in the USA: the 538 
prevented two-step surgical procedures would outweigh the added expenses for miRInform® 539 
testing and increased number of total thyroidectomies – including those for nodules with a 540 
false-positive test (120). In a European setting, treatment and hospitalization costs are 541 
generally lower and miRInform® would most likely not be cost-effective (14). However, 542 
these cost-effectiveness studies both adopted the unequalled test performance from the initial 543 
key publication – true cost-effectiveness may be less optimistic (14,31,120,121). 544 
 545 
1.1.7. Next Generation Sequencing 546 
 547 
To improve the sensitivity of the miRInform® thyroid test, the existing 7-gene mutation panel 548 
was expanded to include additional gene mutations, fusions and translocations, and a 549 
microRNA gene expression panel. In addition, it adopted promising next generation 550 
sequencing (NGS) techniques. NGS enables the simultaneous targeted testing for multiple 551 
mutations in large gene panels and is faster, more sensitive and more cost-effective than 552 
traditional Sanger sequencing and other PCR-based methods (71,80,122). As NGS only 553 
requires a very small amount (5-10 ng) of nucleic acids, remainder material from regular 554 
FNAC passes suffices and no additional aspirates are required (80,122). The first thyroid-555 
specific NGS-based gene panel was the ThyroSeq® v1, presented in 2013. It detected gene 556 
variations in 110 of 145 investigated thyroid cancer tissue samples and 5 of 83 benign 557 
specimens. Unfortunately, indeterminate FNAC samples were not analyzed separately in this 558 
study. Nonetheless, Nikiforova et al. demonstrated that NGS had a very high success rate and 559 
could be a promising molecular technique for thyroid FNAC samples (122).  560 
 561 
Following the ThyroSeq® v1, the road was paved for further exploration of NGS-based 562 
diagnostics. Soon, the ThyroSeq® v2 (CBLPath, Ocala, FL, USA) was developed, with a 563 
number of primers for TERT promotor variants added to its panel. It simultaneously tested for 564 
point mutations in 13 genes and for 42 types of gene fusion products (80). The ThyroSeq® v2 565 
was tested on 143 Bethesda IV thyroid nodules. Forty-two genetic alterations were found, 566 
most frequently NRAS. Diagnostic accuracy of the ThyroSeq® v2 was 92%, with astonishing 567 
90% sensitivity and 93% specificity (80).  568 
More recently, Nikiforov et al. tested the ThyroSeq® v2.1 – including point mutations in 14 569 
genes and 42 gene fusion transcripts – in 462 Bethesda III nodules. Based on the promising 570 
results of the previous study, surgery was withheld for 362 of 431 ThyroSeq®-negative 571 
patients. In the 95 patients with available histopathology, the ThyroSeq® v2.1 demonstrated 572 
91% sensitivity and 92% specificity. Additionally, diagnostic accuracy was estimated for 573 
malignancy rates varying between 6% and 48%: PPV would range from 42% to 91%, NPV 574 
from 92% to 99%. Within reasonable limits the ThyroSeq® v2.1 is highly reliable to rule out 575 
malignancy (21).  576 
Le Mercier et al. retrospectively tested a different commercially available 50-gene NGS 577 
panel, the Ampliseq™ Cancer Hotspot Panel v2 (ThermoFisher, San Diego, California, 578 
USA), which is a tumor-nonspecific NGS panel for detection of somatic tumor variants. This 579 
panel does not include thyroid-specific RET/PTC, PAX8/PPAR and NTRK1 580 
rearrangements. Albeit the study only assessed 34 FNAC samples, with a 71% sensitivity and 581 
89% specificity in indeterminate thyroid nodules the Ampliseq™ panel seems less accurate 582 
than the ThyroSeq® (71). 583 
 584 
The high diagnostic accuracy is also a downside to NGS. Highly sensitive, NGS is able to 585 
identify mutant alleles at very low levels (<10%). A low percentage of mutant alleles might 586 
reflect a subclone within the nodule, which is not histopathologically identified as carcinoma. 587 
This detection of germline or clinically insignificant low-level somatic mutations in benign 588 
nodules could decrease NGS specificity (22,80). Nikiforov et al. suggested that the next 589 
improvement of the NGS-related tests should therefore be to determine accurate threshold 590 
levels for the various gene variations (80).  591 
NGS encompasses crucial technology that is rapidly advancing. The ThyroSeq® v3 was 592 
recently announced, promoting to encompass no less than ~95% of genetic alterations 593 
occurring in PTC. Extraordinary diagnostic accuracy above 90% is anticipated, including high 594 
accuracy in Hürthle cell lesions. Results of the prospective studies validating this new version 595 
will likely be published shortly. Nonetheless, NGS techniques currently have limited global 596 
availability, with the exception of some European countries and the USA. The ThyroSeq® is 597 
available for $3,200 per test (123). In contrast, the thyroid non-specific AmpliSeq™ panel can 598 
be ordered online for only €230 (124). Independent prospective studies are needed to validate 599 
its performance and predicted cost-utility in different patient populations, and confirm the 600 
superior position of the ThyroSeq® and other NGS techniques. 601 
 602 
1.1.8. Afirma® Gene Expression Classifier 603 
 604 
In molecular diagnostics, the chief competitor of the 7-gene mutation panel is the commercial 605 
Afirma® gene expression classifier (GEC) (Veracyte Inc., South San Francisco, CA, USA). 606 
The GEC uses quantification of the mRNA-expression of 167 genes and a proprietary 607 
classification algorithm to determine the probabilities of malignancy in the samples’ 608 
expression patterns. The classification algorithm to discern a ‘benign’ (negative test) from a 609 
‘suspicious’ (positive test) thyroid nodule results from a successful designer study that trained 610 
the GEC in both a tissue set and diverse FNAC sample sets with known histopathology (125). 611 
Alexander et al. performed the first prospective, blinded, industry-sponsored clinical study to 612 
validate this Afirma® GEC in patients with indeterminate thyroid nodules (126). From 49 613 
hospitals 577 Bethesda III, IV and V FNAC samples were collected, obtained by two 614 
additional needle aspirates from thyroid nodules with a diameter of at least 1 cm. After 615 
exclusion of over half (312/577, 54%) of the samples for reasons such as nodules that were 616 
not surgically resected, duplicate specimens from the same nodule, and issues with specimen 617 
shipments to Veracyte, finally 265 FNAC samples were included in the analysis. Sensitivity 618 
of the Afirma® GEC was 90% in the 129 Bethesda III as well as the 81 Bethesda IV nodules 619 
with a useful GEC-negative test result in 38% (100/265), but specificity was merely 53% and 620 
49%, respectively (52% on average). Despite the relatively high malignancy rate in Bethesda 621 
III nodules and the high number of exclusions, this study is well conducted and recognized 622 
worldwide as the landmark study that demonstrated the strength of the Afirma® GEC (126). 623 
After the overwhelming results from this key-publication, popularity of the GEC took flight. 624 
It is marketed as a highly accurate rule-out test for malignancy in thyroid nodules with 625 
indeterminate cytology.  626 
 627 
In 2014, the first multicentre study that retrospectively assessed the clinical utility of the 628 
Afirma® GEC was published. Only 6% of reported GEC-negative Bethesda III, IV and V 629 
nodules eventually underwent surgery, of which one resulted in a 6 mm mPTC. 630 
Unfortunately, data on GEC negative nodules were only reported on an aggregate level; exact 631 
test performance rates in Bethesda III and IV nodules cannot accurately be extracted from the 632 
publication. Less than half of the GEC-negative nodules without surgery (71/163, 44%) had 633 
clinical or radiological follow-up, ranging from 1 to 24 months (median 8 months) – a limited 634 
duration compared to the natural, indolent course of differentiated thyroid carcinoma. The 635 
published paper does not describe whether the remaining 92 patients with GEC-negative 636 
nodules received any follow-up at all. Despite evident limitations to the applied reference 637 
standards, Alexander et al. concluded that their results confirm both the accurate test 638 
performance from their prior study as well as the large impact that the Afirma® GEC has on 639 
clinical decision-making for cytologically indeterminate thyroid nodules (127). 640 
 641 
Yet, physicians indeed seemed reassured by a negative GEC result based on the first studies 642 
alone (126,128). In many institutions in the USA the Afirma® GEC was immediately 643 
implemented in clinical practice. The retrospective studies that followed were mere post-644 
implementation utility studies, and generally reported very high but moderately consistent 645 
sensitivities. GEC-negative nodules were largely managed without surgery and considered 646 
true-negative, resulting in possible overestimation of test sensitivity. Long-term follow-up is 647 
not yet available to endorse a benign diagnosis in these cases (129,130). The high degree of 648 
missing histology was recognized by most of these studies as a major limitation 649 
(127,129,131-134). This was confirmed by the 2015 ATA guidelines: recognizing the 650 
Afirma® GEC as a promising diagnostic tool, the guidelines stress that it is a major 651 
shortcoming that external clinical validation studies with full histological follow-up of 652 
Afirma® GEC-negative nodules are still lacking (23). 653 
Not all studies were able to confirm the potential of the Afirma® GEC. Some struggled with a 654 
low benign call rate (i.e. useful negative test result that could lead to management change) 655 
(130,135). McIver et al. questioned the cost-effectiveness of the Afirma® GEC in their 656 
population, as the mere 22% (16/72) negative test rate was much lower than anticipated. 657 
Moreover, a quarter of these GEC-negative patients rejected the proposed conservative 658 
treatment of ultrasound-based follow-up and underwent surgery anyway; one of them was 659 
diagnosed with a 3.2 cm FTC with focal capsular and vascular invasion. Also, 84% of GEC-660 
positive nodules proved histopathologically benign, overall resulting in a disappointing 83% 661 
sensitivity and 10% specificity (130).  662 
Besides concerns regarding adequate clinical validation of test performance, the post-663 
implementation influence of the GEC on surgical decision-making for individual patients was 664 
also questioned. In line with the results of their preliminary study, Noureldine et al. 665 
demonstrated that Afirma® GEC testing had not aided surgical decision-making (135,136). In 666 
93% (206/222) of the included indeterminate nodules, a ‘benign’ or ‘suspicious’ GEC result 667 
did not affect management at all: the surgical strategy would have been identical had it been 668 
based merely on clinical, cytological or radiological suspicion. However, if management 669 
changes were based on the GEC result, they were more often wrong than right: 11 times 670 
GEC-positive results inappropriately tempted physicians into more aggressive surgery, and 671 
total thyroidectomy was performed instead of the initially recommended lobectomy for 672 
nodules that proved histopathologically benign. In contrast, in just four GEC-positive cases 673 
the more aggressive surgery was appropriate and the nodule was histopathologically 674 
malignant. Also, in just one patient surgery was withheld specifically due to a negative 675 
Afirma® GEC result. In the other unresected GEC-negative nodules surgery was not 676 
clinically indicated to begin with; the negative GEC-result merely endorsed conservative 677 
management (135). As the GEC was still a new technology when this study was conducted, it 678 
is possible that the involved physicians were unsure of the correct interpretation of the GEC 679 
results or hesitant to rely on a negative GEC result. However, clinical suspicions and 680 
physician and patient preference will always be considered when making surgical decisions.  681 
Yang et al. elegantly tried to solve the shortcoming (histological) follow-up by comparing 682 
their findings of GEC performance to a pre-GEC cohort of similar patients from their hospital 683 
in all of whom surgery was performed (11,131). The reported malignancy rates were 684 
comparable pre- and post-GEC implementation (18% versus 17%), and obviously relatively 685 
more surgeries were performed for benign nodules in the pre-GEC period. Assuming the true 686 
malignancy rates in the successively studied populations are indeed similar, the GEC only 687 
modestly reduced the number of futile surgeries for benign thyroid nodules from 66% to 52% 688 
(131). Altogether, the contribution of the Afirma® GEC to the surgical decision-making may 689 
be more limited than expected based on its diagnostic accuracy. 690 
 691 
 692 
Availability, cost-effectiveness and limitations of the GEC 693 
The Afirma® GEC is currently only available for routine use in the USA. There are high 694 
demands for the FNAC specimens regarding sample preservation and shipping. Cytology is 695 
revised by Veracyte cytologists and declined if not strictly Bethesda III or IV, with 14% to 696 
17% discordancy between local assessment and central review, comparable to known 697 
interobserver rates for thyroid cytology (5,126,135). Reported rates of nondiagnostic GEC test 698 
results due to insufficient quantity or quality of the mRNA are substantial, varying from 1% 699 
to 17% (130,132). Insufficient mRNA quality was often caused by problems with long 700 
duration of the sample shipment to Veracyte (126,130). Fourth, Afirma® GEC testing is 701 
expensive and is currently marketed for $3,500 (range $1,750 to $7,000) per test 702 
(121,131,137). Testing for medullary carcinoma and BRAF mutation is not included in the 703 
Afirma® GEC, but can be performed by Veracyte at additional costs (131). Yet, ancillary 704 
BRAF mutation testing may not be relevant, as Kloos et al. found that it improved sensitivity 705 
nor specificity of the GEC (57). 706 
Studies of cost-effectiveness yielded variable results, but most concluded that GEC testing 707 
would not be cost-effective over conventional surgical management or other diagnostic 708 
modalities in various clinical settings (14,121,137-140). The first of these studies proclaimed 709 
cost-effectiveness of the GEC even prior to publication of the first validation study by 710 
Alexander et al., and has been criticized for several important methodological caveats. This 711 
study professedly overestimated test specificity at 75%, overestimated the rate of permanent 712 
complications from thyroid surgery, and did not consider the regularly reported GEC test 713 
failures (15-17,130,137,138,141). A recent study determined population-dependent thresholds 714 
for feasible cost-effectiveness by comparing GEC performance to conventional surgical 715 
management in a local Bethesda III/IV population. GEC-guided management was not cost-716 
effective, adding $1,197 to the $11,119 expenses for conventional treatment while hardly 717 
improving QALYs. Sensitivity analysis showed that the GEC would only become cost-718 
effective if its specificity exceeds 71%, if it costs less than $2,640, or if the population 719 
malignancy rate decreases from the actual 24% to below 9.2%. This price threshold for cost-720 
effectiveness decreases as the malignancy rate increases, as low as $2,023 per test at 35% 721 
cancer prevalence (137). 722 
Furthermore, existing inter-institutional differences in test performance have consequences 723 
for local applicability and effectiveness (127,134). Marti et al. compared GEC performance in 724 
distinct populations of two large hospitals. The reproducibility of the tests’ sensitivity and 725 
specificity was good, but utility strongly depended on the local prevalence of malignancy: as 726 
the population malignancy rate increased, a rarer negative GEC became less reliable to rule 727 
out malignancy. Oppositely, at low malignancy rates a negative GEC merely confirmed that 728 
the probability of cancer was low. In neither situation, the GEC changed the management 729 
strategy. GEC testing was most useful if the malignancy rate ranged between 15% and 21%, 730 
comparable to the prevalence reported by Alexander et al. (126,134).  731 
Finally, the degree of missing histology is a major limitation to the performed studies. None 732 
of the studies following the key publication by Alexander et al. had complete histopathologic 733 
follow-up; histopathological confirmation ranged between 35% and 82% of specimens (126).  734 
Missing histology mainly comprised GEC negative nodules, likely resulting in overestimated 735 
sensitivity (i.e. missing some malignancies in the many unoperated GEC-negative nodules) 736 
and underestimated specificity (i.e. relatively more GEC-positive nodules with benign 737 
histology (false-positives) were operated on than GEC-negative nodules with benign 738 
histology (true-negatives)). The trend that studies with higher surgical rates for GEC-negative 739 
nodules showed more moderate results supports these hypotheses (126,130,142).  740 
A recent meta-analysis by Santhanam et al. included seven studies and reported 96% pooled 741 
sensitivity and 31% pooled specificity for the GEC in Bethesda III, IV and V thyroid nodules 742 
with histopathological follow-up (143). The authors expected that more than 90% of patients 743 
with a negative test would be treated conservatively (143). However, in individual studies up 744 
to 25% of patients pursued surgery or conservative treatment despite GEC-based 745 
recommendation to do the opposite (127,130). This observation is crucial to cost-utility 746 
analyses. In addition, expensive rule-out tests such as the Afirma® GEC should not be 747 
performed in case surgery is considered for other reasons, such as cosmetic or mechanical 748 
complaints. 749 
 750 
GEC in Hürthle cell cytology 751 
Brauner et al. specifically validated the Afirma® GEC in 72 cytology samples suspicious for 752 
Hürthle cell neoplasm. They demonstrated that GEC testing could accurately have reduced 753 
the number of futile surgeries, although through a less profound reduction than in non-754 
oncocytic indeterminate thyroid nodules (132). Similar results were noticed in other studies: 755 
despite a relatively low risk of malignancy, the majority of Hürthle cell nodules were GEC-756 
positive. Regardless of good sensitivity, this unfavourable benign call rate in Hürthle cell 757 
cytology limits diagnostic efficacy in these nodules, increasing the number needed to test and 758 
negatively affecting possible cost-effectiveness (126,131,133,135,142,144). Diagnostic 759 
accuracy of the GEC would likely improve if Bethesda IV cytology suspicious for a Hürthle 760 
cell lesion was excluded from GEC testing. Otherwise, similar to the additional testing for 761 
medullary carcinoma, adaptations should be made to the Afirma® GEC to improve its clinical 762 
utility for Hürthle cell lesions. 763 
 764 
In conclusion, it is generally assumed that the Afirma® GEC accurately reclassifies 765 
approximately two out of five indeterminate thyroid nodules as benign with published 766 
sensitivities ranging between 83% and 100% and similar test performance in Bethesda III and 767 
IV nodules. Withholding diagnostic surgery from these patients seems safe 768 
(130,131,134,144). However, the diagnostic strength and potential cost-utility of Afirma® 769 
GEC strongly rely on its NPV – thus on the prevalence of malignancy and benign call rate in 770 
the targeted population. There are important concerns regarding the currently insufficient 771 
number of clinical validation studies with adequate rates of histopathological confirmation or 772 
long-term clinical follow-up. Physicians are strongly advised to locally validate Afirma® 773 
GEC test performance before considering test implementation in daily practice. Nonetheless, 774 
further large validation studies on the Afirma® GEC may soon become obsolete, as an 775 
updated version of the test, the Gene Sequencing Classifier (Veracyte Inc., South San 776 
Francisco, CA, USA), is currently being put into operation. Improved diagnostic accuracy is 777 
anticipated, with specific attention to the differentiation of Hürthle cell nodules.  778 
  779 
 780 
1.2. MicroRNA 781 
 782 
First described in thyroid cytology in 2006, evaluation of the expression levels of microRNA 783 
(also called miRNA) is among the newer and more promising approaches to differentiate 784 
between benign and malignant thyroid neoplasms (145,146). MicroRNAs are small 785 
endogenous noncoding ribonucleic acids (RNAs) of approximately 22 nucleotides in length. 786 
As negative regulators (i.e. silencers) of protein synthesis at a post-transcriptional level, they 787 
are involved in many intracellular processes, including cell growth, differentiation and 788 
proliferation. Dysregulation of microRNA expression is found in almost all types of human 789 
cancers (147). It reflects the deregulated expression of oncogenes and tumor suppressor genes 790 
(146,148-150). MicroRNA overexpression is present before morphological tissue changes are 791 
seen and therefore considered to be a part of premalignant changes in carcinogenesis (145). 792 
MicroRNA expression profiles are tissue-specific and can not only identify the tissue of 793 
origin, but also the histopathological subtype of the cancer and whether it concerns the 794 
primary tumor or a metastasis (148,151).  795 
MicroRNA expression profiles are similar among the various types of thyroid carcinoma, 796 
even though expression levels are often distinctively different (148). In histopathological 797 
studies, PTC was associated with an up to 11- to 19-fold upregulation of miR-146b, miR-221, 798 
miR-222, miR-181b, miR-187, and a downregulation of miR-1 and miR-138 compared to 799 
healthy thyroid tissue and benign nodules. Upregulation of miR-221, miR-222 and miR-187 800 
was also found in FTC, FTC-OV, poorly differentiated and anaplastic carcinoma 801 
(145,146,148,152,153). Overexpression of miR-146b-3p, miR-146b-5p and miR-375 was 802 
seen in both PTC and FVPTC (152,154). Furthermore, expression levels of miR-221 and 803 
miR-222 were reported about twice as high in FVPTC as compared to PTC or FTC (152). 804 
Only a few microRNAs were differently expressed between follicular neoplasm and FTC 805 
(155). Follicular adenoma was associated with the expression of miR-200a, whereas high 806 
expression of miR-31 was found in Hürthle cell adenoma (148). FTC is related to the 807 
differential expression of miR-146b, miR-7-5p, miR-346, miR-197 and miR-21, but results 808 
among studies are more heterogeneous (148,155,156). FTC-OV showed an expression pattern 809 
slightly similar to FTC, but also distinct overexpression of other microRNAs, such as miR-810 
339, miR-183, miR-197 and miR-885-5p (148,153).  811 
Accordingly, a diagnostic panel of a carefully selected combination of microRNAs and 812 
appropriate expression levels could aid in the preoperative distinction of indeterminate 813 
thyroid cytology (157). Recent meta-analyses struggled to reconcile the studies on microRNA 814 
in FNAC, as the investigated set of microRNAs was never identical and individual microRNA 815 
performance was infrequently described. In unselected cytology, estimated sensitivity of 816 
microRNA expression analysis ranged from 75% to 78% regardless of the investigated set; 817 
estimated specificity from 73% to 81% (156-158).  818 
In indeterminate thyroid cytology, different sets of microRNAs were evaluated; only several 819 
individual microRNAs were analyzed in more than one study. The selected microRNAs were 820 
first assessed in a test set of cytological and/or histopathological specimens and a cut-off for 821 
their expression level was determined. Subsequently, the significantly up- or downregulated 822 
microRNAs were validated in an independent set of (indeterminate) thyroid FNAC samples. 823 
Some studies developed a decision model for the validation step (149,154,159).  824 
The most promising results were presented by Keutgen et al. (159). Of the six microRNAs 825 
investigated in their test set, miR-21, miR-146b, miR-181a and miR-222 were differentially 826 
expressed in malignant nodules with prior indeterminate cytology. The subsequently 827 
developed support vector machine model incorporated miR-21, miR-222 and the 828 
insignificantly expressed miR-197 and miR-328. Prospective validation in an independent set 829 
of 72 indeterminate FNAC samples resulted in 100% sensitivity and 86% specificity. Five of 830 
the seven false positives had Hürthle cell cytology; excluding these, raised specificity to 95% 831 
(159). Notably, even though overexpression of miR-146b is often related to thyroid 832 
carcinoma, it proved not useful to Keutgen et al. to include in their prediction model (159). In 833 
contrast, Agretti et al. and Shen et al. included miR-146b as the key differentiators in their 834 
models. Agretti et al. assessed a frequently quoted set of microRNAs consisting of miR-146b, 835 
miR-155, miR-187, miR-197, miR-221, miR-222 and miR-224 (148,149). Published in 2008, 836 
Nikiforova et al. had demonstrated that this 7-microRNA set in FNAC samples had 100% 837 
sensitivity and 94% specificity if one of the included microRNAs showed an at least two-fold 838 
overexpression (148). Analytic validation of this model by Agretti et al. showed differential 839 
upregulation in PTC of all of these microRNAs except miR-197. In particular, miR-146b 840 
showed a >30-fold higher expression in PTC. A decision tree including miR-146b, miR-155 841 
and miR-221 was 98% accurate in the test set, but validation in an independent set of 842 
indeterminate FNAC samples was unsuccessful, yielding mere 60% sensitivity and 58% 843 
specificity (149).  844 
Vriens et al. used a microRNA array to detect 10 genes that were up- or downregulated by 845 
≥5-fold in thyroid malignancies. Four microRNAs (miR-100, miR-125b, miR-138 and miR-846 
768-3p) were significantly downregulated and accurately differentiated between benign and 847 
malignant follicular and Hürthle cell neoplasms in the test set. In their validation set of 125 848 
indeterminate FNAC samples, only miR-138 was moderately distinctive with 81% NPV. For 849 
Hürthle cell carcinoma, miR-138 and miR-768-3p were both 98% accurate (160).  850 
Finally, in a recent Italian study only miR-375 accurately differentiated between benign and 851 
malignant neoplasms. Subsequently, in TIR3 cytology excluding Hürthle cell lesions, a 12-852 
fold or higher overexpression of miR-375 perfectly distinguished benign from malignant 853 
lesions with 100% accuracy. It was also significantly differently expressed between TIR3A 854 
and TIR3B categories and correlated with a different malignancy risk (161).  855 
 856 
Availability and limitations of microRNA expression analysis 857 
MicroRNA expression analysis has advantages over other techniques. MicroRNAs are more 858 
stable than mRNA at maintaining their expression in formalin-fixed paraffin-embedded 859 
(FFPE) tissue samples as well as FNAC specimens, irrespective of the preservation method 860 
(e.g. archived FNAC slides or nucleic acid preservation solutions) (148,161). Recently 861 
microRNA expression was even successfully measured in serum (162). Moreover, microRNA 862 
expression levels measured with generic methods (e.g. quantitative RT-PCR) correspond well 863 
to their biological effect, as microRNAs affect biological processes without the additional 864 
step of protein synthesis (148).  865 
However, general limitations of FNAC also translate to concerns with microRNA analysis: 866 
scant cellularity or low levels of malignant cells in FNAC specimens could cause a false-867 
negative microRNA test result (149). Another limitation is the plurality of microRNAs 868 
associated with DTC in histopathological studies, causing vast heterogeneity between the 869 
limited number of studies in indeterminate cytology. Validation studies of the same 870 
microRNA set are lacking. Simultaneously, new microRNAs are still correlated to thyroid 871 
carcinoma. Ongoing research has yet to compose the optimal set of microRNAs. Recently, the 872 
first commercial test was marketed as the ThyraMIR™ (Interpace Diagnostics, Parsippany, 873 
NJ, USA). It evaluates the expression levels of miR-29b-1–5p, miR-31–5p, miR-138–1-3p, 874 
miR-139–5p, miR-146b-5p, miR-155, miR-204–5p, miR-222–3p, miR-375, and miR-551b-875 
3p. The ThyraMIR™ demonstrated 57% sensitivity and 92% specificity in 109 Bethesda III 876 
and IV FNAC specimens (22). Prospective clinical validation of the ThyraMIR™ could 877 
affirm the diagnostic value of microRNA expression profiling in indeterminate thyroid 878 
nodules in the pre-operative setting. 879 
 880 
1.3. Immunocytochemistry 881 
 882 
Tissue characterization through selective staining of expressed proteins, i.e. 883 
immunohistochemistry (IHC), is a technique that combines histopathology and biochemistry. 884 
Exploiting basic antigen-antibody interactions, IHC is able to visualize the distribution and 885 
localization of specific cellular components within the cell and in the proper tissue context. 886 
This includes tissue biomarkers specific for e.g. infection or malignancy. IHC has been fully 887 
incorporated in the histopathological routine and is crucial to morphological and molecular 888 
tissue characterization. When immunocytochemistry (ICC) – the application of this 889 
immunology-based technique in cytology – became available, the possibilities were extended 890 
to the preoperative setting, too. Specific immunomarkers have been developed to differentiate 891 
between benign and malignant thyroid nodules. The 2015 ATA guidelines acknowledge ICC 892 
as a technique under development with limited prospective validation studies in indeterminate 893 
cytology (23). In unselected thyroid cytology, the much-used immunomarkers galectin-3, 894 
Hector Battifora mesothelial-1 (HBME-1) and cytokeratin 19 (CK-19) demonstrated 85%, 895 
83% and 80% sensitivity, and 90%, 79% and 79% specificity, respectively (163).  896 
 897 
1.3.1. Galectin-3 898 
 899 
Galectin-3 is a β-galactosyl-binding protein from the lectin group. It is involved in cell-cycle 900 
regulation, including cell migration and adhesion. Its exact function is still to be unraveled, 901 
but a role in the pathogenesis and progression of PTC is presumed (44,163-165). It is related 902 
to inhibition of apoptosis, induced by abnormal p53 expression (165). Galectin-3 can be 903 
present both in the intracellular as well as the extracellular matrix (166). Normal thyrocytes 904 
do not express galectin-3, but the physiological expression of galectin-3 in macrophages, 905 
neutrophils, mast cells and Langerhans cells provides an internal positive control of the 906 
investigated FNAC samples (167,168). Positive cytoplasmic staining – as opposed to nuclear 907 
staining – for galectin-3 is suspicious for malignancy and mainly associated with PTC 908 
(117,169,170). Galectin-3 expression has also been associated with the malignant 909 
transformation of follicular neoplasms, as it was present in follicular adenoma as well as FTC 910 
(166,171,172). Encapsulated FVPTC and minimally invasive FTC showed less frequent and 911 
weaker staining (172,173).  912 
In 2001, Bartolazzi et al. argued that galectin-3 staining could accurately diagnose thyroid 913 
carcinoma in unselected thyroid cytology (117). Subsequent studies in indeterminate thyroid 914 
cytology mostly could not reproduce these promising results. With a positive stain in 915 
approximately a third of all nodules, sensitivity and specificity of galectin-3 ranged from 0% 916 
to 92% and from 68% to 100%, respectively (44,174-177). Merely Saggiorato et al. 917 
demonstrated that galectin-3 accurately differentiated follicular adenomas from FTC with 918 
92% sensitivity and 94% specificity if a cytoplasmic stain in ≥10% of the cells was 919 
considered positive (174). The prospective multicenter clinical validation study by Bartolazzi 920 
et al. demonstrated 78% sensitivity and 93% specificity in Thy3 nodules if a cytoplasmic 921 
galectin-3 stain in >5% of the cells was considered positive. Nineteen of the 22 false-positive 922 
nodules were follicular adenoma. However, a group of 33 difficult-to-diagnose (follicular) 923 
tumor of unknown malignant potential lesions was disregarded, 22 of which were galectin-3 924 
negative. If these neoplasms were considered malignant, sensitivity dropped to 69% (164). 925 
 926 
1.3.2. HBME-1 927 
 928 
HBME-1 is a monoclonal antibody targeting an unknown antigen on the microvilli of 929 
mesothelial cells. It is usually negative in normal thyroid follicular cells. Abnormal 930 
expression of HBME-1 shows cytoplasmic location with membrane accentuation. It is 931 
associated with, but does not necessarily indicate PTC (165,169,178,179). Its low detection 932 
limit enables assessment in liquid based cytology (180). Reported sensitivity and specificity 933 
of HBME-1 in indeterminate nodules ranged from 61% to 100% and from 75% to 96%, 934 
respectively (174,176,180,181). Approximately two out of five nodules showed positive 935 
staining. If only non-oncocytic follicular neoplasms were selected, Saggiorato et al. 936 
demonstrated that HBME-1 had excellent 93% sensitivity and 98% specificity in 937 
indeterminate thyroid nodules (174).  938 
 939 
1.3.3. Cytokeratin 19 940 
 941 
Cytokeratin 19 (CK-19) is a type I keratin. It belongs to the group of intermediate filament 942 
proteins, which arrange the cell cytoskeleton and structural integrity. CK-19 is widely present 943 
in epithelial cells, but also found in basal cells layers of stratified epithelium (174,182). 944 
Strong and diffuse abnormal expression of CK-19 indicates PTC, including FVPTC. 945 
Expression in FTC is less intense and more variable, warranting nuanced interpretation of 946 
CK-19 staining intensity. CK-19 usually shows no or only focal expression in follicular 947 
neoplasms, hyperplastic nodules and adenomatous goiter (174,178,182,183). The reported 948 
sensitivities and specificities for CK-19 staining in indeterminate cytology ranged from 76% 949 
to 88% and 80% to 100%, respectively (174,180,182). Lacoste-Collin et al. demonstrated the 950 
importance of an accurate threshold. CK-19 staining in 31 Bethesda IV nodules accurately 951 
diagnosed five out of six malignancies, including a PTC, two FTC and two out of three 952 
FVPTC. At a threshold of ≥30% stained cells, 5 of 25 benign lesions tested false-positive; at a 953 
more sensitive threshold of ≥10% stained cells, 12 of 25 tested false positive (180).  954 
 955 
1.3.4. Other immunocytochemistry markers 956 
 957 
Immunohistochemistry studies identified more potential ICC markers. Some, like CD44v6, 958 
have not yet been investigated in indeterminate cytology (117). Other markers were 959 
sporadically investigated in preclinical studies, including Ki-67, TROP-2, emerin, keratan 960 
sulphate, thyroperoxidase, CD57 and GLUT-1.  961 
Nuclear protein Ki-67 is expressed in nearly all cell cycle phases in proliferating cells. It is 962 
associated with poor prognosis in PTC (184). The percentage of cells with Ki-67 expression is 963 
considered the tissues’ proliferative index. At a cutoff of ≥1% Ki-67 was 85% sensitive and 964 
71% specific for thyroid carcinoma in Bethesda IV nodules. A combination of HBME-1, CK-965 
19 and Ki-67 immunomarkers was 91% accurate to diagnose malignancy (180). Ki-67 966 
expression is likely only distinctive for follicular type carcinoma; expression in PTC is 967 
generally low (180,184,185).  968 
Glycoprotein human trophoblast cell surface marker (TROP-2) is overexpressed on the cell 969 
surface of different epithelial carcinoma (e.g. breast, colon) and associated with tumor 970 
aggressiveness and poor prognosis. In indeterminate thyroid cytology, it was only assessed in 971 
one small subseries of Bethesda III samples, correctly diagnosing the three included 972 
carcinoma and all but one of the nine benign nodules (186).  973 
Emerin staining emphasizes features of the nuclear membrane often seen in PTC, such as 974 
irregularities and invaginations. Consequently, the stain could facilitate the morphological 975 
diagnosis of PTC and especially the more difficult-to-diagnose FVPTC (176,187). In 53 Thy3 976 
nodules assessed by Asioli et al., positive emerin staining was highly specific for PTC 977 
(including FVPTC), but misdiagnosed all FTCs (176).  978 
Another immunomarker associated with PTC is keratan sulphate, an abnormal 979 
glycosaminoglycan complex. It was 98% specific in indeterminate cytology, but correctly 980 
predicted PTC only; its sensitivity was poor at 48% (174). 981 
The expression of thyroid peroxidase (TPO) is related to benign follicular neoplasms. A 982 
negative TPO stain was 80% sensitive and 86% specific for thyroid malignancy (174).  983 
Finally, CD57 (Leu7) expression is associated with epithelial and nonepithelial malignancies, 984 
including thyroid carcinoma. Cytological staining was only investigated in a small series of 985 
indeterminate cytology, but seemed specific for PTC. In the same series, GLUT-1 was not a 986 
useful ICC marker – there were no positive stains (188).  987 
 988 
Combined use of immunocytochemistry markers 989 
Some research groups have suggested that evident single-marker galectin-3 positivity is 990 
sufficient to refer a patient for total thyroidectomy (164,170,177). The ATA guidelines did 991 
not adopt these suggestions, and many other researchers advocate that a panel of ICC markers 992 
should be applied to strengthen the suspicion of malignancy (23,165,174,179). Several panels 993 
were investigated in literature. Zhang et al. assessed a triple stain of galectin-3, HBME-1 and 994 
p27. P27 is a cyclin-dependent kinase inhibitor related to cell life span in normal thyroid cells. 995 
Downregulated in malignancy, positive P27 stain is related to benign histopathology. In a set 996 
of Bethesda III cytology samples, positive p27 staining with negative galectin-3 and HBME-1 997 
staining was 100% predictive of a benign nodule and occurred in 38% of samples. Loss of 998 
p27 staining in combination with positive galectin-3 and/or HBME-1 staining was 100% 999 
sensitive and 86% specific (165). Another study investigated galectin-3 and HBME-1 in 1000 
combination with a RET proto-oncogene stain, which reflects abnormal intracellular RET 1001 
proto-oncogene activity and presence of the RET/PTC rearrangement. Unfortunately, RET 1002 
staining was inaccurate in indeterminate thyroid nodules (181).  1003 
To find the most accurate combination of immunostains, Saggiorato et al. explored the 1004 
expression of galectin-3, HBME-1, thyroperoxidase, CK-19 and keratan-sulphate in 125 1005 
cytological follicular neoplasms, 24 of which were Hürthle cell lesions. Galectin-3 was not 1006 
only the most accurate marker individually, but also in combination with other stains. 1007 
Sequential HBME-1 staining of galectin-3-negative cases reached 98% sensitivity and 98% 1008 
specificity in non-oncocytic lesions. In oncocytic lesions, sequential CK-19 staining was more 1009 
preferred with 100% sensitivity and 100% specificity (174).  1010 
The common denominator between all these studies is the combined use of galectin-3 and 1011 
HBME-1. Unfortunately, clinical validation studies regarding this combination are limited. Its 1012 
seemingly promising diagnostic accuracy warrants further assessment in future prospective 1013 
studies. 1014 
 1015 
Performance of immunocytochemistry in Hürthle cell cytology 1016 
Expression of ICC markers in Hürthle cell nodules differs from non-oncocytic indeterminate 1017 
cytology. Hürthle cell carcinomas were distinguished in the cytological samples by typical 1018 
overexpression of markers associated with a high degree of cell proliferation, disorganized 1019 
tissue structure and intermediate differentiation, such as Ki-67, laminin, cyclin D1 and cyclin 1020 
D3. Overexpression reflects the known more erratic behavior of Hürthle cell carcinoma 1021 
(185,189). Moreover, markers that were highly diagnostic in indeterminate nodules in 1022 
general, also seem differently expressed in Hürthle cell lesions. Saggiorato et al. 1023 
demonstrated that two combinations of ICC markers were extraordinarily accurate: galectin-3 1024 
and CK-19 staining was 100% sensitive and 100% specific; galectin-3 and thyroperoxidase 1025 
staining was 100% sensitive and 85% specific (174).  1026 
In a previous meta-analysis, inclusion of Hürthle cell lesions was related to between-study 1027 
heterogeneity (163). Hürthle cell lesions require a biotin-free ICC method, as Hürthle cells 1028 
themselves are rich in biotin. Thus, much-used biotin-based methods may consequently cause 1029 
false positive and highly intensive staining in Hürthle cell neoplasms (166,172,181).  1030 
 1031 
Availability, cost-effectiveness and limitations of immunocytochemistry 1032 
Current application of immunocytochemistry is limited. Clinical validation studies for all of 1033 
the described immunomarkers are scarce, and no cost-effectiveness studies are available to 1034 
date. Yet, the technique is widely available, relatively inexpensive and fast in comparison to 1035 
other (molecular) techniques. Costs per immunostain vary up to €20, partly depending on 1036 
simultaneous local application of the technique and similar stains for immunohistochemistry.  1037 
Immunocytochemistry is preferably performed on cell block FNAC specimens, but can be 1038 
performed in all types of cytology, from direct smears to liquid-based cytology (179,181). 1039 
ICC is impossible when the FNAC specimen has poor cellularity or too much obscuring blood 1040 
(190). Also, immunostaining of cytology is technically more difficult than histological 1041 
staining, especially in (destained) cytology smears. Technical inconsistency and interobserver 1042 
variation likely lead to false-negative results (164,182). Stain intensity thresholds or 1043 
percentage of stained cells necessary to raise suspicion of malignancy vary in the available 1044 
literature. Consistent methodology and assessment thresholds should be determined to 1045 
improve reproducibility of ICC results.  1046 
Clinical validation studies of existing ICC markers are ongoing. Meanwhile, new markers are 1047 
also playing the field, searching for the interfaces between mutation analysis of highly 1048 
specific oncogenic driver mutations and accessible ICC techniques. For example, Leslie et al. 1049 
investigated ICC of the BRAFV600E mutation using the mutation specific antibody VE1 in a 1050 
small series of thyroid FNAC samples. Concordance between ICC and conventional 1051 
BRAFV600E mutation analysis was 85%. All samples that were BRAFV600E positive by either 1052 
method were confirmed as BRAFV600E positive PTC on histopathology. Of the eight included 1053 
indeterminate thyroid nodules, seven were histopathologically malignant and BRAFV600E 1054 
mutation was detected in two nodules: one by both methods, one only by molecular analysis. 1055 
The BRAFV600E specific antibody (VE1) stain was much weaker in cytology than in histology. 1056 
Moreover, costs of the VE1 antibody are currently high and optimization of methodology is 1057 
warranted. Yet, Leslie et al. demonstrated that BRAFV600E mutation analysis using ICC is a 1058 
promising alternative to mutation analysis (79). If future studies could validate these results in 1059 
larger cohorts of indeterminate thyroid nodules and detect reliable immunomarkers for other 1060 
oncogenic driver mutations, this technique unites the strengths of gene mutation analysis and 1061 
immunocytochemistry in one technique, though likely at lower costs.  1062 
 1063 
In general, ICC is a widely available and relatively inexpensive technique with a reasonable 1064 
diagnostic accuracy. Many immunomarkers seem to have a pronounced association with PTC. 1065 
Galectin-3 and HBME-1 were most frequently investigated, but their specificities and 1066 
sensitivities seem to fall short of justifying ICC-based surgical decision making. Diagnostic 1067 
accuracy of their combined use seems promising, yet current evidence is limited. Prospective 1068 
validation trials are warranted to confirm the diagnostic potential of ICC, including validation 1069 
of thresholds for stain positivity, panels of multiple immunostains and other methodology.  1070 
 1071 
2. CONVENTIONAL IMAGING 1072 
 1073 
2.1. Ultrasound 1074 
 1075 
Ultrasound (US) is one of the principal steps in the initial work-up of thyroid nodules. It is 1076 
cheap, fast, non-invasive and globally available, but accurate assessment strongly depends on 1077 
operator experience (191). Multiple meta-analyses showed that well-known US features such 1078 
as nodule hypoechogenicity, microcalcifications, irregular margins (including microlobulated 1079 
or ill-defined margins), and a taller-than-wide shape raise the suspicion for thyroid 1080 
malignancy and are mostly associated with PTC (191,192). Nonetheless, no single US feature 1081 
is sufficiently sensitive nor specific to accurately identify a malignant nodule in an unselected 1082 
population (191). Certain combinations of US features, however, may offer accurate closure. 1083 
The current ATA guidelines now include a flowchart recommending FNAC dependent on 1084 
nodule size and various combinations of US characteristics with an incremental risk of 1085 
malignancy (23). Despite the obvious importance of both ultrasound and cytology, the ATA 1086 
guidelines do not provide recommendations regarding (re-)interpretation of US characteristics 1087 
after FNAC has resulted in indeterminate cytology. Follicular-type malignancies typically 1088 
have a different US appearance. More often FTC may be iso- to hyperechoic, with a spherical 1089 
shape, smooth regular margins and no calcifications (193,194). FVPTC may also show FTC-1090 
like or benign features rather than the classic suspicious features, although microcalcifications 1091 
may be distinctive (194-196). In the past years, Brito et al. and Remonti et al. performed 1092 
meta-analyses on US assessment of unselected thyroid nodules. Both also briefly discussed its 1093 
diagnostic value in indeterminate nodules, including a mere limited number of studies and 1094 
also including cytology suspicious for malignancy. Increased central vascularization was most 1095 
predictive of malignancy with reported 96% specificity (192). Yet, in general US seemed less 1096 
accurate in indeterminate nodules than in unselected thyroid nodules (191,192).  1097 
 1098 
In the dozens of available original ultrasound studies, individual US features generally 1099 
demonstrated limited sensitivity in indeterminate thyroid nodules. Only the appearance of a 1100 
solid thyroid nodule – as opposed to varying degrees of cystic content – had high sensitivity. 1101 
Ranging between 46% and 100%, multiple studies demonstrated sensitivity above 90% 1102 
(18,19,197-201).  1103 
A number of classic suspicious US characteristics, such as a taller-than-wide shape, presence 1104 
of irregular margins and presence of microcalcifications, demonstrated valid specificity in 1105 
indeterminate thyroid nodules. Specificities for each of these characteristics ranged from 72% 1106 
to 99% (201-204), 65% to 100% (202,205,206) and 36% to 100%, respectively (207,208). 1107 
Despite the wide range, presence of microcalcifications was more than 90% specific in many 1108 
studies (197,198,200,202-204,206,207,209-211). Large nodule size (defined as a diameter 1109 
larger than 4 cm) was only investigated in a limited number of studies. Reported specificities 1110 
ranged between 69% and 94% (207,212).  1111 
Other features, such as a solitary nodule, hypoechogeneity and absence of a hypoechoic halo 1112 
were associated with thyroid malignancy, but less accurately differentiated between benign 1113 
and malignant indeterminate thyroid nodules (198,201,206,212-217). Additionally, opposing 1114 
the results from one of the mentioned meta-analyses, central vascularization also does not 1115 
seem very accurate in indeterminate thyroid nodules. Specificity ranged from 0% to 100%, 1116 
although multiple studies demonstrated extremely poor specificity (18,202,216-220).  1117 
 1118 
Results regarding two US features are remarkably contradicting. First, the absence of a 1119 
hypoechoic halo is typically considered suspicious for malignancy, but showed overall poor 1120 
and very heterogeneous diagnostic potential in indeterminate thyroid nodules (191). 1121 
Sensitivity and specificity ranged from 17% to 99% and 0% to 93%, respectively 1122 
(200,201,205,221,222). Presence of a hypoechoic halo is typically considered a benign 1123 
feature, but has also been associated with follicular types of thyroid carcinoma (223). Dogan 1124 
et al. reported 88% specificity for presence of a halo in AUS/FLUS nodules and 78% in 1125 
FN/SFN nodules (224). Second, the ultrasonographic nodule shape seems ambiguous. Similar 1126 
to the unselected population, a typically suspicious taller-than-wide shape was generally 1127 
specific for carcinoma, with reported specificities up to 99% (201,202,204). A spherical shape 1128 
is generally considered benign, but has also been associated with FTC (191,193,225). In two 1129 
studies in cytological follicular neoplasms, a spherical shape had an increased risk of 1130 
malignancy, with 86% to 97% sensitivity and 19% to 26% specificity (226,227). Chin et al. 1131 
even suggested that follicular neoplasms with a taller-than-wide shape could be treated 1132 
conservatively (227). The uniquely balanced rates of PTC, FVPTC and FTC resulting from 1133 
indeterminate cytology may explain why these and various other US characteristics have 1134 
different diagnostic accuracy than in the unselected population. Dependent on the local case 1135 
mix, accurate differentiation of indeterminate nodules using the classical suspicious US 1136 
features may or may not be feasible.  1137 
 1138 
Combination of ultrasound characteristics  1139 
A combination of US characteristics likely provides more accurate differentiation than 1140 
individual features. Different combinations were investigated in multiple studies 1141 
(81,197,198,200,204-206,216,228-233). Yoo et al. reported 100% specificity for the 1142 
combination of marked hypoechogenicity and taller-than-wide shape, a pattern that occurred 1143 
in 9.6% (24/249) of the included Bethesda III nodules (201). In the elastosonography study by 1144 
Rago et al., absence of a hypoechoic halo in combination with presence of microcalcifications 1145 
was 95% specific for thyroid malignancy, but only 6.4% sensitive (222). Maia et al. found 1146 
62% sensitivity and 89% specificity in Bethesda III and IV nodules if hypoechogenicity, 1147 
microcalcifications, an irregular margin and increased intranodular vascularity were 1148 
considered suspicious (230). Gulcelik et al. demonstrated that the US pattern of a solid, 1149 
hypoechoic nodule with microcalcifications had 95% sensitivity and 99% specificity. The 1150 
pattern was seen in 21% of cytological follicular neoplasms (234).  1151 
In multiple studies it was argued that cytological follicular neoplasms with a typically benign 1152 
ultrasound pattern – a regular shape, isoechoic, homogeneous, with well-defined margins, 1153 
cystic components or peripheral vascularity only, and not a single malignant feature - could 1154 
be safely followed up clinically instead of undergoing diagnostic surgery (200,225,228). 1155 
Consideration of more features generally increased the sensitivity of the US assessment at the 1156 
cost of its specificity (198,199). The terms of their interpretation were crucial: Norlén et al. 1157 
demonstrated that US was 95% sensitive and 48% specific if a Bethesda III nodule had either 1158 
hypoechoic appearance, irregular margins or microcalcifications. If solely the simultaneous 1159 
presence of all three features was considered suspicious for malignancy, sensitivity dropped 1160 
to 37% but specificity increased to 96% (231).  1161 
Altogether, diagnostic ultrasound scores or step-by-step algorithms could aid the 1162 
classification of US patterns and consequent risk of malignancy (200,228,235). Best-known 1163 
and most validated is the Thyroid Imaging Reporting and Data System (TIRADS), a 1164 
classification to risk-stratify thyroid nodules, designed by Horvath et al. and modified by 1165 
Kwak et al. following the example of the similar BIRADS classification for breast lesions 1166 
(236,237). The TIRADS assigns nodules to a risk category based on five suspicious US 1167 
features: solid appearance, (marked) hypoechogenicity, irregular margins, microcalcifications 1168 
and a taller-than-wide shape. Nodules without any of these features are likely benign and 1169 
categorized as TIRADS 3. Their risk of malignancy is ~1.7% in a cytologically unselected 1170 
population. TIRADS 4 includes suspicious nodules, which are further classified according to 1171 
an increasing malignancy risk into 4a (one suspicious US feature), 4b (two suspicious 1172 
features) and 4c (three or four suspicious features). Nodules with all five suspicious US 1173 
features are classified as TIRADS 5 and associated with a high 88% risk of cancer in an 1174 
unselected population (236). Studies that validated the TIRADS specifically in indeterminate 1175 
thyroid nodules, showed that diagnostic accuracy depended on the chosen cutoff score and 1176 
type of cytology (202,235,238-241). Although TIRADS 5 scores were infrequently assigned 1177 
in indeterminate nodules, a higher TIRADS score (4b/4c/5) was an accurate predictor of 1178 
malignancy, especially in Bethesda IV cytology (202,238,240). In Bethesda III nodules, lower 1179 
TIRADS scores (3/4a) could also rule out malignancy (238,241). Prospective validation 1180 
studies applying the TIRADS in indeterminate cytology are warranted to assess its possible 1181 
clinical utility in indeterminate nodules.  1182 
 1183 
US performance in Hürthle cell nodules 1184 
Cytological Hürthle cell nodules expressed a large variation of US characteristics 1185 
(203,208,212,223). Many malignant and most benign Hürthle cell nodules had a benign US 1186 
appearance (208,223). Only three US features possibly predictive of malignancy were 1187 
reported in individual studies: both hypoechogenicity and hyperechogenicity (as opposed to 1188 
isoechogenicity) (208), large nodule size (223), and microcalcifications (203). Despite limited 1189 
evidence, US evaluation does not seem reliable to differentiate Hürthle cell lesions.  1190 
 1191 
Availability and limitations of ultrasonography 1192 
The major advantages of ultrasound over other additional diagnostics are its already 1193 
permanent position in the workup of thyroid nodules, global availability and low costs. No 1194 
additional resources nor hospital visits are needed to include US interpretations in 1195 
preoperative management decisions and the investigation is noninvasive. Nonetheless, besides 1196 
known limitations concerning interobserver variability and less reliable interpretation of small 1197 
nodules, US feasibility in indeterminate thyroid nodules is limited by the presumed 1198 
differences in US appearance of papillary and follicular thyroid malignancies, illustrated by 1199 
the conflicting results for nodule shape and hypoechoic halo in indeterminate nodules. 1200 
Consequently, local diagnostic accuracy likely follows variations in the local 1201 
histopathological case mix.  1202 
In addition, many of the available ultrasound studies are retrospective, limiting the power of 1203 
the evidence. As the decision to perform FNAC is customarily based on the results of the 1204 
prior US, the prevalence of suspicious US features in indeterminate cytology in these studies 1205 
is presumably overestimated.  1206 
 1207 
Nonetheless, several individual US characteristics seem to have reasonable specificity in 1208 
indeterminate nodules, although insufficient for accurate diagnosis. A combination of US 1209 
features is likely more accurate, although current evidence does not support US-based 1210 
surgical decision-making. We propose that a future meta-analysis should use the individual 1211 
patient data from the large number of available original studies to develop an ultrasound 1212 
algorithm specifically for indeterminate thyroid nodules. The existing TIRADS needs 1213 
prospective validation.  1214 
Even though more advanced and less operator-dependent techniques might be preferred, US 1215 
features should always be assessed in current clinical practice. The presence of one or more 1216 
suspicious US features in a Bethesda III or IV nodule increases the suspicion of malignancy 1217 
and underpins the need for a definite diagnosis. Moreover, to centers or regions with limited 1218 
access to other (molecular) diagnostics, ultrasound may definitely have clinical utility, 1219 
pending local validation in the indeterminate population.  1220 
 1221 
2.2. Elastosonography 1222 
 1223 
Firm consistency of a thyroid nodule upon palpation is considered suspicious for malignancy 1224 
– an established principle during physical examination (242). Ultrasound elastosonography 1225 
(USE) is a dynamic ultrasound technique that is sometimes referred to as ‘electronic 1226 
palpation’. Tissue elasticity is evaluated by measuring tissue distortion while applying a 1227 
standardized dosed external force by the US transducer. It was first applied to the thyroid 1228 
gland by Lyshchik et al. in 2005 (243). Classic real-time qualitative USE is performed by 1229 
free-hand compression and a sine-wave or numerical scale showing how much pressure the 1230 
operator applies with the probe. A color-coded elastosonography image is superimposed on 1231 
the grey-scale US images: red and orange visualizes high tissue elasticity (soft tissue), green 1232 
represents intermediate elasticity and blue low elasticity (firm tissue). Several score systems 1233 
are available. The original score was developed by Itoh et al. in 2006 for the evaluation of 1234 
breast tumors and considers scores 1-3 benign on a scale of 1 (highest elasticity) to 5 (no 1235 
elasticity) (244). Rago et al. first applied it to thyroid tumors and modified it to a 3-point 1236 
score (222,245). Asteria et al. derived a modified 4-point score (246).  1237 
The earliest studies in thyroid nodules reported opportune results of USE as an additional 1238 
modality to B-mode ultrasound, but were heterogeneous in USE technique and study 1239 
population (247). A recent meta-analysis by Nell et al. included twenty studies on qualitative 1240 
USE prior to FNAC and concluded that qualitative USE is fit to diagnose benign nodules and 1241 
safely dismiss FNAC, provided that the usual elasticity score cutoff is abandoned and only 1242 
completely soft nodules (score 1 of all systems) are classified as benign. Pooled 99% 1243 
sensitivity and 99% negative predictive value demonstrated the ability of USE to reliably 1244 
rule-out malignancy in entirely soft thyroid nodules, composing 14% of their pooled study 1245 
population (248).  1246 
 1247 
In individual studies on USE in indeterminate nodules, sensitivity and specificity of 1248 
qualitative USE ranged from 47% to 97% and from 6% to 100%, respectively 1249 
(19,213,221,222,249). Results of several qualitative USE studies stand out. Lippolis et al. 1250 
showed an aberrant 6.1% specificity, because they reported only eight nodules with high 1251 
elasticity – 62 of 66 benign nodules were not elastic. The authors themselves suggest that a 1252 
rather homogenous study population with predominantly small nodules with a solid US 1253 
pattern, absence of cystic areas, and follicular histology with minimal colloid could be 1254 
explanatory for the poor specificity rather than operator-dependent causes (213). Such 1255 
possible relations remain undescribed in other studies. A meta-analysis on the value of USE 1256 
in indeterminate thyroid nodules demonstrated meager pooled 69% sensitivity and 75% 1257 
specificity (250). 1258 
 1259 
As manually applied pressure is difficult to standardize, qualitative USE is strongly operator 1260 
dependent (251). Different USE techniques have been developed to improve objectivity, such 1261 
as semi-quantitative tissue-to-nodule strain ratio indices (also based on manual compression). 1262 
Studies investigating semi-quantitative USE in indeterminate thyroid nodules reported 1263 
sensitivity and specificity ranging from 82% to 100% and from 88% to 100%, respectively 1264 
(215,217,219,249). Furthermore, quantitative shear wave USE measures the propagation 1265 
velocity of focused acoustic pulses – shear waves – from the probe, which correlate to tissue 1266 
stiffness (Young’s modulus) (18,252). It had 82% sensitivity and 88% specificity in a recent 1267 
prospective pilot study by Samir et al.(18). Performance of (semi-)quantitative USE seems 1268 
better than qualitative USE, but results are subject to overfitting from the ROC analysis 1269 
performed to determine the strain ratio cutoff value with the highest sensitivity and 1270 
specificity. None of the studies applied a predefined cutoff or validated their own cutoff 1271 
externally. Consequently, the resulting thresholds were hardly comparable (215,217,219,249).  1272 
 1273 
Altogether, the results from currently available studies cannot support surgical decision-1274 
making in thyroid nodules with indeterminate cytology using elastosonography in any of its 1275 
forms. Whereas color-coded qualitative USE has insufficient sensitivity and specificity, the 1276 
semi-quantitative method lacks validation. The power of the available evidence is additionally 1277 
limited by both methodological heterogeneity and the use of different USE techniques, image 1278 
processing and elasticity scoring methods across studies. Nevertheless, the suggested 1279 
promising rule-out capacity of qualitative USE when applying an alternative cutoff score of 1 1280 
in unselected nodules, deserves clinical validation in indeterminate thyroid nodules. Major 1281 
advantages of the technique are the minor extra costs of USE, as it can be performed during 1282 
regular thyroid US with the same equipment, and only adds approximately 5 minutes to the 1283 
procedure time per patient. Cost-effectiveness will largely depend on performance of USE, 1284 
but no cost-effectiveness studies in indeterminate thyroid nodules are available to date. 1285 
 1286 
2.3. Computed Tomography 1287 
 1288 
There are no studies that investigated computed tomography (CT) scanning in thyroid nodules 1289 
with indeterminate cytology. Prior studies indicated that CT cannot accurately differentiate 1290 
thyroid carcinoma (253,254).  1291 
 1292 
3. FUNCTIONAL AND MOLECULAR IMAGING 1293 
 1294 
3.1. 99mTc-MIBI  1295 
 1296 
Hexakis(2-methoxy-2-methylpropylisonitrile)technetium[99mTc] (99mTc-MIBI) is a 1297 
Technetium-99m-labeled radiopharmaceutical, primarily known for its use in myocardial 1298 
perfusion imaging since the 1980s and more recently the evaluation of hyperparathyroidism. 1299 
Uptake of 99mTc-MIBI, a lipophilic cation, reflects both perfusion and the number of active 1300 
mitochondria in the cells of the thyroid nodule and thus its oxidative burden (70,255).  1301 
99mTc-MIBI scintigraphy is more suitable for the differentiation between benign and 1302 
malignant thyroid nodules than scintigraphy with 99mTc-pertechnetate (99mTcO4
-) or 1303 
radioisotopes of iodide (often 131I-,123I- or 124I-). These latter tracers interrogate the sodium-1304 
iodide symporter of the thyrocyte and are frequently used to assess thyroid nodule functioning 1305 
to distinguish autonomous (“hot”) from hypofunctioning (“cold”) nodules. They are neither 1306 
specific nor effective to detect malignancy: benign nodules can be anything from hyper- to 1307 
hypofunctioning, and far outnumber the carcinomas. Still, thyroid malignancies are almost 1308 
always hypofunctioning: decrease of the sodium-iodide symporter or thyroid peroxidase are 1309 
hallmarks of cell dedifferentiation and lead to loss of iodide-trapping function and thus 99mTc-1310 
pertechnetate or radioiodine uptake (23,255-257). 99mTc-MIBI uptake is independent of iodide 1311 
trapping and organification in the thyrocytes. Nodules with increased uptake and late 1312 
retention of 99mTc-MIBI are suspicious for malignancy (70,255). A 2013 meta-analysis by 1313 
Treglia et al. demonstrated 82% sensitivity and 63% specificity for 99mTc-MIBI scintigraphy 1314 
in clinically suspicious, hypofunctioning, cytologically unselected thyroid nodules. 1315 
Hyperfunctioning benign adenomas can show false-positive increased uptake of 99mTc-MIBI 1316 
due to their increased metabolic needs, thereby decreasing test specificity (255).  1317 
Only three studies investigated the role of 99mTc-MIBI in indeterminate thyroid nodules. In all 1318 
studies, evaluation of thyroid nodules was performed by dual-time planar imaging: an early 1319 
image was made ranging from 10-20 minutes after injection of the radiopharmaceutical and a 1320 
delayed image 60-120 minutes post injection. The intensity of the 99mTc-MIBI uptake within 1321 
the nodule, and possible increased uptake or denoting retention on delayed imaging were 1322 
assessed and compared to the physiological washout of the tracer from normal thyroid tissue. 1323 
A visual pattern of increased 99mTc-MIBI uptake on early images that persisted or further 1324 
increased on the delayed images was generally considered suspicious for malignancy. The 1325 
individual study sensitivity and specificity for this interpretation ranged from 56% to 79% and 1326 
from 52% to 96%, respectively (19,70,258). Despite the limited number of available studies, 1327 
the performance of 99mTc-MIBI in indeterminate thyroid nodules seems insufficient and less 1328 
accurate than in cytologically unselected nodules (255).  1329 
Nonetheless, Giovanella et al. demonstrated that NPV for this method could increase from 1330 
88% to 100% if only the pattern of 99mTc MIBI uptake lower than or equal to the 1331 
pertechnetate uptake within the nodule was considered benign. As few benign lesions 1332 
expressed this uptake pattern, this would decrease the yield of this diagnostic (70).  1333 
Piccardo et al. did not preselect hypofunctioning lesions, but included all indeterminate 1334 
thyroid nodules. As expected given the explanation above, the specificity of 99mTc-MIBI was 1335 
poor: 52% (19). 1336 
Assessment of a retention index of the tracer based on semi-quantitative measurements of the 1337 
lesion to non-lesion uptake ratios for early and delayed 99mTc-MIBI images yielded better 1338 
accuracy. Optimal thresholds for the retention index were determined using ROC analysis and 1339 
unfortunately not externally validated (70,258). As such, it is unclear whether semi-1340 
quantitative 99mTc-MIBI retention indices are truly more accurate than conventional visual 1341 
assessment. Moreover, semi-quantitative analysis is still operator dependent, as it depends on 1342 
the manual definition of ranges of interest (ROI)(19).  1343 
 1344 
99mTc-MIBI in thyroid nodules with Hürthle cell cytology  1345 
Oncocytic cells are rich in mitochondria. Therefore, Hürthle cell lesions – malignant as well 1346 
as benign – frequently show a more intense and persistent 99mTc-MIBI uptake (258-260). Boi 1347 
et al. investigated 99mTc-MIBI in cold thyroid nodules with varying proportions of Hürthle 1348 
cells in the cytology samples. A relation between 99mTc-MIBI uptake and increased tissue 1349 
density of oncocytes was suggested (260). Subsequent studies also concluded that 99mTc-1350 
MIBI is not specific enough to differentiate indeterminate lesions with Hürthle cell cytology 1351 
(70,255,258). Excluding Hürthle cell nodules from 99mTc-MIBI assessment likely excludes 1352 
many false-positive tests while improving benign call rate, specificity and overall diagnostic 1353 
accuracy in indeterminate thyroid nodules.  1354 
 1355 
Availability, cost-effectiveness and limitations of 99mTc-MIBI 1356 
Imaging of 99mTc-MIBI requires conventional gamma cameras (with or without single-photon 1357 
emission computed tomography (SPECT) and CT), which are more widely available than 1358 
PET, especially in non-Western countries. Furthermore, the tracer itself is more widely 1359 
available due to relatively simple complexation using 99mTc-MIBI-kits together with the 1360 
favorable half-life of 99mTc (~6 hours) obtained from on-site generators. The radiation burden 1361 
of the recommended whole-body adult dose is 5-6 millisievert, but can be lowered by a factor 1362 
2-3 by partial-body imaging (261). However, the system resolution of state-of-art gamma 1363 
cameras is a factor 3 lower than of PET/CT cameras. This decreases the measured signal of 1364 
lesions smaller than 30 mm, increasingly limiting test sensitivity in smaller nodules. Average 1365 
costs of 99mTc-MIBI scanning range from €119 to €500 in Europe and from $669 to $1,156 in 1366 
the USA (139,262,263). From a German perspective, 99mTc-MIBI-based management was 1367 
cost-effective over Afirma® GEC-testing and conventional management. However, this study 1368 
inappropriately extrapolated auspicious performance parameters of 99mTc-MIBI in unselected 1369 
thyroid nodules (96% sensitivity and 46% specificity) to the indeterminate population, and 1370 
likely underestimated modelled costs for 99mTc-MIBI scanning and thyroid surgery 1371 
(14,120,138,139,262-264). Therefore, these assumptions regarding cost-effectiveness in 1372 
indeterminate thyroid nodules are decidedly questionable and require careful re-evaluation. 1373 
 1374 
Altogether, there is an increased risk of malignancy in thyroid nodules that show increased 1375 
99mTc-MIBI uptake, provided that hypofunctioning nodules are preselected. Nonetheless, test 1376 
performance in indeterminate thyroid nodules seems insufficient. Excluding Hürthle cell 1377 
lesions suggests high specificity, but does not resolve the reported poor sensitivity. However, 1378 
the number of studies currently available for indeterminate thyroid nodules is limited. We 1379 
believe prospective validation studies in non-oncocytic indeterminate thyroid nodules should 1380 
be performed. Future studies should also focus on external threshold validation for retention 1381 
indices to reduce operator dependency and increase accuracy and objectivity of 99mTc-MIBI. 1382 
Based on the current evidence, we recommend that 99mTc-MIBI scanning is not used in 1383 
surgical management decisions in indeterminate thyroid nodules without another adjunctive 1384 
test.  1385 
 1386 
3.2. FDG-PET 1387 
 1388 
Positron emission tomography (PET) using [18F]-2-fluoro-2-deoxy-D-glucose 1389 
(fluorodeoxyglucose or 18F-FDG), also known as FDG-PET, is an imaging modality that 1390 
exploits the basic principle that (malignant) tumours and inflammatory tissues are much more 1391 
metabolically active than normal tissues. Whereas normal tissues predominantly produce 1392 
energy by low rates of aerobic glycolysis followed by the citric acid cycle in mitochondria, 1393 
glycolytic rates of rapidly growing cancers can be up to 200 times higher. Subsequent lactic 1394 
acid fermentation takes place even if oxygen is plentiful (the Warburg effect) (265). Similar 1395 
to regular glucose, the glucose analogue 18F-FDG is internalized by transmembranous GLUT 1396 
transporters and converted by hexokinase to 18F-FDG-6-phosphate. However, unlike the 6-1397 
phosphorylation product of regular glucose, 18F-FDG-6-phosphate cannot be metabolized 1398 
further. It is trapped intracellularly and thus accumulates in the tissue. Subsequently, PET 1399 
scanning can visualize the increased glucose metabolism of the (abnormal) tissue (266). 1400 
Nowadays, FDG-PET is generally performed in combination with computed tomography 1401 
(FDG-PET/CT), mainly to correlate metabolically active regions to their anatomic substrates 1402 
and to correct for tissue-attenuation of the radioactive signal. It is increasingly applied in the 1403 
diagnostic work-up, staging and therapeutic response monitoring of various malignancies. For 1404 
thyroid cancer, FDG-PET is frequently used to characterize recurrent disease, especially if 1405 
dedifferentiation is expected in thyroid carcinomas that lost the capacity to concentrate 1406 
radioiodide, yet still have measurable serum values of the tumour marker thyroglobulin. It 1407 
may also be considered in the initial staging of poorly differentiated or invasive Hürthle cell 1408 
carcinoma. Moreover, FDG-avid thyroid incidentalomas require additional work-up by FNAC 1409 
when >1 cm (20,23). In the current ATA guidelines FDG-PET is not routinely recommended 1410 
for the diagnostic workup of indeterminate thyroid nodules due to limited clinical validation, 1411 
despite a 2011 meta-analysis by Vriens et al. that demonstrated 95% sensitivity and 96% 1412 
NPV in indeterminate thyroid nodules larger than 15mm (23,267).  1413 
Results of available individual studies were mutually consistent despite limited sample sizes. 1414 
Especially the first studies showed extremely promising results, each reporting 100% 1415 
sensitivity (266,268-270). De Geus-Oei et al. argued that implementation of FDG-PET could 1416 
reduce the number of futile hemithyroidectomies for benign nodules by 66%, likely 1417 
outweighing the costs of the extra scans and suggesting cost-effectiveness of this technique in 1418 
the preoperative setting (269). A subsequent study suggested a less optimistic 39% reduction 1419 
in futile surgeries, following a lower benign call rate (270). More recent studies demonstrated 1420 
more modest performance of FDG-PET(/CT) (19,20,271-273). Overall, reported sensitivity 1421 
and specificity of FDG-PET(/CT) to detect thyroid carcinoma in indeterminate thyroid 1422 
nodules ranged from 77% to 100% and from 33% to 64%, respectively. A negative index test 1423 
was reported in approximately 40% of patients (19,20,266,268-274).  1424 
Several reasons for false-negativity were proposed, foremost small nodule size. It is how 1425 
Traugott et al. explained their 20% false negative FDG-PET scans: eight lesions were 1426 
histopathologically smaller than 1 cm. Excluding these, sensitivity and NPV increased to 1427 
100% (271). FDG-avidity in very small nodules may be missed on FDG-PET due to the low 1428 
volume of malignant cells and due to the partial volume effect: the detected FDG-1429 
concentration is underestimated dependent on nodule size in relation to the (limited) spatial 1430 
resolution of the scanner. In larger nodules, this effect is negligible (20,269). Although the 1431 
improving resolution of state-of-the-art PET scanners pushes the detection limit towards 10 1432 
mm, PET is less sensitive in lesions smaller than 15 mm on US. It less reliable to rule-out 1433 
microcarcinomas (267). Theoretically, the improving spatial resolution could also become a 1434 
limitation of the technique: not only will there be less false-negatives, but likely also more 1435 
false-positive results - leading to a decrease in the already limited specificity over time. In the 1436 
currently available literature no such downward trend is noted, but future studies should 1437 
monitor this possibility.  1438 
 1439 
Semi-quantitative FDG-PET 1440 
Semi-quantitative analysis of FDG-PET is performed using the maximum standardized uptake 1441 
value (SUVmax): the ratio between the maximum radioactivity concentration measured within 1442 
a region of interest on the PET image (the ‘hottest’ voxel) and the decay-corrected amount 1443 
injected radiotracer per unit of body mass. It reflects the FDG-concentration factor compared 1444 
to a homogenous distribution of the radiotracer (275). The SUVmax is generally significantly 1445 
higher in malignant than in benign lesions (20,269,270,272,273,275,276). There is a possible 1446 
correlation between higher SUVmax values and increasing size in nodules, insufficiently 1447 
explained by the abovementioned partial volume effect (20,276). Also, in FTC a higher SUV 1448 
was associated with capsular or vascular invasion (274). Nonetheless, even though Kresnik et 1449 
al. demonstrated that all carcinoma and Hürthle cell adenoma had an SUVmax ≥2 and all other 1450 
benign lesions an SUVmax <2, in multiple other studies the SUVmax of benign and malignant 1451 
indeterminate thyroid nodules overlapped. No threshold could accurately tell them apart 1452 
(20,269,270,272,273,275,276). Moreover, as SUVmax calculations strongly depend on image 1453 
acquisition and reconstruction methods, type of PET-scanner and other variable methodology, 1454 
reported absolute SUVmax thresholds are not simply valid for other institutions (20). 1455 
Standardized optimized FDG-PET protocols are required for inter-institution comparison of 1456 
study results and advancement of PET research (277,278).  1457 
 1458 
FDG-PET in thyroid nodules with Hürthle cell cytology 1459 
Multiple studies observed aberrant FDG-PET characteristics in indeterminate nodules with 1460 
Hürthle cell cytology: both benign and malignant lesions are mostly FDG-positive. Twenty-1461 
nine Hürthle cell lesions were reported by Deandreis et al., consisting 52% of their study 1462 
population and providing an explanation for their limited sensitivity (273). Moreover, Hürthle 1463 
cell adenoma generally demonstrated a significantly higher SUVmax than other benign lesions 1464 
(20,266,268,269,273,279). The proportion of Hürthle cell cytology in individual studies is 1465 
relatively small, but overall FDG-PET seems inadequate in these neoplasms. 1466 
 1467 
Availability, cost-effectiveness and limitations of FDG-PET 1468 
PET systems are less widely available than conventional gamma cameras. Moreover, 18F used 1469 
for 18F-FDG synthesis is produced in cyclotrons, and transport distances are limited due to the 1470 
short half-life of this isotope (~110 min). In Europe, FDG-PET/CT is approximately 1.5-2 1471 
times more expensive than 99mTc-MIBI SPECT/CT. The radiation exposure of FDG-PET/CT 1472 
is largely accounted for by the FDG dosage at approximately 19 μSv/MBq, i.e. about 3-4 mSv 1473 
for a typical activity of 185 MBq administered to an average adult (280). Insights regarding 1474 
common practice total-body FDG-PET/CT imaging are changing (271,273). The CT radiation 1475 
dose greatly varies, and can be less than 0.5 mSv for a low-dose CT of the neck region only. 1476 
When scanning the thyroid region only, a longer imaging time can compensate for a reduction 1477 
in FDG dose, which would lower the radiation burden as well as the costs. Such solutions 1478 
may counter prevailing reservations regarding ionizing radiation exposure. Additionally, 1479 
partial-body acquisition could limit the number of coincidental PET-positive findings. Much 1480 
of the criticism on FDG-PET focuses on these potential incidental findings, which require 1481 
additional diagnostics, are not always clinically relevant and may negatively impact potential 1482 
cost-effectiveness (281,282). Malignant ipsi- or contralateral thyroid incidentalomas are 1483 
reported while the nodule under investigation was histopathologically benign (271,272). PET-1484 
positive incidentalomas are histopathologically malignant in about 20% of patients (282). 1485 
Cost-effectiveness of FDG-PET/CT was modelled by Vriens et al. (14). From a Dutch health 1486 
care perspective, FDG-PET/CT driven treatment would decrease the rate of unbeneficial 1487 
diagnostic hemithyroidectomies for benign thyroid nodules by 35% and reduce the costs per 1488 
patient by €822 compared to the €8,804 expenses for conventional surgical treatment. Also, 1489 
FDG-PET/CT was favoured over the miRInform® and Afirma® GEC (14).  1490 
Contrasting the generally strong sensitivity, specificity of FDG-PET is consistently poor. The 1491 
underlying mechanism is not yet fully elucidated. The negative influence of Hürthle cell 1492 
cytology may be partly responsible. It could also be explained by cellular atypia, which was 1493 
significantly and independently related to FDG uptake, and found in both benign and 1494 
malignant lesions. Atypia was also related to the presence of Hürthle cells (273). Sebastianes 1495 
et al. hypothesized that FDG uptake is related to variations in gene expression patterns. They 1496 
suggested that genetic variations between populations may also explain the varying diagnostic 1497 
accuracy of FDG-PET between studies (270).  1498 
 1499 
In conclusion, FDG-PET(/CT) has the potential to accurately rule-out malignancy in all 1500 
indeterminate nodules except Hürthle cell lesions. It could prevent unnecessary diagnostic 1501 
surgery for a significant number of benign thyroid nodules. Sample sizes of existing studies 1502 
are small, but larger prospective trials are currently ongoing to settle the diagnostic value of 1503 
this technique and its utility in clinical practice. We recommend that these studies also focus 1504 
on identifying (genetic) causes for the occasional false-negativity and generally low 1505 
specificity of this technique. 1506 
 1507 
3.3. DW-MRI 1508 
 1509 
Diffusion-weighted magnetic resonance imaging (DW-MRI) is a functional nuclear magnetic 1510 
resonance imaging technique that evaluates the rate of random (Brownian) motion of water in 1511 
tissue, also called diffusivity. By applying diffusion-sensitizing magnetic gradients (the 1512 
strength and duration of which are expressed as b-values) different levels of diffusion-1513 
weighting are obtained: from non-diffusion images (b-value = 0 s/mm2) to highly diffusion 1514 
weighted images (i.e. b-value >800 s/mm2)(283). Lesions that show high signal intensity on 1515 
DW-MRI images with a high b-value thus show restricted diffusion. The apparent diffusion 1516 
coefficient (ADC, in mm2/s) is calculated based on the exponential relationship between 1517 
signal intensity and the corresponding b-value according to S(b)=S(0)*e-b*ADC. A high ADC 1518 
represents a high degree of diffusion; a low ADC represents diffusion restriction (283,284). 1519 
DW-MRI thus allows noninvasive quantification of tissue properties without ionizing 1520 
radiation exposure for the patient. Differentiation between benign and malignant tissues by 1521 
DW-MRI is based on the assumption that increased cell proliferation, cellular-density and 1522 
disorganized structures in malignant tissue restrict random motion and thus diffusion of water: 1523 
a lower ADC-value, together with high signal intensity at high b-values, is more suspicious 1524 
for malignancy (283,284). Oppositely, increased ADC-values suggest free movement of water 1525 
molecules in the tissue. It is found in for example edema, colloid follicles, fibrous tissue, 1526 
hemorrhage and calcification, all of which associated with benign tissues (285). Prior 1527 
application of DW-MRI in i.e. neuroradiology, breast and lymph nodes showed high 1528 
diagnostic accuracy (286,287). 1529 
Recent exploratory studies in small cohorts of thyroid nodules found distinctively higher 1530 
ADC values for benign than malignant nodules (283-285,288-292). A recent meta-analysis in 1531 
765 cytologically unselected thyroid nodules estimated that DW-MRI had 90% sensitivity and 1532 
95% specificity to distinguish thyroid carcinoma (293). Among the individual studies, 1533 
however, presented optimum ADC thresholds varied and were not externally validated (283-1534 
285,288-292).  1535 
Only one small study had assessed DW-MRI in indeterminate thyroid nodules to date. 1536 
Nakahira et al. reported a mean ADC value of 1.27 ± 0.29 *10-3 mm2/s in malignancies 1537 
opposite 1.95 ± 0.24 *10-3 mm2/s in benign nodules with indeterminate cytology. These 1538 
results were similar to those of their entire study population (n=42), in which a cutoff ADC 1539 
value of 1.95 ±0.24 *10-3 mm2/s was 95% sensitive and 83% specific (283). 1540 
 1541 
Availability and limitations of DW-MRI 1542 
DW-MRI is infrequently and only experimentally used in the workup of thyroid nodules. 1543 
Nonetheless, the worldwide availability and application of MRI is growing. As it uses no 1544 
ionizing but only radiofrequency radiation, the associated risk to the patients is limited, 1545 
provided that specific measures are taken for patients with MRI-incompatible implanted 1546 
devices or metal. No MRI-contrast is necessary for DW-MRI, thus avoiding gadolinium-1547 
associated toxicity. As the spatial resolution of MRI-scanners is still improving, technical 1548 
limitations of DW-MRI with regard to minimal lesion size are becoming less relevant 1549 
compared to SPECT and probably also PET. Still, spatial resolution of DW-MRI sequences is 1550 
less than that of conventional anatomical MRI-sequences.  1551 
There are several major limitations to DW-MRI. MRI is still a rather costly technique; 1552 
additional sequences such as DW-MRI adds scanner time (~5-10 min) per patient and thus 1553 
further increases costs. DW-MRI methodology is not standardized yet and its optimal settings 1554 
still unsettled, leading to varying ADC and b-values (283,289,292). Suboptimal methodology 1555 
or artifacts cause poor image quality, impede accurate interpretation and caused undesirable 1556 
exclusions from already small-sized studies, with reported exclusion rates up to 28% 1557 
(283,284,292). Image artifacts are often caused by inhomogeneity in pathologic tissues or by 1558 
their vicinity to interfaces between soft-tissues and bone or air, a source of MRI-artifacts 1559 
specifically in the thyroid region. Besides viable tumor tissue, malignant tumors partly exist 1560 
of components with high diffusivity, such necrosis, cystic components or intratumoral 1561 
hemorrhage (283,285). For accurate ADC measurement, such macroscopic areas should be 1562 
manually avoided when drawing a region-of-interest. However, avoiding microscopic areas of 1563 
similar origin, invisible to the human eye, is an impossible task (283). Furthermore, it is 1564 
hypothesized that the substantial amounts of follicular or Hürthle cells limit the diagnostic 1565 
accuracy of DW-MRI, specifically in indeterminate thyroid neoplasms. Follicular and Hürthle 1566 
cell neoplasms are known for their varying colloid tissue involvement. Histologically they 1567 
contain more fluid. Thus, DW-MRI would inaccurately provide a more benign image 1568 
(283,292). These hypotheses are currently based on very limited evidence. Further 1569 
prospective validation studies are desired to determine the possible diagnostic value of DW-1570 
MRI in indeterminate thyroid nodules. Future prospects also include improvements of the 1571 
technique, including consensus on methodology and standardization of acquisition 1572 
techniques.  1573 
 1574 
4. COMBINED AND MULTISTEP DIAGNOSTICS 1575 
 1576 
The previous chapters of this review addressed the large number of available diagnostic tools 1577 
to assess indeterminate thyroid nodules. Most studies focused on a single diagnostic technique 1578 
only. The elimination of between-study population-level differences is a major advantage 1579 
when comparing the performance of multiple diagnostics independently in one study, 1580 
optimally in a prospective, independent and blinded fashion. Moreover, assessment of 1581 
multiple techniques in one study allows investigation of the complementary value of multiple 1582 
techniques as a diagnostic tool by means of simultaneous or sequential testing while at the 1583 
same time aiding to further unravel tumor biology as a research tool, especially in the current 1584 
multidisciplinary in-hospital working environment. For example, the question how the 1585 
presence of a certain oncogenic mutation relates to the (positive) result of an FDG-PET scan 1586 
could be addressed.  1587 
Piccardo et al. compared 99mTc-MIBI, FDG-PET/CT and US plus USE in 87 indeterminate 1588 
TIR3 nodules with a 21% malignancy rate. FDG-PET/CT was the superior technique with 1589 
94% sensitivity and 58% specificity. Following a non-specific positive FDG-PET result, 1590 
review of ultrasound characteristics offered slight further differentiation; it improved 1591 
specificity to 77%. However, an additional negative 99mTc-MIBI scan increased specificity to 1592 
94%; this combination was found in 13% of patients (19). 1593 
Giovanella et al. performed both 99mTc-MIBI and a 7-gene mutation panel in cold 1594 
indeterminate thyroid nodules. Combined testing did not improve diagnostic accuracy. 1595 
Performance of the gene mutation panel was inferior to 99mTc-MIBI imaging. Of the seven 1596 
(11%) mutation-positive nodules (four RAS mutations and three PAX8/PPAR 1597 
rearrangements), only four were malignant. It is unclear whether the low sensitivity of the 1598 
gene mutation panel in this study can be explained by the selected population of 1599 
hypofunctioning nodules (70).  1600 
 1601 
Elastosonography and Ultrasonography 1602 
USE is superior to ultrasound in indeterminate thyroid nodules – both individual US 1603 
characteristics as well as combined US patterns described in various articles 1604 
(210,213,215,217,219,221,222). Two recent prospective studies demonstrated that additional 1605 
USE evidently improved the diagnostic accuracy of US. Garino et al. included nodule 1606 
stiffness as additional characteristic into a panel of US characteristics and demonstrated that 1607 
USE identified eight additional malignancies that would have been missed by US assessment 1608 
alone. Presence of one or more suspicious US/USE features was 100% sensitive; two or more 1609 
88% sensitive and 77% specific. Benign test results were found in 57% of patients. The 1610 
authors suggested that the 6.4% remaining risk of malignancy– similar to the benign cytology 1611 
category – would justify follow-up instead of diagnostic hemithyroidectomy in this group 1612 
(210). In another study of 315 Thy3 nodules, semi-quantitative USE correctly diagnosed 75% 1613 
of the histopathologically benign lesions that were considered suspicious for malignancy on 1614 
US, and 83% of the malignancies that were misdiagnosed as benign on US (217). These 1615 
results suggest that the existing TIRADS classification could be extended with tissue 1616 
elasticity features. In unselected thyroid nodules this improved TIRADS sensitivity, but not 1617 
specificity (240,294). The combination is a suitable topic for future research in indeterminate 1618 
thyroid nodules. Major benefit is that the two techniques are individually inexpensive and 1619 
obviously easily combined during one diagnostic procedure. Cost-effectiveness can be 1620 
anticipated.  1621 
 1622 
US and Mutation Analysis 1623 
US assessment was also reported in various studies on gene mutation analysis, presumably 1624 
because US data were usually readily available in clinical studies at no additional costs and 1625 
thus easily combined with results of more experimental techniques. Even though US 1626 
assessment improved the diagnostic accuracy of both FDG-PET and elastosonography, 1627 
combined use of ultrasound with the sensitive Afirma® GEC or specific BRAF mutation 1628 
analysis demonstrated little additional diagnostic value (57). Suspicious US features such as 1629 
hypoechogenicity, presence of calcifications and hypervascularity were not predictors of 1630 
malignancy in Afirma® GEC-positive nodules (144). Also, as expected by their individual 1631 
association to classic PTC, a positive BRAFV600E mutation was correlated to the presence of 1632 
suspicious US features in unselected nodules, including hypoechogeneity and the presence of 1633 
microcalcifications (29,66,78). BRAF mutation less frequently occurred in thyroid nodules 1634 
without suspicious US features (66,78). In Bethesda III and IV thyroid without suspicious US 1635 
features the prevalence of the BRAF mutation was only 1.5% (1/67) in the study by Seo et al. 1636 
– very low, particularly for a South Korean population – all while the malignancy rate was 1637 
still 18% (12/67)(66). Considering the negligible yield at additional costs, BRAF mutation 1638 
analysis might not be contributory in indeterminate nodules without suspicious US features. 1639 
An even lower yield from BRAF mutation analysis in US-unsuspicious nodules is presumed 1640 
in populations with a lower general prevalence of BRAF mutations. Additionally, these results 1641 
suggest a different US appearance of BRAF mutation-negative malignancies – or a different 1642 
molecular profile of thyroid carcinoma without suspicious US features. 1643 
RAS mutation analysis and assessment of the typical suspicious US features could be 1644 
complementary in the differentiation of indeterminate thyroid nodules, as follicular-type 1645 
thyroid carcinomas are associated with RAS mutations and infrequently showed the typically 1646 
suspicious US features (1,29,193-196). Combined assessment could improve diagnostic 1647 
accuracy of either technique in indeterminate thyroid nodules, identifying papillary thyroid 1648 
malignancies through classic suspicious US features and follicular-type carcinoma by RAS 1649 
mutation analysis. However, challenges for clinical practice continue to exist in the imperfect 1650 
specificity of RAS mutation analysis, and the interobserver variability and ambiguity of 1651 
certain US features.  1652 
 1653 
Immunocytochemistry and Mutation Analysis 1654 
In histopathology samples, certain genetic alterations were correlated to positive staining for 1655 
specific immunomarkers: PAX8/PPARγ rearrangement was associated with galectin-3 1656 
reactivity, and RAS point mutation with HBME-1 (105). Only one study investigated this 1657 
combination of techniques in indeterminate thyroid cytology. Although no significant 1658 
correlation was demonstrated between positive BRAFV600E mutation and galectin-3 1659 
overexpression – benefitting possible complementary use – no additional diagnostic value 1660 
was demonstrated either (44).  1661 
 1662 
MicroRNA and Mutation Analysis 1663 
Combined microRNA expression profiling and mutation analysis could accurately aid 1664 
diagnosis and prognosis of thyroid malignancy. Distinct microRNAs have been related to 1665 
oncogenic mutations. For example, miR-221, miR-222 and miR-146b were more 1666 
overexpressed in BRAF- and RAS-mutated PTC. High expression of miR-187 was associated 1667 
with RET/PTC rearrangement (148,295). The first step towards diagnostic integration of the 1668 
two techniques was taken by Labourier et al., who tested the commercially developed 10-1669 
microRNA thyroid classifier ThyraMIR™ simultaneously with the miRInform® thyroid (22). 1670 
The ThyraMIR™ was designed to increase the sensitivity of the miRInform® without 1671 
affecting its specificity. Combined use demonstrated 89% sensitivity and 85% specificity 1672 
(22). A recent decision analytics model for Bethesda III and IV nodules estimated that 1673 
combined miRInform® and ThyraMIR™ testing was cost-effective, reducing the rate of 1674 
unnecessary surgery (diagnostic hemithyroidectomy as well as two-step thyroidectomies) 1675 
from 88% to 20% and saving $1,384 per patient in the first year of treatment or $3,170 per 1676 
avoided surgery. However, it is not described how the economic consequences of the 15% 1677 
missed malignancies are accounted for in this model (140). The economic as well as medical-1678 
ethical consequences of such a high number of missed malignancies question the current 1679 
clinical utility of this combination of expensive techniques. 1680 
 1681 
In brief, the combined or sequential use of multiple diagnostics in indeterminate thyroid 1682 
nodules was infrequently studied. Regrettably, the available studies also mostly remained 1683 
within their own field of expertise: comparing tests either within the domain of pathological 1684 
(molecular) techniques or within the domain of imaging. Although a sequential combination 1685 
of a sensitive and an uncorrelated specific test might bring the solution that this clinical issue 1686 
has been waiting for, the most accurate combination of tests cannot reliably be determined 1687 
yet. 1688 
 1689 
5. RECENT DEVELOPMENTS AND FUTURE PROSPECTS 1690 
 1691 
5.1. The Cancer Genome Atlas 1692 
 1693 
Papillary thyroid cancer was one of the cancers targeted by the cancer genome atlas (TCGA) 1694 
research network, a large collaborative project by the National Cancer Institute (NCI) and 1695 
National Human Genome Research Institute (NHGRI). The incentive of the project is to map 1696 
genomic alterations occurring in 33 types of cancer in 11.000 patients and improve the 1697 
understanding, classification and extending possibilities for targeted therapy of these cancers 1698 
(296). Genetic alterations of all kinds were detected in nearly five hundred clinically non-1699 
aggressive PTCs (classical, follicular and tall cell variants) using one proteomic and six 1700 
genomic platforms. PTC harbored fewer somatic mutations than other human cancer types, 1701 
but if they were present, driver mutations were detected in the majority of the cancer cells. As 1702 
expected, the known driver mutations in the MAPK/ERK pathway were dominant, 1703 
confirming the mutually exclusive relation for BRAF and RAS point mutations and RET/PTC 1704 
rearrangements. Other detected genetic alterations included genetic variations of the TERT 1705 
promoter, PI3K and PPAR pathways, as well as new alterations of known and new drivers, 1706 
such as EIF1AX, PPM1D and CHEK2. Moreover, molecular subtypes of for example BRAF-1707 
mutated PTC were identified and linked to different clinical subtypes. The role of microRNA 1708 
in determining cancer phenotype was elaborated, allowing better understanding of clinical 1709 
behavior of various genetic variants of PTC. Somatic copy number alterations were mostly 1710 
linked to FVPTC. Ultimately, the TCGA Research Network envisions a reclassification of 1711 
thyroid carcinoma, abandoning the discrimination between PTC and FTC, and classifying 1712 
according to molecular subtypes instead of by histopathological subtype first (297). The 1713 
identified markers may not just have an application in the diagnosis of thyroid carcinoma, but 1714 
also in better risk-stratification of the different cancers and in targeted therapies. The plurality 1715 
of applications is best known for the BRAFV600E mutation, which has an association with 1716 
clinically more aggressive tumor behavior on several fronts. Also, non-thyroid malignancies 1717 
carrying a BRAF mutation are now (experimentally) treated with RAF inhibitors (298,299).  1718 
There is little doubt that molecular classification systems are the future of oncology 1719 
diagnostics in all types of human cancers. The position of histopathological assessment is 1720 
changing, but cannot be renounced. With the current knowledge of thyroid genomics, the 1721 
need to distinguish the mutated malignant from the mutated benign – premalignant – 1722 
neoplasms remains, with all due consequences for the surgical and postoperative treatment 1723 
strategy.  1724 
 1725 
Cytological application of the TCGA set was also already investigated in a recent study. 1726 
Pagan et al. validated a panel containing the genomic alterations identified by the TCGA in 1727 
88 FNAC samples selected from a previous cohort study, including 22 indeterminate thyroid 1728 
nodules (126,300). In the latter, 33% sensitivity and 84% specificity were demonstrated. In 1729 
the same set of patients, Pagan et al. also performed the Afirma® GEC. The GEC yielded less 1730 
false negatives and a much higher sensitivity. Even though technical limitations of the applied 1731 
sequencing techniques could leave RNA transcriptions with low expression levels undetected 1732 
and thus negatively influence sensitivity of the TCGA set, the scopes of the TCGA and GEC 1733 
most likely explain their difference in performance. The TCGA was developed using PTC 1734 
only. It did not include follicular lesions and their distinctive genetic alterations. Moreover, in 1735 
contrast to the GEC, the TCGA set was not optimized for preoperative diagnostic application 1736 
in indeterminate thyroid nodules (300). Consequently, the comparison performed by this 1737 
Veracyte-sponsored study seems unjust: it is obvious that the Afirma® GEC yielded better 1738 
diagnostic performance in this specific clinical setting. Yet, the results of this study did prove 1739 
that a large panel of genetic alterations such as the TCGA was not useful in clinical practice 1740 
without further expansion of the scope of the panel towards follicular thyroid neoplasms. Still, 1741 
the genetic alterations and their relations detected by TCGA are groundbreaking for the 1742 
progression of research. From these comprehensive sets of biomarkers, we may select new 1743 
combinations of genetic alterations for future clinical research to develop an accurate rule-in 1744 
or rule-out molecular test for indeterminate thyroid nodules.  1745 
 1746 
5.2. Proteomics 1747 
 1748 
Other molecular advances include protein expression diagnostics, or proteomic profiling. 1749 
These techniques allow for more detailed insight in the molecular biology and protein 1750 
expression of thyroid neoplasms. For example, matrix-assisted laser desorption ionization / 1751 
mass spectrometry imaging (MALDI-MSI) is able to simultaneously visualize the spatial 1752 
distribution of proteins and profile up- and downregulated protein expression in relation to the 1753 
morphological features of the thyroid specimen. These and related proteomic techniques 1754 
could identify new biomarkers for preoperative cytological diagnosis, but require high levels 1755 
of expertise. Application to thyroid cytology has so far been investigated by few studies 1756 
(301,302). Ex-vivo cytology studies show accurate and reproducible differentiation between 1757 
various lesions, including the currently difficult to diagnose Hürthle cell neoplasms (302). No 1758 
studies investigated the diagnostic value of proteomics in in-vivo indeterminate thyroid 1759 
cytology yet. 1760 
 1761 
DISCUSSION 1762 
 1763 
This review provides a comprehensive overview of the available literature on molecular and 1764 
imaging biomarkers as additional diagnostics for thyroid nodules with indeterminate cytology 1765 
(Bethesda III and IV) and their application in a clinical preoperative setting. Clinical utility 1766 
requires more from a diagnostic than mere well-validated test performance and high rule-in or 1767 
rule-out capacity. The 2015 ATA guidelines suggested that the ideal rule-out diagnostic for 1768 
thyroid carcinoma should have a NPV similar to a benign cytological diagnosis (~96.3%) and 1769 
the ideal rule-in test a PPV that is at least similar to a malignant cytological diagnosis 1770 
(~98.6%) (10,23). The balance between test sensitivity and specificity – and their prevalence-1771 
dependent derivatives PPV and NPV – directly reflects on feasibility and cost-effectiveness 1772 
estimates. A diagnostic with (near) perfect sensitivity but limited specificity is inefficient and 1773 
unlikely cost-effective: the NPV will be close to 100%, but the majority of nodules will test 1774 
positive. Therefore, instead of focusing on the reproducible highest sensitivity or specificity, a 1775 
diagnostic is better appreciated by end points such as desired minimal rates of accurately 1776 
prevented unbeneficial surgeries or accurately diagnosed carcinomas. More importantly, 1777 
clinical utility demands that implementation of the ancillary test leads to changes in patient 1778 
management and overall health benefits (303). All these requirements directly depend on a 1779 
plurality of epidemiological and economic factors within the tested population, such as the 1780 
local test availability, professional expertise and case mix – prevalence of malignancy as well 1781 
as the balance of various subtypes of indeterminate cytology including especially Hürthle-cell 1782 
neoplasms and BRAF-mutation. Additionally, clinical utility considerations should include 1783 
less tangible factors such as physician and patient preference, multidisciplinary decision 1784 
making and compatibility with everyday clinical routine and logistics in endocrine practice. 1785 
All things considered, global perspectives regarding the preferred diagnostic for indeterminate 1786 
thyroid nodules likely greatly differ.  1787 
 1788 
Recommendation for clinical use of rule-out tests 1789 
The most accurate currently available rule-out tests are the Afirma® GEC and FDG-1790 
PET(/CT) imaging. The Afirma® GEC had strikingly high sensitivity in nearly all studies 1791 
(127,129,131-134). However, there are concerns regarding the lack of strong validation 1792 
studies. With a high degree of missing histology, especially in GEC negative nodules, there is 1793 
a potentially strong diminution of the tests’ sensitivity if unresected GEC-negative lesions 1794 
were less often benign than presumed. In the USA, physicians should locally validate the 1795 
tests’ utility prior to implementation. However, with its limited global availability, high costs 1796 
and low probability of cost-effectiveness, clinical implementation of the Afirma® GEC 1797 
outside the USA is currently not favored (14,121,137-140).  1798 
FDG-PET/CT may be the preferred rule-out test for indeterminate thyroid nodules in a 1799 
European setting. With sufficient validation studies with complete histopathological follow-1800 
up, it demonstrated consistent high sensitivity and a benign test result in 40% of the patients, 1801 
although the number of currently published patients is moderate. Cost-effectiveness of FDG-1802 
PET over other diagnostics is presumed (14). Its popularity in the USA is more limited, 1803 
although the efficacy of this molecular imaging technique could likely compete with 1804 
molecular biomarkers panels, even if the costs per scan are somewhat higher than in Europe. 1805 
The main drawback of FDG-PET/CT is its – admitted minor – risk to the patient by using a 1806 
limited dose of ionizing radiation.  1807 
The recently announced version 3 of the ThyroSeq® may become a prime contender. 1808 
Dependent on the case mix, the ThyroSeq® v2.1 anticipated high negative predictive value 1809 
(21). However, the number of studies to confirm test performance and clinical utility in 1810 
different patient populations is limited. Clinical results for the ThyroSeq® v3 are eagerly 1811 
awaited. 1812 
Semi-quantitative elastosonography could be a suitable alternative, in particular in case a 1813 
more economic test is required. However, overfitting and lack of external cut-off validation 1814 
likely overestimated the performance of this technique in the limited number of available 1815 
studies. If future prospective studies can confirm its performance and thresholds of this 1816 
operator-dependent but globally accessible method, USE could become a more important 1817 
diagnostic in this field.  1818 
None of the diagnostic techniques under investigation in this review has a perfect NPV or 1819 
fulfills the threshold proposed by the ATA. A number of malignant nodules will be 1820 
misdiagnosed as benign on first assessment. Considering the typical indolent clinical course 1821 
of differentiated thyroid cancer, follow-up of these initially false-negative nodules will most 1822 
likely still result in timely diagnosis without relevant treatment delay and dismal prognostic 1823 
consequences. 1824 
 1825 
Recommendation for clinical use of rule-in tests 1826 
The best rule-in performance was unmistakably demonstrated by BRAF mutation analysis, 1827 
which showed perfect 100% specificity in an abundance of studies. Yet, strong regional 1828 
differences in prevalence of BRAF mutations have a major impact on its clinical utility, 1829 
especially when comparing South Korea to other countries. Moreover, the analysis most 1830 
likely has very low yield in Bethesda IV nodules, in which the mostly follicular type 1831 
malignancies are more frequently RAS-mutated (31,50,70,76). Testing for individual genetic 1832 
alterations other than the BRAFV600E point mutation is not useful. In American and European 1833 
settings, a gene mutation panel is likely preferred over any individual mutation analysis.  1834 
Promising rule-in capacity was also demonstrated for Galectin-3 immunocytochemistry. An 1835 
infrequently applied technique with limited validation studies, further prospective studies are 1836 
warranted to validate its performance in indeterminate thyroid nodules and endorse its 1837 
possible clinical use.  1838 
Besides BRAF mutation analysis, none of diagnostics meet the 2015 ATA requirements of an 1839 
ideal rule-in test. Compared to ruling-out tests, ruling-in tests face an additional challenge. 1840 
With a generally low frequency of thyroid carcinoma in indeterminate thyroid nodules, 1841 
achieving a reliable PPV – higher than 95% – can be a major challenge despite adequate test 1842 
specificity. Such high demands to a ruling-in test advocate the use of a ruling-out test in 1843 
populations with a limited pre-test probability of malignancy.  1844 
 1845 
Clinical recommendation for a step-wise approach 1846 
Most of the diagnostic modalities are optimized for either ruling in or ruling out malignancy. 1847 
No single diagnostic addressed in the current review currently has it all: both a near-perfect 1848 
sensitivity and a near-perfect specificity, and (proven) cost-effectiveness. It is extremely 1849 
challenging to develop such test performance parameters in a single diagnostic. Even 1850 
promising new diagnostics, such as the ThyroSeq® and ThyraMir™, require significant 1851 
further optimization to get near this diagnostic utopia.  1852 
With the diagnostics currently available in the clinical setting, a multimodality stepwise 1853 
approach could offer a conclusive diagnosis for indeterminate thyroid nodules, sequentially 1854 
combining one sensitive rule-out and one specific rule-in test. Unfortunately, thus far few 1855 
studies investigated this approach (19,70). Combinations of (molecular) imaging and somatic 1856 
genetics were especially scarce. There is currently insufficient evidence to accommodate 1857 
reliable interpretation of sequentially used tests, as performance of the second test is unknown 1858 
in a population preselected by the first. Besides choosing two accurate and uncorrelated tests 1859 
to achieve maximum diagnostic accuracy, the sequence of testing, local availability and costs 1860 
of the selected diagnostics are crucial. Costs of two or more additional tests may compromise 1861 
cost-utility estimates. Available cost-effectiveness studies for individual diagnostic modalities 1862 
were additionally greatly susceptible to global variations in population-dependent factors such 1863 
as pre-test probability of thyroid carcinoma and local test performance, and varying health 1864 
care costs including the surgical reimbursement rates (14,121,138,139). Reported surgical and 1865 
hospitalization costs range from $4,628 to $6,549 for hemithyroidectomy, $5,272 to $7,068 1866 
for completion thyroidectomy and $5,680 to $11,265 for initial total thyroidectomy. 1867 
Secondary expenses following surgery should be considered as well, including postoperative 1868 
observation, thyroid hormone replacement (approximately $150 per patient per year), 1869 
treatment for hypoparathyroidism (approximately $860 per patient per year), and resolution of 1870 
rare but potentially serious surgical complications (14,120,138,264). Secondary endpoints 1871 
such as quality of life and survival are of minor importance to cost-effectiveness, due to the 1872 
generally indolent course of differentiated thyroid cancer, adequate treatment options and 1873 
overall low disease-related mortality (14,138,139).  1874 
 1875 
Recent discussions in thyroid histopathology 1876 
Histopathology is classically based on microscopic assessment of tumor phenotype, aided by 1877 
immunohistochemistry. However, this ‘gold standard test’ is also subject to advancing 1878 
insights regarding tumor phenotype, increasingly aided by knowledge regarding tumor 1879 
genotype. Mutation-negative malignancies resulting from indeterminate cytology were 1880 
frequently identified as encapsulated follicular variants of papillary thyroid carcinoma without 1881 
histologic features of aggressive behavior (21,22,31,59,80). Also, several studies defined a 1882 
separate intermediate histopathological category called ‘(follicular) tumor of uncertain 1883 
malignant potential’ for encapsulated, well-differentiated follicular tumors with questionable 1884 
PTC-type nuclear changes (71,164,177,273). These examples illustrate one of the important 1885 
ongoing discussions in thyroid histopathology. In 2016, Nikiforov et al. proposed an official 1886 
downscaling of the classification of proven noninvasive encapsulated FVPTCs, renaming 1887 
them ‘noninvasive follicular neoplasm with papillary-like nuclear features’ (NIFTP). The 1888 
behavior of these neoplasms is benign unlike other thyroid carcinoma subtypes, showing no 1889 
evidence of recurrent disease after a median 13-year follow-up. About one in four of the 1890 
neoplasms in the retrospective cohort were mutated, most frequently carrying RAS (NRAS) or 1891 
PAX8/PPARγ alterations. Presence of a mutation likely predisposes the NIFTP to progress 1892 
into an invasive encapsulated FVPTC, justifying surgical resection. Treatment of NIFTP 1893 
should most likely be limited to hemithyroidectomy, waiving totalizing thyroidectomy and 1894 
radioiodine ablation (304). Although revolutionizing, this new nomenclature complicates 1895 
mutation-based preoperative decision-making (21,31,80). The justification to skip two-stage 1896 
surgery and perform a total thyroidectomy at once for mutation-positive nodules is the driving 1897 
force of the 7-gene mutation panel and similar tests, but would be overkill for the subgroup of 1898 
NIFTP (31). Nonetheless, most of the undesirable possible overtreatment for NIFTP is likely 1899 
resolved if RAS-mutated indeterminate nodules are treated with hemi- instead of total 1900 
thyroidectomy, as previously suggested. No comprehensive diagnostic test is currently 1901 
available to diagnose mutation-positive NIFTP preoperatively, as follicular tumor 1902 
invasiveness and encapsulation cannot be distinguished on cytology. 1903 
 1904 
Hürthle cell cytology 1905 
The Achilles heel of many diagnostics investigated in this review is cytology suspicious for a 1906 
Hürthle cell neoplasm (Bethesda IV SHCN/HCN). Hürthle cells are oxyphilic cells with 1907 
abundant cytoplasm and an enlarged nucleus with a prominent nucleolus. They are found in 1908 
benign thyroid diseases such as Hashimoto’s thyroiditis, but also occur in the notorious 1909 
Hürthle cell adenoma and carcinoma, the oncocytic variant of follicular adenoma and 1910 
carcinoma (4,185). Although Hürthle cell carcinomas (FTC-OV) are rare, their aberrant 1911 
clinical course and association with invasive features justifies the special attention given to 1912 
Hürthle cell cytology by the Bethesda and other classification systems. An accurate additional 1913 
diagnostic is desired. Disappointingly, several studies concluded that the investigated test was 1914 
accurate in all except Hürthle cell lesions (70,132,258,273). Immunocytochemistry handed 1915 
some solutions, although promising results of combined galectin-3 and CK-19 staining have 1916 
not yet been validated (174). Besides that, BRAF, RAS, RET/PTC or PAX8/PPARγ alterations 1917 
are only occasionally found (70,76). These findings support previous presumptions that 1918 
oncocytic thyroid nodules are a completely separate entity with a unique molecular and 1919 
phenotypic profile (305-308). Malignant transition in Hürthle cell nodules most likely 1920 
involves the PIK3CA-Akt-mTOR and Wnt/bèta-catenin pathways rather than the 1921 
MAPK/ERK pathway (305,308). Rare TP53 mutations, usually associated with poorly 1922 
differentiated and anaplastic carcinoma, were recently also identified in well-differentiated 1923 
Hürthle cell nodules (306). Also, recurrent FTC-OV have shown genome haploidisation, a 1924 
rare phenomenon in other types of differentiated thyroid carcinoma (309). Specific markers 1925 
for the preoperative molecular differentiation of Hürthle cell nodules should be developed. 1926 
Adaptation of existing tests to additionally suit Hürthle cell nodules (e.g. the Afirma® GEC) 1927 
is a strategy being explored, for example by the ThyroSeq® v3 and the Afirma® Gene 1928 
Sequence Classifier. Caution should be taken that these adaptations do not decrease the 1929 
diagnostic accuracy for non-oncocytic lesions. MicroRNA expression profiling of these 1930 
lesions is currently also under investigation (148,152). 1931 
 1932 
Strengths and limitations of the current review 1933 
There are several important strengths and limitations to this comprehensive review. This 1934 
review provides a complete overview of the available additional diagnostics for indeterminate 1935 
thyroid nodules, resulting from a careful and systematic literature selection and quality 1936 
appraisal. Different types of clinical data of various levels of evidence were considerately 1937 
presented. Nonetheless, this review is generally prone to inaccuracies from low study quality, 1938 
study heterogeneity and different types of bias. For some of the assessed diagnostics, the 1939 
limited number of available publications and small study cohorts contribute to heterogeneity 1940 
of data and loss of applicability. This mainly concerns studies on non-routine imaging 1941 
techniques. By nature, these clinical studies need to prospectively include subjects to 1942 
voluntarily undergo an extra investigation with – at least in the clinical validation phase – no 1943 
implications for individual patient management. These types of studies require more resources 1944 
than ‘further use’ tissue biobank studies. Consequently, the number of studies is more limited 1945 
and published series often are small. In contrast, cytological biomarker research gratefully 1946 
profits from available large tissue biobanks for initial validation studies. We believe 1947 
consistent results from properly designed imaging studies should not be disregarded due to 1948 
mere their sample size, but be appreciated by the quality of their study design and statistics.  1949 
Population-level study differences were often observed, not only related to test performance 1950 
but also strongly varying malignancy rates that were oftentimes much lower or higher than 1951 
expected from indeterminate thyroid nodules. Besides insuperable epidemiological variations, 1952 
the selection of indeterminate cytology, and the retrospective nature of many studies may 1953 
have contributed to these discrepancies.  1954 
The type of indeterminate cytology included by individual studies varied, likely leading to 1955 
between-study heterogeneity. Besides global variations and known intra- and interobserver 1956 
discordance, diverse definitions of indeterminate cytology were adhered (5). Nowadays, the 1957 
Bethesda system differentiates indeterminate from benign and suspicious cytology in a more 1958 
standardized manner in both literature and clinic. Bethesda III and/or IV and similar 1959 
categories from other classification systems were frequently applied. Unfortunately, some 1960 
studies also included small numbers of Bethesda V nodules without presenting results for 1961 
individual categories separately (127). Many other studies adhered to their own definition of 1962 
indeterminate cytology. This especially, but not exclusively, concerns studies published 1963 
before the introduction of the Bethesda system in 2009.  1964 
Retrospective study designs and subsequent selection bias – only including indeterminate 1965 
thyroid nodules that had undergone both thyroid surgery and (routine) pre-operative testing – 1966 
likely also caused overestimation of the true efficacy of certain techniques (e.g. BRAF 1967 
mutation analysis or ultrasound).  1968 
 1969 
CONCLUSION AND RECOMMENDATIONS 1970 
 1971 
In current-day practice, there are numerous additional diagnostics available to further assess 1972 
thyroid nodules with indeterminate cytology, all with advantages and disadvantages. This 1973 
review provided a comprehensive overview of the available literature on these techniques, 1974 
addressing both molecular and imaging biomarkers, aiming to provide an objective and 1975 
nuanced comparison of their performance and cost-effectiveness with regard to rightful 1976 
surgical decision-making. Many of these diagnostics have either an adequate rule-in or rule-1977 
out capacity, but no single currently available test seems to serve both purposes well. 1978 
Diagnostics from the different research fields likely complement each other in a 1979 
multimodality stepwise diagnostic approach towards. Notwithstanding, test performance is 1980 
always population-dependent. To correctly interpret the results, the prevalence of malignancy 1981 
and the performance, costs and feasibility of the desired diagnostic in the local patient 1982 
population should be known beforehand. Local implementation studies are strongly 1983 
recommended to confirm clinical utility. Most importantly, the local decision favoring or 1984 
opposing a certain diagnostic should be a deliberate and multidisciplinary one. Cooperation 1985 
between clinical endocrinologists, endocrine surgeons, pathologists, radiologists and nuclear 1986 
medicine physicians is crucial.  1987 
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Table 1. Overview of classification systems for thyroid cytology 
 
Bethesda System for the Reporting of 
Thyroid Cytology (4)  
British Thyroid Association 
(BTA)(6)  
SIAPEC-IAP (Italy)(7)    
Category Description Category  Description Category  Description Malignancy 
rate (4)  
Proposed management (2015 
ATA guidelines (23)) 
I Nondiagnostic / unsatisfactory Thy1 
Thy1c 
Nondiagnostic 
Nondiagnostic Cystic 
lesion 
TIR1 
TIR1c 
Nondiagnostic 
Nondiagnostic-cystic 
1%-4% Repeat FNAC with US guidance  
II Benign Thy2 
Thy2c 
Nonneoplastic 
Nonneoplastic Cystic 
lesion 
TIR2 Nonmalignant / benign 0%-3% No clinical follow-up or 
treatment required 
III Atypia of undetermined 
significance / follicular lesion 
of undetermined significance 
(AUS/FLUS) 
Thy3a Atypical features present TIR3a Low-risk 
indeterminate lesion 
~5%-15% Repeat FNAC. If second 
Bethesda III result, consider 
additional tests and/or diagnostic 
hemithyroidectomy 
IV Follicular neoplasm / 
suspicious of a follicular 
neoplasm, including Hürthle 
cell (oncocytic) type 
Thy3f Suspicious of follicular 
neoplasm 
TIR3b High-risk 
indeterminate lesion 
15%-30% Consider additional tests and/or 
diagnostic hemithyroidectomy 
V Suspicious of malignancy Thy4 Suspicious of malignancy TIR4 Suspicious of 
malignancy 
60%-75% Thyroid surgery recommended. 
Consider preoperative additional 
(molecular) testing to determine 
extent of surgery 
VI Malignant Thy5 Malignant TIR5 Malignant 97%-99% Thyroid surgery recommended 
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Table 2. Overview of test performance and utility of main additional diagnostics in indeterminate thyroid nodules 
   Sensitivity Specificity Main advantages Main limitations Cost-effectiveness 
Molecular Biomarkers  
 Gene Mutation Analysis and Gene Expression  
  BRAF  0%-83% 
(34,59,61,65) 
99%-100% 
(21,29-31,35-
38,41-76) 
Perfect specificity at low 
cost 
Strong geographical variation in 
occurrence, clinical utility likely 
limited to gene mutation panels in 
countries other than South Korea 
Presumed, though 
unpublished; 
€7.50 to $123 per test 
(53,63,72,88)  
  RAS  0%-77% 
(39,60) 
75%-100% 
(39,60,90)  
High prevalence, 
frequently detected 
Often found in follicular adenomas 
(false-positive); clinical utility 
limited to gene mutation panels 
Unpublished  
  RET/PTC 0%-29% 
(31,49)  
73%-100% 
(29,31)  
Specific for PTC Low prevalence; clinical utility 
limited to gene mutation panels 
Unpublished 
  PAX8/PPARγ 0%-29% 
(55,59,109)  
96%-100% 
(37,59,70)  
No significant advantages Low prevalence; utility limited to 
gene mutation panels 
Unpublished 
  7-gene mutation panel 18%-69% 
(22,61)  
86%-99% (37,61)   Comparatively 
inexpensive mutation 
panel  
Specificity often insufficient for 
surgical decision-making 
USA: likely (120);  
Europe: unlikely (14); 
$425 to $1,700 per test 
(120,121)  
  NGS  71%-91% 
(21,71)  
89%-93% (71,80)  Highly accurate; rapidly 
advancing technology  
Limited availability outside the 
USA; limited clinical validation 
studies 
Unpublished;  
€230 to $3,200 per test 
(123,124)  
  Afirma® GEC 83%-100% 
(130,131,134,
144)  
10%-52% 
(126,130)  
High rule-out capacity  Limited availability outside the 
USA; limited high-quality clinical 
validation studies  
Unlikely (14,121,137-
140); $3,500 ($1,750 to 
$7,000) per test 
(121,131,137)  
 MicroRNA 57%-100% 
(22,159,161)  
58%-100% 
(149,161)  
Stable expression 
irrespective of preservation 
medium (148,161)  
Limited clinical validation, research 
ongoing   
Unpublished 
 Immunocytochemistry  
  Galectin-3 0%-92% (44-
174)  
68%-100% 
(44,175-177)  
Global availability; 
inexpensive. 
Limited current application in 
cytology; no methodological 
consensus; limited validation 
studies for combinations of 
immunostains. 
Unpublished.  
Up to €20 per test. 
  HBME-1 61%-100% 
(174,176,180,
181)  
75%-96% 
(174,176,180,181)  
  CK-19 76%-88% 
(174,180,182)  
80%-100% 
(174,180,182)  
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Table 2 (continued). Overview of test performance and utility of main additional diagnostics in indeterminate thyroid nodules 
Conventional imaging  
 Ultrasound Dependent on 
(combination 
of) feature(s) 
Dependent on 
(combination 
of) feature(s) 
Global availability, low cost Operator dependency; limited 
prospective clinical validation; 
diagnostic accuracy of 
individual US features 
insufficient for surgical 
decision-making  
Presumed, though 
unpublished. 
 Elastosonography 47% to 97% 
(19,222)  
6% to 100% 
(213,221,249)  
Global availability, low cost, 
easily performed during 
standard US work-up 
Operator dependency; limited 
clinical utility studies; 
alternative elasticity cut-off 
possibly more useful 
Presumed, though 
unpublished. 
 Computed Tomography Unavailable Unavailable Unavailable Not investigated in 
indeterminate thyroid nodules 
n.a. 
Functional and Molecular Imaging  
 99mTc-MIBI scintigraphy 56%-79% 
(19,258)  
52%-96% 
(19,70)  
More widely available and 
lower cost than PET 
Limited test performance; 
limited clinical validation 
studies; exposure to limited 
dose of ionizing radiation 
Unclear. USA $669-
$1,156, Europe: €119-
€500 per scan 
(139,262,263)  
 FDG-PET 77%-100% 
(266,268-
270,273)  
33%-64% 
(269,272)  
High rule-out capacity; 
increasing global availability 
Exposure to limited dose of 
ionizing radiation. 
USA: unpublished.  
Europe: likely (14).  
 
 DW-MRI Unpublished Unpublished  No ionizing radiation Limited evidence; no 
methodological consensus; 
research ongoing  
unpublished 
 
BRAF: BRAF point mutation analysis. GEC: Gene Expression Classifier. n.a.: not applicable. NGS: Next Generation Sequencing. RAS: RAS 
point mutation analysis. 
 
Essential points 1	
 2	
- Indeterminate thyroid cytology (Bethesda category III and IV) corresponds to 3	
follicular-patterned benign and malignant lesions, which are difficult to differentiate 4	
on cytology alone.  5	
- Approximately 25% of indeterminate thyroid nodules harbor malignancy. 6	
- The value of additional diagnostics is best defined by endpoints such as desired 7	
minimal rates of accurately prevented unbeneficial surgeries (rule-out capacity) or 8	
accurately diagnosed carcinomas (rule-in capacity). 9	
- None of the diagnostic techniques currently available has near-perfect sensitivity, 10	
near-perfect specificity and cost-effectiveness.  11	
- A multimodal stepwise approach using a sensitive rule-out and specific rule-in test 12	
might offer the most conclusive diagnosis for indeterminate thyroid nodules. 13	
- The decision favoring or opposing a certain diagnostic technique strongly depends on 14	
population-dependent variations in cytology (e.g. Hürthle cell cytology), tumor 15	
genetics and prevalence of malignancy, and on the costs and feasibility of the desired 16	
diagnostic in the local patient population. 17	
 18	
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